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Abstract 
Free radical formation and DNA damage in the cytotoxicity of 
alkylaminoanthraquinone antitumour agents. 
Geoffrey Roy FISHER 
The role of NAD(P)H dependent reductase mediated redox cycling in DNA 
strand breakage and cytotoxicity by doxorubicin (DOX), mitozantrone 
(MIT), CI941 and a series of alkylaminoanthraquinones (AQ) based on MIT 
has been investigated in MCF-7 human breast cancer cells. lAQ, 1,8AQ 
and DOX were found to redox cycle in MCF-7 cells as evidenced by 
stimulation of NADPH oxidation, superoxide anion formation and hydroxyl 
radical formation associated with generation of a drug free radical in 
MCF-7 S9 cell fraction. Furthermore, DOX formed a free radical, 
stimulated oxygen consumption and produced hydroxyl radicals in intact 
viable MCF-7 cells. 1,5AQ formed a free radical species and produced 
hydroxyl radicals but did not stimulate NADPH oxidation or superoxide 
anion formation in MCF-7 S9 fraction. Reactive oxygen formation 
correlated with the DNA strand breakage and cytotoxicity produced by 
IAQ, I,SAQ, 1,8AQ and DOX in MCF-7 cells. DOX also produced plasmid DNA 
strand breakage in the presence of purified cytochrome P4S0 reductase or 
xanthine oxidase. lAQ, 1,SAQ and 1,8AQ mediated plasmid DNA strand 
breakage only in the presence of purified cytochrome P4S0 reductase. 
MIT, CI941 and 1,4AQ did not redox cycle in MCF-7 cell S9 fraction yet 
produced equivalent cellular DNA strand breakage to DOX and AQ's at LDSO 
concentrations. The order of cytotoxicity of these compounds after a 1 
hour exposure ~nd at least 6 d~ys further cell growth was;- (LDSO);-
CI941(I.SxlO- lUM) >MIT(S.2xlO- YM) >lAQ(6.0xlO- 8M) >1,8AQ(O.5xlO- 6M) 
>1,4AQ(I.2xIO- 6M) >DOX(3.0xlO- 6M) >1,SAQ(12.3xIO- 6M). Variation in 
cellular uptake between the agents did not account for differences in 
cytotoxicity and DNA strand breakage observed. The 1,4 substitution 
pattern of MIT, CI941 and 1,4AQ appears to prevent metabolic activation. 
In further studies;- i) MIT and CI941 were more potent inhibitors of 3 
MCF-7 topoisomerase I activity than other quinones, ii) MIT and DOX-Fe + 
complexes mediated plasmid DNA strand breakage in the presence of 
reduced glutathione iii) Only MIT was oxidatively activated by 
horseradish peroxidase!H202' producing plasmid DNA damage. The results 
indicate that future development of quinone anti tumour agents should 
concentrate on compounds which do not redox cycle but have functional 
groups that assist iron binding, activation by peroxidases and/or 
topoisomerase inhibition. In this respect, these agents should possess 
chromophore hydroxyl groups as these appear to be responsible for the 
increased cytotoxicity of MIT and CI941 compared to the other AQ's. 
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Cancer is a major disease worldwide, with an estimated 5.9 million cases 
occurring throughout the globe each year. One half of these cases 
involve cancer of the stomach, lung, breast, colorectum and cervix. An 
estimated 1 in 3 people will suffer from cancer during their lives 
[Cancer Research Campaign, Annual report, 1987]. 
In the United Kingdom cancer deaths account for 25% of all deaths each 
year. Despite more than 70% of cancer deaths occurring in people over 
65 years of age, cancer is the main cause of death in children and young 
adults after accidents and violence. The commonest cancers and the 
cancer mortality rate in the United Kingdom are shown in table 1.1. 
Clearly cancer is a major problem, hence the need to fully understand 
its nature and origin, find new therapeutic approaches and refine and 
gain better understanding of existing ones. A major part of the studies 
in progress is the design, synthesis and screening of new anti tumour 
agents. However, further success in this area relies to a large extent 
on a full understanding of the mechanism of action of antitumour agents 
used effectively in the clinic to date. 
1.2 The nature of cancer 
An understanding of the origin and nature of cancer is important before 
consideration of the therapeutic approach to treating this disease. 
A malignant tumour or neoplasm consists of an abnormal and uncontrolled 
proliferation of cells which invades the surrounding tissues and can 
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Other 46% 
Lung 29 ,540 (35', ) 
Prostate 7,3 10 (9', ) 
Stomach 6 ,6 20 (B', ) 
Colon 5,5BO (7', ) 
Rectum 3 ,660 (4', ) 
Bladder 3 ,570 (4"0 ) 
Pancreas 3,410 (4"' ) 
Oesophagus 3,090 (4', ) 
Leukaemia 2, 190 (3"' ) 
Non-Hodgkin's 1,650 (2', ) 
Lymphoma 
Others 16 ,900 120 %) 
Cancer Mortality - UK 1985 
Lung 25% 
Stomach 7% Breast 10% 
Numbers of Cancer Deaths in the UK 1985 
Male Female 
Breasl 15,070 (20',) 
Lung 11 ,320 (15',) 
Colon 7,170 (9'0) 
Stomach 4 ,600 (6'0) 
Ovary 4,290 (6',) 
Pancreas 3,400 (4"0) 
Rectum 3,110 (4"0 ) 
Cervix 2,200 (3"0) 
Oesophagus 2,140 (300) 
Leukaemia 1,950 (3' ,) 
Others 20,7 40 (27"0 ) 
All cancers 83,520 (100% ) All cancers 75,970 (100% ) 
Table 1.1. Cancer Incidence zn th e United Kingdom. 
(from Cancer Research Campaign factsheet 3.1, 1987) 
metastasise to other parts of the body. Cancer has been ascribed to a 
'malady' of genes arising from genetic damage such as recessive and 
dominant mutations, rearrangements of DNA and point mutations, leading 
to various distortions of gene expression or the biochemical function of 
gene products (Bishop, 1987). The theory that genetic damage might be 
responsible for cancer evolved from several lines of evidence (reviewed 
by Emery, 1985): 1) the detection of damaged chromosomes in cancer 
cells; 2) the susceptibility to cancer of cells unable to repair DNA; 3) 
the hereditary disposition of some people to cancer; 4) evidence that 
relates the mutagenic potential of substances to carcinogenicity; 5) the 
discovery that cellular genes (proto-oncogenes) in the form of oncogenes 
can cause neoplastic growth (reviewed by Nishimura and Sekiya, 1987). 
1.2.1 Genetic factors and cancer 
Cancers can be grouped into four categories with respect to genetic 
factors (reviewed by Emery, 1985):-
1) Rare genetic forms of cancer such as Xeroderma pigmentosum, and the 
increased frequency of acute leukaemia associated with Down's 
syndrome. 
2) Common cancers which are inherited in an autosomal dominant trait in 
some rare families. The same type of cancer occurs over several 
generations of a family eg ovarian cancer. 
3) The 'cancer family' syndrome, where a predisposition to cancer is 
inherited in an autosomal dominant trait. 
4) The common cancers which are the largest group of cancers. These 
have a multifactorial basis possibly involving a genetic 
predisposition to cancer and exposure to an environmental 




~l~Z.Z VIruses and cancer 
The seminal discovery in this area was that made by Rous in 1910, who 
found that a cell free filtrate from chicken sarcoma could induce the 
same tumour in other chickens. Many viruses are now known to cause 
tumours including hepatitis B virus [liver cancer], Epstein Barr virus 
[Burkitt's lymphoma] and human papillomavirus [cancer of the cervix]. 
The events which occur when a virus infects a cell are shown in figure 
1.1. Some viruses are able to transform the infected cell into a 
tumour cell. These viruses carry transforming genes or oncogenes 
(reviewed by Emery, 1984; Aaronson et a1., 1985; Nishimura and Sekiya, 
1987) which code for a protein which mediates this transformation. The 
use of viral oncogenic gene probes from animal retroviruses has shown 
that human transforming sequences are homologous to various viral 
oncogenes [v-onc] and have been referred to as cellular oncogenes [c-
onc]. It is believed that retroviral oncogenes originated from cellular 
genes or proto-oncogenes which were picked up at some point in their 
sojourn as proviruses. Many cellular oncogenes have now been identified 
in humans. Activated oncogenes have been found in a variety of 
malignant tumours including bladder, breast, lung colon and pancreas 
[all c-H-ras], Burkitt's lymphoma [c-myc] and neuroblastomas and 
sarcomas [c-N-ras] and chronic myeloid leukaemia [c-abl]. 
An important question is how do cellular oncogenes become activated to 
produce cancers? Several proposals exist to answer this question 
(reviewed by Bishop, 1987; Emery, 1985):-
1) A point mutation in a cellular oncogene which interferes with its 
expression. eg c-H-ras in bladder cancer (Reddy et a1., 1982). 
2) A cellular oncogene may become activated by a relevant viral 
promoter when the virus becomes integrated into the DNA adjacent to 
the oncogene. eg T cell leukaemia (Gelmann et a1., 1984). 
3) A chromosomal rearrangement involving translocation of a cellular 
oncogene to an adjacent site to a promoter or enhancer sequence, eg 
Burkitt's lymphoma and myeloid leukaemia (Rowley, 1983). 
4) Induction of a point mutation in a cellular oncogene by a chemical 
carcinogen (Eva and Aaronson, 1983). 
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Vi rus particle L 
Figure 1.1. Sequence of events which occur when a retrovirus infects a cell 
[RT=reverse transcriptase1. (Emery, 1985). 
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The protein products of oncogenes have not yet been fully identified, 
however several oncogenes have been found to produce products similar to 
growth factors and growth factor receptors [reviewed by Aaronson et a1., 
1985; Nishimura and Sekiya, 1987). For example platelet derived growth 
factor has been found to be structurally related to P28sis protein of 
Simian sarcoma virus (Hunter, 1984; Waterfield et a1., 1983) 
It can be seen from section 1.2 that DNA is the critical molecule 
involved in the initiation of cancers. Before considering the treatment 
of cancer it is necessary to consider some important aspects of the 
structure and function of DNA. 
1.3 Deoxyribonucleic acid 
The primary structure of the deoxyribonucleic acid [DNA] duplex is shown 
in figure 1.2 (reviewed by Alberts et a1., 1983). The natural form of 
DNA is the B form in which the double helix is coiled in a right-handed 
direction, the chains turning to the right as they move upwards. 
However, local regions of the DNA molecule can have a left-handed 
configuration, known as Z form DNA because of the zig-zag path of the 
sugar-phosphate backbone. Another form of DNA is the A form which 
occurs due to puckering of the sugar backbone. 
1.3.1 Higher order packing of DNA 
In order to accommodate the long DNA molecules into the nucleus, a 
higher order structure of DNA exists. A series of DNA binding proteins 
exist, which mediate processes such as RNA synthesis, gene expression 
and act as structural proteins. These proteins are divided into histone 
and non-histone proteins. The non-histones are a multitude of proteins 
which have a wide range of functions, whilst the histones are primarily 
structural. When DNA is associated with histones it is known as 
chromatin. Four different orders of packing can be identified in 
chromatin (see figure 1.3) [reviewed by Alberts et a1., 1983; Nelson et 
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Figure 1.2. The structure of Deoxyribonucleic acid. 
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1. Primary coiling involves the supercoiling or further twisting of the 
DNA duplex in the direction of turn of the DNA strands. 
2. Secondary coiling involves the coiling of the DNA duplex around a . 
core of histone proteins (Composed of an octamer of histone 
proteins, two each of H2A, H2B, H3 and H4). Known as the nucleosome 
this repeating subunit with 166 to 168 base pairs (bp) of DNA 
wrapped in two left-handed superhelical turns around each histone 
core is separated by a region of linker DNA (variable up to 70bp 
long) giving it a 'beads on a string' structure. 
3. Tertiary DNA folding involves the arrangement of the nucleosome into 
a higher order structure, the 30nm chromatin fibre or solenoid 
[cylindrical in shape]. This consists of either a helix with 6 
nucleosomes per turn or a superbead configuration. Histone HI is 
responsible for arranging DNA into this structure, lying outside the 
nucleosome, the central globular portion of this molecule spans the 
points of entry and exit of the DNA coil. It protects 15 bp on 
either end of the core associated coils but not the linker DNA. 
Removal of histone HI causes the nucleosome to separate. 
4. Finally, quarternary DNA folding involves the folding of the 
chromosomes into looped domains. Eighteen of these loops form a 
radial array around the core of the chromosome to produce a 
miniband. The continuous formation of these radial loops produces a 
stack of minibands forming a metaphase chromatid. 
DNA folding with relation to function is described in more detail by 
Alberts et al., (1983), Nelson et al., (1986), Eisenberg, (1987) and 
Yaniv et al., (1986). 
1.3.2 Function of DNA 
Detailed accounts of the replication, transcription and translation of 
DNA into protein are given by Alberts et al. (1983). The way DNA is 
organised and its physical relationship with nuclear protein is highly 















106 kbpl chromatid 
Figure 1.3. Schematic diagram of the organisation of 
DNA within the chromosome. 
(Bohr et al 1987) 
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DNA into chromatin means that the conformation of active genes within 
this higher order structure must be modified so as to be accessible to 
transcription. This change is thought to be dependent on nuclear 
proteins, the structure of the nuclear matrix, methylation of DNA and 
other changes in the association between histones and DNA which are 
still to be elucidated. 
1.4 The control of gene expression 
The individual cells of an organism are distinct both in morphology and 
function. Highly specialised cells synthesise large amounts of one or 
several specific proteins. This differentiation of cell structure and 
function depends on changes in the selection of DNA sequences for 
decoding into proteins without irreversible changes to the DNA sequences 
themselves. Three classes of gene activity are recognised as being 
required for determining the characteristics of a particular cell: 
activation of housekeeping genes for general cell metabolism; 
activation of genes for 'luxury' proteins which typify a cell type eg 
muscle actin and myosin; hormone induced gene products. The regulation 
of gene expression may be exercised at several different levels [see 
figure 1.4]. One of the most important areas of gene regulation has 
been found to be at the transcriptional level (reviewed by Darnell, 
1982). All gene regulation in prokaryotes is known to occur at the 
transcriptional level. There are considerable differences between the 
functional details of prokaryote gene control systems but the 'operon 
model' (reviewed by Sang, 1984) outlines the general principles of these 
systems. 
1.4.1 The operon model 
This model is based on the existence of a regulatory gene which codes 
for a regulatory protein which 1) interacts with a specific DNA sequence 
or operator which is located adjacent to the polymerase binding site 


















" mRNA degradation 
~ control 
Inactive mRN A 
Figure 1.4 . The different levels at which gene expression may be 
controlled in eukaryotes 
1: see text, 2: reviewed by Darnell (1982), Mattaj (1984) 
3: reviewed by Robertis (1983), 
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operator modified by a signaling ligand. The signaling ligand binds to 
the protein by weak secondary bonds [hydrogen bonds, ionic interactions 
and van der Waals forces]. Two types of control system are possible, a 
positive system where the regulatory gene product switches on the gene 
when combined with the signaling ligand and a negative system where this 
combination switches off the gene. These systems are outlined in figure 
1.5 and table 1.2. 
There is indirect evidence for regulatory proteins in eukaryotes acting 
as positive and negative regulators of gene expression, however in a 
typical eukaryotic cell only 7% of the total DNA sequences are ever 
transcribed, hence thousands of repressor proteins would be required for 
the remaining 93%. Hence it is believed that gene repression is 
controlled differently in eukaryotes, with gene regulatory proteins 
acting as gene activators (Alberts et a1., 1983). 
1.4.2 The Britten and Davison model of gene expression (1969). 
This model (reviewed by Sang, 1984) [figure 1.6] assumed that:-
a) There are effector substances which are signals external to the 
genome which interact with genome sensors. 
b) The sensor is a sequence of DNA and a specific sensor protein which 
specifically binds its appropriate effector. 
c) Effector-sensor interaction results in transcription of an adjacent 
integrator gene set which codes for sequence specific activator 
proteins. 
d) These proteins recognise receptor sequences and the associated gene 
or genes are transcribed. 
e) Unlike the operon model a particular receptor sequence is not unique 
to a particular gene set. There maybe more than one receptor 
sequence associated with a gene or gene set, thus an activator may 
switch on more than one gene and one gene may be switched on by 
more than one activator. 
f) The integrator set determine the activator messages, which may not 
be exclusive as the same message may be repeated in different 
13 






































-The mutation prevents binding with the co-activator, but not with the operator. 
The presence of a normal regulatory gene cannot interfere with this so the mutant 
effect is dominant. 
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Figure 1.5. Operon organisation. 
(a) Negatively controlled inducible system in which the regulatory product 
(R) combines with the operator (0) to prevent transcription of the two 
structural genes (SG1 and SGII), but is inactivated by the inducer thus 
permitting transcription. (b). Positively controlled inducible system, in 
which the operon is activated by the regulatory gene product (apo-inducer) 
combining with the substrate (co-inducer) and acting at the initiator 
sequence to initiate transcription. <c). Negatively controlled repressible 
system, where the regulatory gene product is inactive until combined with 
the co-repressor (usually end product) which inhibits the operator. 
P, promoter sequence; I, initiator sequence. Table 1.2 summarises the 




l Integrator set A 







~ Integrator set 8 
[]i " DNA 
Al 81 82 
~RNA 
mAl mBl mB2 
~ G'lI"' ~ \..U.. ~ v.L Protein 
PAl PAl PAJ ~ PAl PBl PB2 
Activator proteins "" / / 
~ J ~~::;::I ~ 1/1" I = 
RAl SGl RAl SG2 SG3 RAJ RBl SG4 RB2 RBX RBY SGS 
Receptor sequ~nces------
Effector a activates Sus 1, 2, 3 and 4 
Effector b activates SGs 1, 4 and 5 
Figure 1.6. The Britten and Davidson model. 
For simplicity only two integrator gene sets are illustrated. Each is activated 
by its specific effector a or b which combine specifically with the proteins of 
their sensor sites. This causes the coordinate transcription of the entire 
integrator gene set, and the formation of the activator mRNA (mAl etc.) 
and of the activator proteins (pAl etc.). These activator proteins (or 
mRNAs) combine with specific receptor (RAl etc.) sites (operators) adjacent 




g) The activator message set (RNA) may be involved with the selective 
transcription of genes without being translated into protein. This 
allows the activation process to be intranuclear and independent of 
protein synthesis. 
However this model was later modified as it assumed that the most 
important control of gene expression was transcriptional. 
1.4.3 The Davidson and Britten model of gene expression (1979) 
Like the genome most nuclear RNA [nRNA] contains interspersed repeated 
sequences. Regulated transcription of these sequences (for example 
Darnell, 1982; Konarska et a1. 1985; Mattaj, 1984) has been found to 
have a key role as opposed to structural gene transcription as in the 
previous model. An interaction between the structural gene nRNA's and 
the transcriptionally-regulated nRNA's is assumed since the structural 
gene mRNA's are selectively processed. 
The constitutive gene transcript [CT] carries the coding sequence 
flanked by short repetitive sequences, accounting for the complexity of 
this mRNA class in the nucleus. The integrating transcription unit 
[IRTU] is preceded by a nucleoprotein sensor which when activated by an 
external signal, results in selective transcription of the unit in a 
cell specific fashion. The IRTU carries interspersed repetitive and 
single copy sequences. The IRTU transcript [IRT] is the cell specific 
nRNA which can combine only with the gene transcripts carrying 
complementary, matching repeated sequence. Only this CT-IRT complex 
can be processed. Since the repetitive sequences of an IRT may be 
matched by repetitive sequences of a number of CT's the IRT will control 
the processing of a battery of CT's as in the previous model with the 
integrator gene sets. The gene battery of that model now becomes the 
set of genes bearing the same repeated sequences. This model is 
illustrated in figure 1.7. 
The above models (reviewed by Sang, 1984) are concerned with the 
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Figure 1.7. The Davidson and Britten model. 
The CTU contains the structural gene, its introns and flanking sequence, 
including the initiation site (I) and the repetitive sequences A and B. This is 
constitutively transcribed into the CT (nRNA). Three possible forms of of 
IRTUs are shown, each with different arrangements of interspersed 
repetitive sequences (A,B,C,D and E). Their transcription is controlled by 
nucleoprotein sensors (55) which respond to external signals and then make 
the IRT(nRNA). The IRTs duplex with the CTs, by sequence dependent base 
pairing between the repeated elements. Three possible arrangements are 
shown. These IRT-CT complexes must form before the mRNA can be 
processed and then translated. (Sang, 1984). 
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differential regulation of transcription and assume there is no specific 
role in the organisation of chromatin in this respect. The opposite 
view allocates a regulatory function to the chromatin proteins including 
non-histone proteins. The packaging of DNA into chromatin is a feature 
unique to eukaryotes which is important in gene regulation. DNA must be 
transcribed whilst it is bound to the nucleosome however most chromatin , 
is highly condensed and inaccessible to polymerases so it must be 
decondensed to allow transcription to take place. Transcribable DNA 
regions have been found to be accessible to digestion by the 
endonuclease DNase I indicating that it is the state of chromatin which 
determines the accessibility of this enzyme. Histone H1 is found to be 
bound less tightly to some transcribed regions and histones in active 
nucleosomes are unusually highly acetylated. The small non-histone 
proteins HMG14 and HMG17 have been found to be bound to active 
nucleosomal genes [reviewed by Sang, 1984). In addition, topoisomerase 
enzymes [see section 1.7] have been found to be intimately involved in 
mediating the topology of DNA during transcription. All of these 
factors may play an important role in uncoiling the chromatin of active 
genes (reviewed by Alberts et a1., 1983). It is thought that eukaryotic 
gene activation occurs in two stages, firstly the binding of a gene 
regulatory protein to a specific DNA sequence and secondly, this causes 
a structural change in the neighbouring chromatin which is propagated 
for the length of the gene or the entire length of a chromosome looped 
domain (reviewed by Alberts et a1., 1983). 
The control of gene activation has been described at the molecular 
level. At the cellular level, the growth and division of cells is 
controlled by the cell cycle. It is the events of this cycle and its 
relationship to the growth of normal and tumour tissue which determine 
the effectiveness of antitumour agents. Before specifically describing 
the interactions of anti tumour agents with DNA it is necessary to 
describe these relationships. 
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1.5 Chemotherapy and the cell cycle 
1.5.1 The cell cycle 
The cell cycle (reviewed by LLoyd et al., 1987; Alberts et al., 1984) 
is the period between one mitosis and the next one in either of the 
daughter cells. This period is divided into four phases as shown in 
figure 1.8. Gl phase is the period between mitosis and the onset of DNA 
synthesis, S phase the period of DNA synthesis, G2 phase the period 
between completion of DNA synthesis and mitosis and M phase is the 
period of mitosis (or nuclear division) and cytokinesis (or cytoplasmic 
division). Within Gl there is a restriction point (R). When this is 
reached the cell is committed to divide. Cells in any given population 
are divided into three categories with respect to the cell cycle:-
1. Continuously dividing or cycling cells. 
2. Resting or non-cycling cells which can be induced to start dividing 
with an appropriate stimulus. 
3. Cells that have left the cell cycle and will die without dividing 
again. 
Resting cells are termed as being in GO' a term which has been 
derived to acount for the variability of G1 phase of cultured 
cells. This variability in time span of G1 is the major determinant of 
the cycle time of a cell population. There are two main theories for 
how cells transit from Gl phase to S phase (reviewed by Lloyd et al., 
1987):-
1. It has been proposed that a critical concentration of a 'trigger 
protein' is required in order for a cell to progress from G1 to S 
phase. 
2. The transition probabilty model proposes that the cell cycle is 
divided into two states:- the B state [containing S, G2 , M AND G1 ) 
in which cells are proceeding towards division and the A state 
[contained in G1 ] where the cells are awaiting a random triggering 
event before proceeding. This model suggests a cell may remain in 
20 
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Figure 1.8. The Cell Cycle 
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the A state for any length of time, but l.'n steady state conditions 
the probability of a cell leaving the A state and entering the B 
state is constant. 
1.5.2 Tissue growth kinetics 
1.5.2.1 normal tissue 
In a similar manner to cells within a population, normal tissues can be 
divided into four categories (reviewed by Pardee, 1985):-
1. Cell renewal tissues where there is extensive birth and death of 
cells ego mucosa of bladder and skin. 
2. Non-proliferating tissues such as nonstriated muscle and neuronal 
tissue, 
3. Cells with little tendency for proliferation in the steady state 
such as smooth muscle and capillary endothelium. 
4. Cells that proliferate in response to physiological requirements 
~(foT.ax~mple liver cells after hepatectomy). 
I \ 
The cells within a population are divided into compartments as shown in 
figure 1.9. The stem cells are the progenitors of the cell 
compartment. In the steady state they are resting and act as reserve 
cells. However, they give rise to the proliferation compartment when 
expansion and maturation is occurring. It is this compartment which is 
most susceptible to cytotoxic agents. Finally, the cells no longer 
divide and are incapable of cell.division. These cells have a finite 
lifespan. As long as the mature compartment is equal to cell death the 
population of cells does not expand. 
1.5.2.2 Tumour tissue 
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Figure 1.9. Diagrammatic representation of the 
organisation of a cell renewal system. 
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compartments. However, unlike normal tissue cell growth does not 
normally equal cell death, so a net increase in tumour size is the 
result (reviewed by Buick and Pollak, 1984; Hill, 1978; Pardee, 1985). 
In consequence tumour tissue has a higher 'growth fraction' [higher 
number of dividing cells]. This difference between normal and tumour 
cell populations is the basis of the differential effect of chemotherapy 
to the two tissue types. As in normal tissue, the stem cells are 
responsible for maintaining the integrity and continued survival of the 
cell population. The stem cells are capable of an infinite number of 
cell divisions, in contrast to other cell types. The malignant stem 
cells in a tumour mass are capable of self renewal and migration, 
allowing the primary tumour to grow as well as initiating metastases. 
Within the stem cell population there may be cycling cells which are 
sensitive to chemotherapeutic agents which affect proliferating cells, 
or resting cells which are insensitive to such agents. The state of the 
cells will depend on their accessibility to the capillary blood supply 
for oxygen and nutrients. Resting cells may re-enter the cell cycle to 
replace cells destroyed by therapy. Therefore in chemotherapy the stem 
cells must be regarded as the critical target. Successful therapy 
depends on differential activity of agents on malignant and normal 
cells. 
Antitumour agents produce three distinct classes of survival curves when 
used in the treatment of normal and malignant cells:-
1. No difference in toxicity to normal and malignant cells, ego X-
irradiation, therefore termed as 'non-specific'. 
2. More toxic to malignant than normal cells, cell kill being directly 
related to concentration until a plateau is reached. This is termed 
phase specific because the drug is killing cells at specific parts 
of the cell cycle. Resting cells are not affected. 
3. Survival curves exponential with dose, no difference in slope being 
seen with normal and malignant cells. This is termed cycle specific 
because the drug kills proliferating and resting cells. However, 
dividing cells are more sensitive than resting cells throughout the 
cell cycle. 
Thus specificity for tumour cells relies on the greater growth fraction 
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in this tissue. Examples of the classification and sites of action of 
antitumour agents is given in figure 1.10. Generally drugs can exert 
two main effects on cells which mayor may not be expressed at the same 
point of the cell cyc1e:-
a) A lethal cell killing effect which is maximum at certain phaseS of 
the growth cycle. Generally occurs at high drug doses. 
b) An effect which stops cell cycle progression by arresting cells at a 
specific phase. This is often reversible. This generally occurs at 
low doses of drug. By arresting the cell at a specific point a drug 
may inhibit its own lethal effect if this is expressed at a 
different phase. 
It is quite clear from what has been described in this section that 
there is an intimate relationship between chemotherapy and cell 
division. The central event of cell division is the replication of DNA. 
This process is therefore a vulnerable target in cell populations which 
are continuously renewing or expanding such as tumours and some normal 
tissues. Indeed the majority of antitumour agents have been shown to 
interact with DNA, disrupting its structure, synthesis and function. 
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VM26 
Cis-Platinum 
Figure 1.10. The phases of the cell cycle where some antitumour 
agents exert their effects 
*indica tes more than one site of drug action 
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1.6 The interaction of antitumour agents with DNA 
There are several mechanisms by which antitumour agents have been shown 
to interact with DNA. The concept of DNA being a 'receptor' for 
antitumour agents has recently been reviewed by Hurley and Boyd (1988). 
1.6.1 Indirect effects on DNA 
The antimetabolites are agents that by virtue of structural similarity 
with physiological intermediates are accepted as imitation substrates 
for biochemical reactions which are vital for a particular cell process. 
An example is the antifolate methotrexate which exerts its effect 
through inhibition of the enzyme dihydrofolate reductase. This enzyme 
is responsible for maintaining the intracellular pool of reduced folates 
[tetrahydrofolates] which are the source of one carbon groups for 
synthesis of purine nucleotides and thymidylate. Therefore, the net 
effect of this drug is an inhibition of purine synthesis, hence a 
disruption of DNA synthesis (reviewed by Chabner and Myers, 1985). 
1.6.2 Binding of antitumour agents to DNA 
1.6.2.1 Intercalative binding 
Reviews of DNA intercalation are given by Neidle and Abraham (1987). 
The basic postulate for intercalation is that the flat polycyclic 
aromatic ring system of a drug molecule can fit between the stacked base 
pairs of the double helix. There are three basic requirements for a 
drug to be considered as intercalated (Waring, 1981):-
a) The helix must be extended 
b) The helix must be locally unwound by drug binding. 
c) The plane of the aromatic chromophore of bound drug must be parallel 
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to that of the base pairs. 
All these characteristics vary considerably for different drugs, the 
standard reference intercalator being ethidium (figure 1.11). As the 
amount of intercalator bound increases the negative (right handed) 
supercoiling of DNA is reduced, lost then reversed [followed by falling 
sedimention coefficient, viscosity or mobility on gels] . 
Antitumour agents that intercalate include the anthracycline antibiotics 
(Aubel-Sadron and Londos-Gagliardi, 1984) [see section 1.16.1], 
aminoacridines (Neidle and Abraham, 1987), quinoxaline antibiotics (eg 
Echinomycin), antitumour alkaloids (eg ellipticine) and other 
antitumour agents such as Actinomycin D [reviewed by Waring, 1981]. 
Bifunctional intercalative agents have also been developed in an attempt 
to increase binding affinity and also to attain more selective binding 
to preferred sites in DNA (eg diacridines, reviewed by Waring, 1981). 
However, the antitumour activity of these agents has not always been 
more effective than monomeric intercalators. 
1.6.2.2 Non-intercalative binding 
This category contains drugs which bind to DNA but not by a proven 
intercalative mechanism. These drugs bind mainly to the surface of the 
DNA molecule by electrostatic interactions. An example of this type of 
drug are Mithramycin antibiotics (Waring, 1981). 
1.6.2.3 Covalent binding 
Bifunctional alkylating agents including nitrogen mustards, 
nitrosoureas, triazenes and ethyleneimines form covalent bonds to 
nucleophilic centres, especially proteins and nucleic acids (reviewed by 
Chabner and Myers, 1985). Most alkJlating agents- form a carbonium ion 
in aqueous solution (Chabner and Myers, 1985). When the alkylating 
groups are chloroethyl groups [eg nitrogen mustard], a preliminary 
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Figure 1.11 The structure of ethidium. 
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cyclisation to form an unstable imonium ion occurs, with spontaneous 
opening of the three membered ring to give the alkylating intermediate 
R-CH2 -CH2+· This charged group then attacks nucleophilic sites on 
nucleic acids, proteins and other small molecules. The N(7) position of 
guanine accounts for 90% of alkylated sites in DNA [Reviewed by Gianni 
et a1., 1983]. 
When two alkylating groups are situated on each drug molecule such as in 
nitrogen mustard which has two chloroethyl groups,DNA cross-linking 
occurs, which is thought to be the major effect of these agents 
[Chabner and Myers, 1985]. 
Other alkylating agents such as mitomycin C require activation by NADPH 
dependent enzyme systems before alkylation and crosslinking can occur 
(Hoey et a1., 1988; reviewed by Kennedy et a1., 1980) [see section 
1.8.2]. Mitomycin has two reaction centres, one is the strained three 
membered aziridine ring and the other being the methylurethane side 
chain at position 10 [see figure 1.12]. Other alkylating agents include 
cyclophosphamide, Cisplatin (reviewed by Chabner and Myers, 1985), 2,5-
bis(carboethoxyamino)-3,6-diaziridinyl-l,4-benzoquinone (AZQ) {figure 
1.18} [reviewed by Gutierrez, 1989], and 2,5-bis(2-hydroxyethylamino)-
3,6-diaziridinyl-l,4-benzoquinone (BZQ) [Butler et a1., 1989]. 
1.6.3 Strand breaking interactions 
A common characteristic of many DNA interactive drugs is the production 
of DNA strand breaks. This includes the DNA intercalators, non-
intercalators and alkylating agents. Single and double strand breakage 
of DNA by intercalating agents may arise due to attack by reactive drug 
intermediates or as a result of DNA repair activity or topoisomerase 
activity [see section 1.7] being disrupted by the presence of the drug. 
The number of single strand breaks caused by excision repair 
endonuclease activity is balanced by the resealing of single strand 
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Figure 1.12 Alkylation of DNA by mitomycin C. 
Three kinds of modified nuc1eotides isolated from DNA 
alkylated with reductively activated mitomycin Care 
shown. 
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Friedberg, 1987]. DNA repair synthesis is required for this process. 
Consequently, an inhibition of any part of this process may lead to an 
increase in strand breakage. The nature and causes of DNA strand 
breakage produced by drug free radical intermediates is considered in 
greater detail in section 1.9.2. Several types of DNA damage are 
specifically seen with a1ky1ating agents:-
1.6.3.1 Alkali-labile sites 
These are proposed to be an indicator of genetically significant DNA 
damage caused by a1ky1ating agents, which react with DNA at multiple 
sites (reviewed by Kohn, 1981 and 1983). The guanine 06 position, a 
major site of nucleophilic damage is a relatively weak nucleophile which 
reacts only with potent nuc1eophi1es. 06-alky1-guanine residues are 
lesions that are repaired by alkyl transferase mechanisms which do not 
involve strand breaks as an intermediate [D'Incalci et al., 1988). Such 
weak nucleophilic sites are converted to strand breaks in the presence 
of an alkaline solution. In addition, alkylated DNA phosphate groups 
tend to form strand breaks in alkali. These strand breaks can be 
measured by the alkaline elution technique [see section 1.11.1], 
Alkylation sites at guanine N7 , a strong nucleophilic site are repaired 
by glycosy1ase and alkaline phosphatase-endonuclease reactions which do 
involve strand breaks so drug induced strand breakage may occur via this 
mechanism. 
1.6.3.2 Interstrand cross links 
Agents that bind to DNA at two sites are much more cytotoxic than 
monofunctional agents. Most bifunctional agents produce inter and 
intra-strand cross links and DNA-protein cross1inks between DNA and 
nuclear proteins which can block DNA and RNA synthesis eg mitomycin C 
(reviewed by Kennedy et al., 1980), bis-p1atinum(II) complexes, AZQ 
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lL~Y.~~~~ ~J ~~~.~LL~w, 1989; King et al., 1984; Szigiero and Kohn, 
1984] and BZQ (Butler et al., 1989). 
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1.7 Interaction of antitumour agents with nuclear enzymes 
Within the nuclear matrix there are a large number of enzymes which are 
intimately involved in the management of DNA and its functions, 
including topology, replication, transcription and repair. In recent 
years it has been found that certain antitumour agents possibly exert 
their cytotoxicity by specifically interfering with some of these 
enzymes. The main focus of attention has been the DNA topoisomerases 
(reviewed by Drlica and Franco, 1988). 
1.7.1 Interaction of anti tumour drugs with topoisomerases 
Reviews on this subject are given by Lock and Ross (1987), Ross (1985) 
and Bodley and Liu (1988). DNA topoisomerases are enzymes that alter 
the topological state of DNA. Cellular processes such as replication, 
transcription and recombination require these topological changes in the 
structure of DNA (reviewed by Wang, 1985). Topoisomerase II has 
recently been reported to act specifically during mitosis (Holm et al., 
1989). Thus, the topoisomerases are essential in cell growth processes. 
Topoisomerases catalyse DNA relaxation/supercoiling, catenation/ 
decatenation and knotting/ unknotting [see figures 1.13 and 1.14] 
(Maxwell and Gellert, 1986). 
The topological state of closed-circular duplex DNA that is not 
catenated or knotted is characterised by its linking number, which 
expresses the number of times the two strands are interwound. There are 
two types of topoisomerases, defined by their mechanism of action with 
respect to the changes in linking number they confer. 
1.7.2 Type II topoisomerases 













CATENATION I OECA TENATION 
Figure 1.13. Reactions of type I topoisomerases 
Note the catenation or decatenation of circular duplexes will 
occur only if one DNA molecule bears a single strand break 
(Maxwell and Gellert, 1986) 
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Figure 1.14. The reactions of type II topoisomerases. 
(Maxwell and Gellert, 1986) 
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between the cuts, allowing a second duplex to pass through the break 
before it is resealed. The linking number of the DNA is therefore 
changed by two. Eukaryotic topoisomerase II [reviewed by Zwelling, 
1985; Wang, 1985; Glisson and Ross, 1987] has a molecular mass of 
340,000 Da, having two 170,000 Da subunits. The hydrolysis of ATP is an 
integral part of its action. 
The addition of a strong protein denaturant such as sodium dodecyl 
sulphate [SDS] to a reaction mixture of topoisomerase II, duplex DNA and 
some anti tumour agents produces single and double strand breaks in the 
DNA, with a subunit of topoisomerase covalently attached to each 5' 
phosphoryl end of the break (see figure 1.15). The double strand break 
is a four base pair staggered cut with recessed 3' hydroxyl ends. It 
has been proposed that the covalent DNA-protein adduct is derived from 
an intermediate of the topoisomerase reaction, the 'cleavable complex'. 
This complex consists of DNA and enzyme in a conformation which is 
cleaved or susceptible to cleavage 
The observation that there were similarities between the cleavable 
complex formation and DNA protein crosslinks caused by some anti tumour 
agents led to investigation of the role of topoisomerases in the 
mechanism of action of these drugs (Zwelling et a1., 1981). Studies with 
alkaline elution [see section 1.11.1] showed that DNA damage induced by 
intercalative agents (Tewey et a1., 1984) such as doxorubicin (Tewey et 
a1., 1982) , and 4'-(9-acridinylamino)methanesulfon-m-anisidide [m-
AMSA] (Nelson et a1., 1984) was associated with formation of protein 
linked strand breaks. Similar effects were seen with non-interca1ative 
drugs such as etoposide, (Chen et a1., 1984). However, it has recently 
been found that these drugs, including etoposide, teniposide and the N-
acyl anthracyclines AD32 and AD4l, do bind to DNA (Chow et a1., 1988). 
All these agents interfered with the breaking and rejoining reaction of 
topoisomerase II by trapping an abortive enzyme-DNA 'cleavable complex' 
[see figure 1.15]. When this complex was treated with protein 
denaturants such as SDS and proteinase K DNA, strand breaks were revealed 
[single (Muller et a1., 1988) and double (Wang, 1985)]. These drugs are 
effectively converting the enzyme 
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Figure 1.15. A model for drug-induced topoisomerase II mediated 
DNA cleavage and cell death, 
A, Unbound topoisomerase IT and substrate DNA, 
Cell Death 
B. Reversible formation of a non-cleavable tapa IT-DNA complex, 
C, Reversible formation of a drug induced cleavable complex, 
D. Revealing of a double strand break by 50S, 
E, Cellular processing of cleavable complex resulting in cell death, 
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into a 'cell poison' . 
1.7.3 Type I topoisomerases 
These enzymes break one strand of the DNA helix, allowing the adjacent 
strand to pass through [or rotate around the phosphodiester bond 
opposite the nick] before resealing. The DNA linking number is changed 
by one. Topoisomerase I (reviewed by Gellert, 1981; Lock and Ross, 
1987) is a single polypeptide with a molecular mass of 100,000 Da. It 
does not require ATP for its action (Liu, 1983). Topoisomerase I has 
also been shown to be a target for some antitumour agents, including 
camptothecin (Avemann et al., 1988). The mechanism of action is 
ana1agous to that described for topoisomerase II targeting drugs, with 
formation of a cleavable complex [on a single strand] with the enzyme 
covalently bound to the 3' phosphoryl end of the break and a free 5' 
hydroxyl end [see figure 1.16]. Treatment with denaturants results in 
revealing of single strand breaks. 
Cleavable complex formation results in formation of a bulky DNA-enzyme 
adduct, protein concealed strand breaks and an inhibition of enzyme 
function. It is not yet clear which factor is most important in 
expressing cytotoxicity. In addition, there is no clear understanding of 
how topoisomerase cleavable complexes are converted to lethal DNA strand 
breaks in vivo. Avemann et al. (1988) showed that camptothecin induced 
topoisomerase I mediated strand breakage at the replication forks of 
SV40 minichromosomes. Also, Schneider et al. (1989) found that mAMSA 
was maximally cytotoxic in cells undergoing RNA and protein synthesis. 
When RNA and protein synthesis were inhibited mAMSA produced no change 
in the level of cleavable complexes formed, suggesting an active event 
is required for conversion of cleavable complex formation to cell kill 
(Schneider et al., 1989). Topoisomerases have also been implicated in 
the regulation of gene expression. For example topoisomerase II 
cleavage sites have been identified in the regulatory flanking sequences 
of a number of genes including heat shock genes (HSP70) (Yang et a1., 
1985) and the enhancer sequence of immunoglobulin kappa and other genes 
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Figure 1.16. A model for drug-induced, 
topoisomerase I mediated DNA cleavage and cell 
death 
A. Unbound topo I and substrate DNA 
B. Reversible formation of a nonc1eavable 
topo I-DNA complex. 
C. Reversible formation of a drug-induced 
cleavable complex. 
D. Revealing of a single strand break by SDS 
E. Cellular processing of c1eavablecomplex 
leading to cell death 
o = covalent linkage 
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(reviewed by Bodley and Liu, 1988). Topoisomerase II has also been 
implicated in the expression of c-fos oncogene (reviewed by Bodley and 
Liu, 1988). The topoisomerase inhibitor novobiocin has been shown to 
induce expression of heat shock genes in Drosophila (Francis et a1., 
1987). Similarly, VM26 was found to induce heat shock proteins via 
interaction with topoisomerase II (Rowe et a1., 1986). The 
topoisomerase I inhibitor camptothecin was found to inhibit heat induced 
transcription of the HSP70 heat shock gene via interaction at the DNase 
hypersensitive sites of this gene (Rowe et a1., 1986). Furthermore, 
camptothecin mediated DNA strand breakage has been located near to 
transcriptionally active genes (reviewed by Bodley and Liu, 1988). 
mAMSA has been found to mediate DNA cleavage at the c-myc proto-oncogene 
locus (Riou et a1., 1986). Topoisomerase I (Stevsner et a1., 1989) and 
topoisomerase II (reviewed by Glisson and Ross, 1987) have been shown to 
bind to specific DNA sequences. Topoisomerase I (Lim et a1., 1986) and 
topoisomerase II inhibitors (Dillehay et a1., 1987; Anderson and 
Kihlman, 1989) have also been shown to result in an increase in DNA 
sister chromatid exchanges which result in a disruption of gene 
expression. Such sister chromatid exchanges could be responsible for 
the lethality of drug-induced cleavable complexes. This has been 
proposed to be due to exchange of topoisomerase subunits on adjacent DNA 
strands (Pommier et a1., 1985). 
Thus, topoisomerases are likely to be involved in the expression and 
activation of oncogenes. Oncogenes have been shown to be involved in 
tumourigenesis and the maintenance of the transformed phenotype of 
tumour cells (reviewed by Bishop, 1987) [see section 1.2.2]. A link is 
therefore being established between anti tumour drug interactions with 
topoisomerases and effects on the expression of oncogenes. Therefore, 
it is likely that the role of topoisomerases in the control of cell 
growth, cell division and the maintenance of the tumourigenic state is 
the key feature of this enzyme being a target for anti tumour agents in 
proliferative tumour tissue as opposed to normal tissues. 
As described in section 1.6.3 antitumour agents can bring about damage 
to DNA and other cellular macromolecules by the formation of reactive 
drug intermediates or by the formation of oxygen free radicals. In the 
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next section the cellular events which lead to these processes are 
described as well as their effects on macromolecular targets within the 
cell. 
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1.8 Free radical generation by ant1tumour agents 
Before the formation of oxygen free radicals by antitumour drugs is 
ccnsidered the nature, chemistry and biological consequence of these 
radicals needs to be considered. 
1.8.1 The chemiscry of oxygen free radicals 
A free radical is defined as " a chemical entity which contains one or 
more unpaired electrons and is capable of an independent existance". An 
unpaired electron is one that individually occupies one atomic or 
molecular orbital. 
Ground state oxygen has two unpaired electrons of parallel spins [figure 
1.17] each one located in a different Pi* antibonding orbital and is 
therefore a free radical. However, ground state oxygen is not very 
reactive as an oxidising agent since it can only accept electrons one at 
a time due to the spin restriction of the unpaired electrons as they 
both have parallel spin. 
Singlet oxygen [figure 1.17], which is a more reactive form of oxygen 
which is formed by input of energy into ground state oxygen. 16g0 2 is 
not a radical, having an energy 22.4 Kcal above the ground state. 1Ig+ 
is even more reactive [37.5 Kcal above ground state], but usually decays 
rapidly td6g02before reacting with other chemical entities. 1Lg+ 
state can be produced by illumination of biological pigments such as 
flavins and porphyrins in the presence of oxygen [reviewed by Halliwell 
and Cutteridge, 1984]. 
If a single electron is added to ground state oxygen it must enter one 
of the Pi* antibonding orbitals producing the superoxide anion radical 
[°2-], This has a short life span under aqueous conditions and 
undergoes dismutation by reaction (1). The first step in this reaction 
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Figure 1.17 Bonding in the diatomic oxygen molecule. 
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is the protonation of superoxide anion to form a hydroperoxyl radical 
[H02 ·] . 
+- }-L 0 - H02 - + 02 - - 02 + H202 + OH- (1) 
This reaction has a rate constant of 10 5 M- 1S- 1 , which is increased to 
10 9 M- 1S- 1 in the presence of superoxide dismutase (Koppenol and 
Butler, 1985). 
Addition of a second electron to ground state oxygen gives the peroxide 
ion [022-] which is not a free radical. The occupation of antibonding 
orbitals by electrons in the superoxide anion and peroxide radical 
results in a weakening of the 0-0 bond. Addition of two further 
electrons to the peroxide ion (which enter ~*2p orbitals) results in 
destruction of the 0-0 bond and formation of two 02- species. In 
biological systems the peroxide ion is usually protonated to form 
hydrogen peroxide [H202 ] (equation 2). Hydrogen peroxide is stable and a 
good oxidant. Addition of a further two electrons to the peroxide ion 
results in the formation of water (equation 3). 
+4e- +4H+ 2 ° ----.... ~ H2 
(2) 
(3) 
The hydroxyl radical [·OH] is formed by the homolytic fission of the 0-0 
bond in hydrogen peroxide. This can be achieved by heat, ionising 
radiation or a mixture of H202 and transition metal salts 
especially iron (II) and copper salts [Fenton reaction (reaction 4)] 
(reviewed by Walling, 1975). The hydroxyl radical is a highly reactive 
and potent oxidant and has a very short life span. 
(4) 
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The generation of oxygen radicals can have serious implications in the 
cellular environment, as will be described in section 1.9. Formation of 
oxygen radicals is believed to be involved in the cytotoxic effect of a 
number of anti tumour agents and hence has important therapeutic 
implications. 
1.8.2 Free radical formation by quinone anti tumour agents 
A characteristic feature of the quinone moiety is the ability to undergo 
reversible oxidation-reduction. Simple antitumour quinones [eg 2-
methyl-l,4-napthoquinone (menadione)] (figure 1.18 ) can undergo one 
electron reduction to a semiquinone free radical (QH·) [equation 5] or 
two electron reduction to a hydroquinone (QH2). A semiquinone can also 
be formed by comproportionation between a quinone and a hydro quinone 
(equation 6). 
Q - QH' (5) 
-- 2QH' (6) 
These reductions can occur non-enzymatically under physiological 
conditions by reduction with pyridine nucleotides, with cellular thiols 
(eg glutathione), by electron transfer from less electron affinic 
semiquinones or from an oxygen free radical such as superoxide 
anion (reviewed by Powis, 1989). 
Quinones can also undergo enzymatic reduction by flavin containing 
enzymes, resulting in formation of semiquinone free radicals (see figure 
1.19). Enzymes which can catalyse one electron reduction of quinones 
include NADPH cytochrome P450 reductase and NADH cytochrome b5 reductase 
which are the major enzymes involved in reduction of quinones. These 
enzymes normally catalyse transfer of electrons from reduced 
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nicotinamide adenine dinucleotide phosphate (NADPH) and reduced 
nicotinamide adenine dinucleotide [NADH] to cytochrome P4S0 and 
cytochrome bS respectively. These reductases form the flavoprotein 
component of the mixed function oxygenase system located in the 
endoplasmic reticulum of most cell types. The term cytochrome P4S0 
encompasses a range [Johnson, 1979] of monooxygenases that metabolise a 
wide range of xenobiotics by aromatic and aliphatic hydroxylation, 
nitrogen, oxygen and sulphur dealkylation, sulfoxidation and 
epoxidation [Orrenius and Ernster, 1974]. The physiological function of 
the monooxygenases is the metabolism of steroids. The efficiency of 
electron transfer from the reductases to the cytochrome component is 
absolute so the reductases can reduce other electron acceptors such as 
quinones (Bachur et al., 1979) and quinoneimines (Van De Straat et al., 
1987). 
Other enzymes that can catalyse the simultaneous one and two electron 
reduction of quinones include Xanthine oxidase, a cytosolic enzyme which 
is involved in the degradation of purines (requiring the cofactor NADH) , 
NADH-lipoamide oxidoreductase, a member of the pyruvate dehydrogenase 
complex which oxidises pyruvate to acetyl Co A [reviewed by Stryer, 
1988] and NADH dehydrogenase, which is involved in electron transport in 
the mitochondrial electron chain (transfers electrons to ubiquinone) 
[reviewed by Nicholls, 1981]. 
NADPH oxidoreductase (formerly termed DT diaphorase) [Lind, 1982], 
catalyses only two electron reduction of quiones to hydroquinones. This 
enzyme is involved in vitamin K metabolism. The conversion of the 
quinone directly to the hydro quinone is thought to bypass toxic effects 
associated with semiquinone formation [section 1.9]. However the 
hydroquinone can form the semiquinone by reaction with the quinone by 
comproportionation [equation 6]. Under aerobic conditions the semi-
quinone autoxidises to form the superoxide anion and regenerate the 
quinone. The reaction with 02 is rapid with a rate constant [typically 
4.8xl06 M-lsec- l ] which depends on the type of quinone. The quinone 
becomes available for further enzymic reduction in a futile cycle of 
events. This process of repeated semiquinone formation and 
autooxidation back to the quinone is termed redox cycling (reviewed by 
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Hochstein, 1983, and Smith, 1985). The rate limiting step of superoxide 
anion formation is enzymic reduction of the quinone. This depends on 
the substrate specificity for the enzyme as well as its reduction 
potential. The above reactions are controlled by strict equilibria 
between formation of the semiquinone and re-formation of the quinone on 
reaction of the semiquinone with molecular oxygen (equation 7]. The 
direction of the reaction depends on the concentration of the 
semiquinone, molecular oxygen and the rate constants kl and K_ l . 
Q + 0-2 ~. __ --__ Q' 
Types of quinones that undergo enzymic reduction to semiquinones and 
redox cycling (reviewed by Powis, 1989) include menadione (Smith, 1985), 
anthraquinones (reviewed by Powis, 1989), anthracyc1ines (reviewed by 
Gianni, 1983), mitomycin C (Hoey et al., 1988; reviewed by Pritsos and 
Sartorelli, 1986) and aziridinylbenzoquinones reg AZQ (Gutierrez et 
al., 1985 and 1986; Lea et al., 1988) and BZQ (Butler et al., 1989)], 
Fe(III)-b1eomycin (Burger et al., 1981; Scheulen et al., 1981; Turner et 
al., 1989), quinoimmines reg Actinomycin D (Powis et al., 1987; Flitter 
and Mason, 1988)] and Lapacho1s (reviewed by Powis, 1989). Figure 1.18 
shows the structures of some of these agents. 
1.B.3 Formation of superoxide anions a precursor for 
production of other oxygen radicals 
The formation of superoxide anions by quinone redox cycling can lead to 
a cascade of oxygen free radicals with potentially injurious or lethal 
consequences to the cell. The superoxide anion can act as an oxidant 
but is a better reductant (McCord, 1979). The dismutation of this 
unstable free radical either spontaneously [equation 1] or catalysed by 
superoxide dismutase, results in formation of hydrogen peroxide. This 













Figure 1.18 The structure of some redox active antitumour agents. 
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of formation through cellular membranes. In the presence of trace 
amounts of iron (II) salts hydrogen peroxide reacts with superoxide 
anion to form the hydroxyl radical by the so-called iron catalysed 
Haber-Weiss reaction [equation 7, 8 and 9] (reviewed by Halliwell and 
Gutteridge, 1985). 
Fe3+ + 0 - ----- Fe2+ + 0 
2 • 2 (7) 
(8) 
(9) 
Regeneration of iron (II) required for further iron catalysed Haber-
Weiss reaction can be carried out by superoxide anion [equation 7] or a 
semiquinone free radical under anaerobic conditions [equation 10] 
(reviewed by Powis, 1989). 
-H 
(10) 
The Haber-Weiss reaction can also give rise to singlet oxygen [McCord, 
1979] (equation 11). 
(11) 
These reactions can also be catalysed by copper salts (equations 12, 13, 
14, 15 and 16], with resultant hydroxyl radical formation (reviewed by 









The hydroxyl radical is a highly reactive and potent oxidant which will 
react immediately with the nearest cellular component upon its 
formation, causing damage [see section 1.9]. A schematic diagram of 
quinone redox cycling and resultant reactive oxygen formation is shown 
in figure 1.19. The formation of oxygen free radicals by redox cycling 
of anti tumour quinones is associated with a number of toxic consequences 








~ 0" ~ I Hydrogen peroxide, 




semiquinone free radical 
Figure 1.19 Reductase mediated redox cycling of quinone 




1.9 Consequences of oxygen free radical generation in cells 
1.9.1 Protein damage and inactivation 
Exposure of proteins to oxygen free radicals has been shown to result in 
aggregation and fragmentation (Davies, 1987), amino acid modification 
(Davies et al., 1987a), modification of secondary and tertiary structure 
(Davies and Delsignore, 1987) and an increase in proteolytic 
susceptibility (Davies et al., 1987b). Intracellularly, this could lead 
to inactivation of vital proteins such as enzymes. Oxygen free radicals 
have been shown to oxidise the sulphydryl groups of functional and 
structural proteins including enzymes (Slater, 1984). This process 
involves hydrogen abstraction from the thiol groups of the protein 
(Slater, 1984). 
1.9.2 Lipid peroxidation 
Lipid peroxidation (shown in figure 1.20) is defined as the oxidative 
deterioration of polyunsaturated lipids. This process involves the 
reaction of oxygen free radical species with polyunsaturated lipids to 
form lipid radicals and semi-stable lipid hydroperoxides (reviewed by 
Bus and Gibson, 1979; Halliwell and Gutteridge 1985). Lipid 
peroxidation can be divided into three distinct stages:-
a) Initiation:- Polyunsaturated lipids are susceptible to lipid 
peroxidation as the presence of a double bond weakens the C-H bond 
on the adjacent carbon atom to the unsaturated C=C bond. These 
allylic hydrogens are therefore considered as being partially 
activated and susceptible to abstraction by oxidants such as singlet 
oxygen and hydroxyl radical. The product of initiation is a lipid 
radical (L·) [equation 1]. 
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There is some evidence which shows that initiation is carried out by 
an iron chelate catalysed Haber-Weiss reaction as in equation 2 and 
3 [reviewed by Halliwell and Gutteridge, 1984]. 
(2) 
----1~~ ADP-Fe3+ + OH + OH- (3) 
In opposition to this, other workers propose that the initiating 
species is an ADP-perferryl ion complex [ADP-Fe3+-o2/ ADP-Fe 2+-o2-] 
(Minotti and Aust, 1987, Ursini et a1., 1989). 
b) Propagation:- The lipid radical [L·] formed by initiation 
rearranges to form a conjugated diene [figure 1.20]. This then 
reacts with oxygen to give a lipid peroxy radical [LOO·] (equation 
4). The peroxy free radical can abstract a hydrogen atom from 
another unsaturated lipid molecule forming a lipid hydroperoxide 
[LOOH] and another lipid free radical [L·] (equation 5). Thus 
another chain of lipid free radical formation is initiated. 
L· + 0 ----II~~ LO . 2 2 (4) 
LOO· + LH --....... ~~ LOOH + L· (5) 
Lipid hydroperoxides can decompose in the presence of transition 
metal complexes to form alkoxy and peroxy free radicals [equations 6 
and 7 respectively]. 
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LOOH + Mn+ ---•• ~ LO' + OH- + M(n+l)+ (6) 
LOOH + M(n+l)+ ---•• ~ LOO' + H+ + Mn+ (7) 
c) Termination:- this involves formation of non free radical products 
[aldehydes, ketones, ethers, acids, ethane and pentane] by reaction 
of two lipid radicals, stopping the propagation process [equations 
8, 9 and 10]. 
L' + L' ---•• ~ non radical [stable] species (8) 
L' + LOO' ----•• ~ non radical [stable] species (9) 
LOO' + LOO·----•• ~non radical [stable] species (10) 
1.9.2.1 Consequences of lipid peroxidation 
The self propagating nature of lipid peroxidation can lead to oxidative 
stress in the cell with several possible consequences. However, it is 
difficult to dissociate causative lipid peroxidation and peroxidation 
due to cell death. 
1. The intimate positioning of membrane lipids and proteins allows 
interaction between them. Lipid peroxidation can cause lipid-lipid 
and lipid-protein cross linking and in this way has been shown to 
inactivate enzymes and associated proteins including cytochrome P450 
and calcium-ATPases [Kappus, 1985]. 
2. Peroxidation of membranes leads to cell and organelle permeability 
changes as a result of loss of structural integrity of the membrane 
(reviewed by Richter, 1987). 
3. Lipid peroxidation products [radical and non radical] have been 
shown to cause damage to DNA (Vaca, 1988), including nucleic acid 
56 
base damage and ribose sugar ring opening and cleavage. The site of 
nuclear membrane-chromatin attachment is a possible site for lipid 
radical attack on DNA. 
4. Production of lipid radicals places a demand on glutathione 
dependent detoxific~tion mechanisms [section 1.10.1]. This system 
requires NADPH for reduction of oxidised glutathione. Thus cellular 
reducing equivalents can be depleted leading to a compromise of 
essential cellular processes and a reduced ability of the cell to 
cope with oxidative stress. In support of this glutathione 
deFleting agents have been shown to increase lipid peroxidation in 
cells [Comporti, 1987]. Kappus, (1985) and Tribble et al. (1987) 
discuss the significance of quinone redox cycling with relation to 
lipid peroxidation. 
1.9.3 DNA damage caused by oxygen free radicals 
The formation of oxygen radicals has been shown to have many damaging 
effects to DNA structure and function and subsequent detrimental effects 
on cell survival. Most information on radical damage to DNA has been 
gained from studying the effect of X-ray and gamma radiation on isolated 
or cellular DNA. Quinone antitumour agents, hydrogen peroxide and other 
oxy-radical generating systems have been shown to produce similar 
effects to irradiation. In either case the critical species in DNA 
damage is considered to be the hydroxyl radical. With antitumour agents 
this is formed by redox processes via the iron catalysed Haber-Weiss 
reaction [see section 1.8.2]. Irradiation produces hydroxyl radicals 
via photochemical processes or by direct radiolysis of water molecules 
(reviewed by Ward, 1985). 
The integrity of DNA is essential for the survival of cells. The cells 
of an organism are continually exposed to physical and chemical hazards 
that can lead to DNA damage. Consequently cells have a wide range of 
repair systems available to counteract this. In order to assess the 
consequences of DNA lesions, the availability and capacity of repair 
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processes needs to be considered. 
1.9.3.1 Formation of single [SSB] and double strand [DSB] 
breaks 
It has been proposed that hydroxyl radical formation can be 'site 
specific' being formed close to the DNA duplex by the iron catalysed 
Haber-Weiss reaction, catalysed by transition metal ions bound to the 
DNA (Ward, 1987; Chevion, 1988) [equation 1-5] . 
+ M + H202 • M2+ + OH' (1) 
DNA + OH' • DNASSB (2) 
M2+ ~~ (3) 
+ M + H202 • ~+ + OH' (4) 
DNASSB + OH' • DNADSB (5) 
Equation 3 involves reduction of the metal ion by a free 
radical species such as superoxide anion or drug semiquinone or a 
cellular thiol such as glutathione (see section 1.10.1). A double 
strand break will be formed if after generation of a single strand break 
another hydroxyl radical is produced by the metal ion bound at this or 
an adjacent site resulting in 'multiple hits' on the DNA. 
It is thought that hydroxyl radical attack on DNA occurs primarily by 
hydrogen abstraction from the 2' and 3' carbon atom of deoxyribose, 
followed by hydrolysis to generate an SSB [see figures 3.19 and 3.20]. 
Alternatively sugar modification ca~ lead to purine/pyrimidine base loss 
and a resultant apurinic/ apyrimidinic site [see section 1.6.3.1 and 
figure 3.21]. Another site of reaction is addition to the carbon double 
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bond of DNA bases [see figure 3.22]. At the site of an SSB a 
deoxynucleotide is deleted leaving 3' or 5' monophosphate termini which 
are favourable for enzyme repair. However, saturation of the repair 
process may lead to lethal damage especially when the SSB is unstable 
and decays to an irrepairable state if not repaired quickly. 
When two adjacent damaged sites occur on opposite strands the result is 
a DSB. This has a low probability compared to SSB. Alternatively, it 
is claimed that one hydroxyl radical can give rise to a DSB by radical 
transfer [interstrand H-transfer] from one strand to another [Schulte-
Frohlinde, 1987]. 
Figure 1.21(a) illustrates a DSB which will possibly be lethal to the 
cell as repair processes cannot repair it effectively. Even if the 
strand break is resealed, base loss and hence a loss of DNA template 
integrity will occur. Additionally, the diffusion of the DNA strands 
away from each other may make repair difficult. Figure 1.21(b) and (c) 
illustrate staggered SSB. It is not known whether these breaks are 
repairable. 
1.9.3.2 Base damage or loss and strand breakage 
Reaction of DNA with the hydroxyl radical produces a series of base 
modifications (reviewed by Wallace, 1987). Pyrimidines, and in 
particular thymidine are more susceptible to hydroxyl radical attack 
than purine bases [see figure 3.22]. This is because hydroxyl radicals 
are electrophilic and hence when they react with carbon-carbon double 
bonds they react with the site of highest electron density. The C5 
position on pyrimidines is particularly vulnerable to hydroxyl radical 
addition with a C6 carbonyl radical the result. The formation of base 
radicals has been confirmed by esr spectrometry (Cullis and Symons, 
1986). Attack can also occur on the C6 position resulting in a C5 
carbonyl radical. The hydroxyl radical adducts of the pyrimidine react 
rapidly with one another to form dimers, or disproportionation may 
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Figure 1.21. Schematic representation of types of 





occur yielding a series of products (Dizdaroglu and Bergtold, 1986; 
Dizdaroglu et a1., 1987). The glycols predominate in these products. 
Molecular oxygen can react in a diffusion controlled manner with the 
carbonyl radicals forming peroxyl radicals, which on reaction with 
hydroxide ions at the Nl position results in peroxyl anions. 
Elimination of superoxide anion from this yielding the corresponding 
isopyrimidine (Von Sonntag, 1988). 
Purines also react at C4 , Cs and C8 with hydroxyl radicals giving rise 
to a number of unimolecular reactions such as ring opening and formation 
of radical cations [Von Sonntag, 1988; Teebor et a1., 1988] 
The conversion of base radicals to modified bases can lead to 
decomposition or hydrolysis at the glycosidic linkage resulting in 
apurinic or apyrimidinic sites [AP's]. These sites are alkali labile 
and on treatment with alkali hydrolysis of the phosphodiester bond is 
promoted resulting in single or double strand breakage. These sites are 
susceptible to alkaline phosphatase endonucleases (AP) which can also 
result in strand breakage. The base radicals may also react with the 
sugar moiety to give strand breaks (Von Sonntag, 1988). 
Altered DNA bases will be misread during DNA replication or 
transcription and are thus detrimental to the cell unless excised by 
specific endonucleases. In the case of figure 1.21(d) loss of 
information will be the result as bases on opposite strands are modified 
and will be excised. It is not known if offset base damage [figure 1.21 
(e) and (f)] is repairable. In a similar manner to that described for 
strand breakage, one hydroxyl radical can damage complementary or 
neighbouring base pairs by radical transfer [Baverstock and Cundall, 
1988]. 
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1.9.3.3 DNA interstrand, intrastrand and DNA-protein 
cross1inks 
Hydroxyl radicals can lead to DNA crosslinking or DNA-protein cross links 
[Teebor et a1., 1988]. Cross1inks between DNA and histones and other 
nuclear proteins have been identified (Oleinick et a1., 1987). This 
damage is also believed to occur due to formation of radical species 
within the DNA (or protein) molecule. The repair mechanism of such 
cross1inks has not been identified therefore cross linking might 
represent lethal damage. 
The net effect of the types of DNA damage described above is a 
disruption of DNA function which is likely to range from damage to a 
specific gene involved in essential cellular processes to disruption of 
DNA relication and RNA transcription. Section 1.6.3 describes DNA 
lesions caused by anti tumour agents which are not initiated by radical 
processes. 
1.9.3.4 DNA repair mechanisms 
There are likely to be many types of enzyme involved in repair of 
oxidative damage to DNA. These include:- i) formamidopyrimidine-DNA 
glycosylase, which catalyses the release of potentially cytotoxic purine 
residues, ii) a DNA glycosy1ase which releases urea (a remnant of urea 
and several other derivatives with fragmented pyrimidine rings including 
thymine glycol (Doetsch et a1., 1986), iii) Mg2+ independent 
endonuclease which recognises apurinic sites on DNA (reviewed by 
Lindahl, 1987). A simplified scheme of DNA repair involves excision of 
the damaged base by a DNA glycosy1ase followed by removal of adjacent 
bases by a repair endonuclease which cuts the DNA phosphodiester 
backbone at the site of base excision. These events are followed by 
catalysis of DNA repair synthesis by DNA polymerase and resealing of the 
nick left in the repaired strand by a DNA ligase. These repair 
processes are also able to repair single, and with less efficiency, 
double DNA strand breakage (reviewed by Alberts, 1983; Bohr et a1., 
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1987). Other enzymes such as 06-a1ky1guanine alkyl transferase can 
repair alky1ated DNA sites produced by monofunctional a1kylating agents 
and bifunctional alkylating agents (reviewed by Fox and Roberts, 1987). 
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1.10 Cellular protection against the formation of oxygen 
free radicals 
1.10.1 Enzymic defences 
Sections 1.8 and 1.9 describe the formation of oxygen free radicals and 
how they are detrimental to the cell. This subject area is reviewed by 
Ishikawa (1986) and Southern and Powis (1988). Two types of enzymes 
metabolise hydrogen peroxide in cells namely catalases and peroxidases. 
1. Catalase is a a peroxisomal enzyme (reviewed by Halliwell and 
Gutteridge, 1985) and consists of four protein subunits, each of 
which contains a haem [Fe(III)-protoporphyrin] group bound to the 
active site. The reaction mechanism is:-
Catalase-Fe(III) + H202 ----.... ~Compound I 
Catalase-Fe(III) + 2H20 + O2 
Compound I is thought to be an Fe(IV) intermediate between Fe(III)-
HOOH [ferric peroxide] and Fe (V)-O. This enzyme will O')(IO\S8') a wide 
range of substrates including methanol and ethanol (reviewed by 
Mason and Chignel1, 1982). 
2. Glutathione peroxidase [reviewed by Meister and Anderson, 1983] 
catalyses the oxidation of reduced glutathione [GSH] to the oxidised 
form [GSSG] during the reduction of hydrogen peroxide and lipid 
peroxides to water and alcohols respectively (Niki, 1987): 
GSSG + 2~0 
2LOOH + 2GSH -------------.. GSSG + 2LOH 
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Phospholipase A is an enzyme which cleaves lipid peroxides from 
membranes which are then substrates for glutathione peroxidase. 
Glutathione peroxidase consists of four subunits each containing one 
atom of selenium at the active site in the form of selanocysteine 
which is the amino acid cysteine with the sulphur atom replaced by 
selenium. GSH reduces the selenium and the reduced form of the 
enzyme reacts with hydrogen peroxide. The ratios of GSH:GSSG need 
to be kept high by the cell in order to provide this protective 
mechanism. This is maintained by the glutathione reductases which 
consist of two protein subunits, each with the flavin FAD at the 
active site-
GSSG + NADPH + H+ -----------.a 2GSH + NADP+ 
NADPH reduces FAD which then reduces a disulphide bridge (S-S) 
located between two cysteine residues in the enzyme. The two 
protein-SH groups interact with GSSG and reduce it to two GSH 
groups. NADPH is provided by the pentose phosphate pathway which 
involves the action of the enzyme glucose-6-phosphate dehydrogenase 
(equation 1) followed by the action of 6-phosphog1uconate (6-PG) 
dehydrogenase (equation 2). 
glucose-6-P + NADP+ --- 6-phosphogluconate + NADPH + H+ (1) 
6-PG + NADP+ --- CO2 + NADPH + H+ + ribulose-5-P (2) 
As NADPH is oxidised, the pentose phosphate pathway or pentose 
phosphate 'shunt' increases its rate of production of NADPH. 
Besides acting in concert with glutathione peroxidase, glutathione 
can act directly as a scavenger of hydroxyl radicals and singlet 
oxygen. Additionally many toxic compounds are conjugated with GSH 
by glutathione-S-transferase enzymes during metabolism (reviewed by 
Moldeus and Quangan, 1987; Ross, 1988). Figure 1.22 illustrates the 
complex relationship of the glutathione pathway to other cellular 
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processes. 
Superoxide dismutase [SOD] (reviewed by McCord, 1979 and Bannister et 
a1. I 1987) was first identified by McCord and Fridovich (1969). Copper-
zinc SOD is located in the cytoplasm and has a molecular weight of 32000 
and contains two protein subunits each of which has an active site 
containing one copper ion and one zinc ion. Its function is to cata1yse 
the dismutation of superoxide anions:-
+2H+ 
02- + 02- --- H202 + 02 [ground state] 
The zinc ions [Zn2+] do not participate in the catalysis but stabilises 
the enzyme. The copper ions function in this dismutation by undergoing 
alternate oxidation and reduction:-
2+ -Enzyme-Cu + 02 
+ - 2 + 2+ ° Enzyme-Cu + 02 + H ------~~~ Enzyme-Cu + H2 2 
Another type of SOD is also found in the mitochondrial matrix. This has 








Figure 1.22 Diagrammatic representation of the inter-relationship 
of glutathione [GSH] with other cellular systems. 
(Mitchell and Russo, 1987) 
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1.10.2 Non-enzymic defences 
These are reviewed by Halliwell and Gutteridge (1984 and 1988). There 
are several important non enzymic antioxidants located in the cell. 
Ascorbic acid [vitamin C] is a cofactor for the enzymes proline 
hydroxylase, lysine hydroxylase and dopamine-beta-hydroxylase. However, 
it also acts alone as a reducing agent and can detoxify various organic 
radicals. Donation of one electron by ascorbate [figure 1.23] gives the 
semihydroascorbate radical. This can be further oxidised to 
dehydroascorbate. The semihydroascorbate radical is not very reactive 
and disproportionates:-
2 semihydroascorbate ascorbate + dehydroascorbate 
Ascorbate will react rapidly with superoxide anion, hydrogen peroxide 
and hydroxyl radicals:-
- + Ascorbate + 02 + H H202 + semihydroascorbate 
The enzyme dehydroascorbate reductase converts oxidised ascorbate back 
to the reduced form at the expense of GSH:-
2 dehydroascorbate + 2GSH-------.-GSSG + ascorbate 
Alpha-tocopherol [vitamin E] is a lipid soluble antioxidant [figure 
1.23] which protects against lipid peroxidation. Vitamin E reacts with 
lipid peroxy radicals to produce vitamin E radicals that are 
insufficiently reactive to participate in propagation reactions 
[equation 1]. Therefore vitamin E is termed a chain terminating 
antioxidant. The vitamin E radicals formed can be reduced back to 
vitamin E by ascorbate [see figure 1.23]. 
Vitamin E + R02 ' -------.. R02H + Vitamin E' 
(1) 
Other vitamin E type antioxidants include the sulphydryl group 









[r: = lipid radical] 
Figure 1.23. Interaction of Vitamin E and Vitamin C. 
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1.11 Measurement of DNA damage in mammalian cells 
Several assay methods are available for measuring DNA damage by 
antitumour agents in vivo. These include filter elution, HPLC 
determination of base damage for example detection of 8-hydroxyguanine 
(Floyd et a1., 1988; Kasai et a1., 1986), the fluorescent enhancement 
assay for DNA unwinding (Kanter and Schwartz, 1982), measurement of the 
viscosity of alkaline cell 1ysates (Marshall and Ralph, 1982)] and 
sedimentation of DNA fragments through alkaline sucrose gradients (Lett, 
1981). Some of these techniques are useful in making a rapid determi-
nation of total strand breakage, or are useful in determination of 
specific types of DNA damage. The filter elution technique enables 
quantification of a wide range of different types of damage to DNA which 
is not possible by other techniques. Prior to the advent of this 
technique the most common method for single strand break determination 
was sedimentation of DNA through alkaline sucrose gradients using 
centrifugation. This technique however had var~ous difficulties 
attached to its use (Lett, 1981). In recent years therefore the filter 
elution technique has come to the fore as a standard method for 
determining the extent and type of DNA damage by irradiation and other 
agents. 
1.11.1 Filter elution of DNA 
This technique, developed by Kohn et a1. (1976) utilises 
filters to discriminate DNA strand breaks in mammalian cells produced by 
cytotoxic drugs or radiation. The filters are used as a mechanical 
barrier to the passage of large DNA strands. Variations in this 
technique allow determination of single strand breaks [SSB], DNA-protein 
cross links [DPC] , DNA interstrand cross links [DIC], DNA double strand 
breaks [DSB] and protein concealed single strand breaks [PSSB] (Kohn et 
a1., 1976). The methodology is fu1~y described in section 3.2.4. The 
elution rate of DNA (through the filter) isolated from cells treated 
with a particular agent is determined by collecting eluted samples of 
the DNA over a long time period and measuring the DNA content by 
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scintillation [if the DNA has been initially radiolabelled] (Kohn et 
a1., 1976) or fluorometrically using the DNA intercalating fluorescent 
dyes 3,5-diaminobenzoic acid dihydrochloride [DABA] (Kissane and Robins, 
1958) or bisbenzamide [Hoechst 33258] (Erickson et a1., 1980). 
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1.12 Detection of Free radicals 
1.12.1 Biochemical methods 
There are two biochemical methods available for detection of superoxide 
anions in biological systems. The first method is dependent upon the 
reduction of acetylated cytochrome c by the superoxide anion, this 
reduction being followed by measuring the absorbance change at 550nm. 
Acetylation of more than 60% of the lysine residues of horse heart 
ferricytochrome c results in more than a 95% decrease in its ability to 
be reduced by microsomal reductases. However, its ability to be reduced 
by superoxide anion is maintained. Therefore this derivative is useful 
in detecting superoxide anions in systems containing cytochrome c 
reductases or oxidases. This assay is more specific if superoxide 
dismutase is used to confirm that acetylated cytochrome c is being 
reduced by superoxide anions (Azzi et al., 1975). 
The second method, the adrenochrome assay, is based on the oxidation of 
adrenaline to adrenochrome by superoxide anions (Misra and Fridovich, 
1972) [see figure 1.24]. However, this assay has several disadvantages 
including the oxidation of adrenaline by hydroxyl radicals and 
autooxidation of adrenaline to adrenochrome (Heikkila and Cohen, 1973). 
This assay can be made more specific by the use of superoxide dismutase 
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Adrenochrome 
Figure 1.24. Detection of superoxide anions by adrenochrome 
formation. 
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1.12.2 Electron spin resonance spectrometry 
1.12.2.1 Principles 
Esr spectrometry (reviewed by Carrington and McLachlan, 1979; Foster, 
1984) is based on the fact that the spin of an unpaired free electron 
produces a small but detectable magnetic moment. Yhen an unpaired 
electron is subjected to an external magnetic field, the magnetic 
moment of the electron can take up two possible orientations, parallel 
or antiparallel with respect to the applied magnetic field and hence can 
occupy two different energy levels. Since electrons in the parallel 
orientation have lower energy, this is the preferred orientation. 
Electromagnetic radiation in the microwave frequency range can induce 
transitions or changes in spin orientation (resonance) from the lower to 
the higher energy level. This energy is equivalent to the energy 
difference between the two states [see figure 1.25]. Mathematically, 
this is expressed as the energy difference (~E) between the two spin 
states, which is proportional to the applied field, H, the value for the 
electron's magnetic moment, B and the spectroscopic splitting constant, 
g. Therefore, the equation for transition between energy 
levels for an unpaired electron is:-
~E=gBH 
An esr spectrometer detects the resonance of an unpaired electron by 
varying the magnetic field in relation to the microwave frequency. The 
first derivative of the absorption curve is recorded, representing a 
rate of change of absorption. This allows better sensitivity and 
resolution [see figure 1.26]. The area under the absorption curve is 
proportional to the effective spin population and is therefore 
indicative of the free radical concentration. 
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6E = h" = g(JH 
H=Q 
Figure 1.25. The splitting of electron energy levels by a magnetic field 
The difference in the energy between the levels with opposed electron spin 
is ~E=hv=g iSH, where v is the frequency of the absorbed radiation, g is the 
spectroscopic splitting factor, is is the Bohr magneton and H is a magnetic 







Magnetic field strength, H. 
Figure 1.26. Curves used m the presentation of electron spm resonance 
spectra. 
(a) the variation in the absorption of microwave power of the sample as the 
magnetic field is varied. (b) the first derivative of the microwave power 
absorption is plotted against the magnetic field to give the representation 
usually depicted for esr spectra. wand h represent the peak to peak width 
and height respectively. The area under the curve or peak to peak height for 




In a magnetic field an unpaired electron in a radical possesses, in 
addition to its spin angular momentum, a small amount of extra orbital 
angular momentum. The interaction between these, called spin-orbital 
coupling, results in the electron having a slightly different magnetic 
moment from that of the free electron. Consequently, the condition for 
resonance is altered, g being dependent on the radical. Hence, for a 
given frequency, radicals with different g values resonate at different 
field strengths, the g value being characteristic for a given radical. 
1.12.2.3 Detection of oxygen free radicals using spin 
trapping agents 
Free radicals can only be detected by esr if they are sufficiently long 
lived. However, oxygen free radical species are so reactive that they 
never reach the steady state levels required for detection by esr. 
Spin trapping techniques (reviewed by Mason, 1984; Samuni et al., 1986; 
Pou et al., 1989) can be used to overcome this problem. This method 
involves the use of a compound, usually a nitrone or nitroso compound 
[eg DMPO, figure 2.26] that can form a more stable nitroxide radical by 
reacting with short lived species such as superoxide anions and 
hydroxyl radicals. In this way the short lived species is 'trapped' as 
a species which can be detected directly by esr. In addition, hyperfine 
splitting constants of the adduct can provide information on the identi-
ty of the original radical [for example see figure 2.3]. Hyperfine 
splitting arises from the interaction between a nuclear magnetic moment 
with that of the unpaired electron [see figure 1.27]. The type of spin 
trap used depends on the lipophilic or hydrophilic nature of the 
environment in which the radical is generated. 
77 
Number of Equivalent 
Nuclei 
1: 1 
1: 2 : 1 
Line Intensity 
1:4:6 :4:1 
Figure 1.27. The effect of interaction of the electron with increasing 
numbers of nuclear spin of 1/2. The bottom line shows the signal which 
would be observed, the intensity of each line of the signal being given by 
the figures beneath the splitting diagram. 
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1.12.3 Strand breakage of plasmid DNA as an indicator of 
free radical formation 
This assay utilises strand breakage of pBR322 plasmid DNA as an 
indicator of oxygen free radical formation by radiation, enzymically or 
chemically reduced quinone antitumour agents and other radical 
generating systems. 
The genetic material of a bacterial cell is contained in a single double 
helical DNA molecule in the form of a closed circle. This 'chromosome' 
carries all the genes required for reproduction and propagation of the 
bacterium. Many bacteria also contain extra-chromosomal DNA in the form 
of small circles, known as plasmids. These carry genetic information 
for a variety of special functions including antibiotic resistance, 
toxin production and promotion of bacterial conjugation (reviewed by 
Stanier et al., 1983). Plasmids can replicate independently of the 
chromosomal DNA, hence there may be many copies of a plasmid per 
bacterial cell. Plasmid pBR322 is found in Escherichia coli where it 
confers resistance to the antibiotics ampicillin and tetracycline. 
Plasmid pBR322 recA- is used for strand breakage studies as the presence 
of this repair enzyme causes formation of undesirable DNA species of 
different molecular weight [concatomers]. The basis for the isolation 
of this plasmid is described by Boffey (1983). The bacterial cells 
containing pBR322 are selected for by growing them in the presence of 
ampicillin. The amount of plasmid DNA can be enriched in relation to 
chromosomal DNA by selectively inhibiting chromosomal DNA replication. 
The plasmid DNA is separated from the chromosomal DNA by taking 
advantage of the large difference in molecular weight of the two species 
using isopycnic ultracentrifugation with a caesium chloride density 
gradient (reviewed by Williams and Wilson, 1983). 
Plasmid pBR322 DNA in its native form consists of double stranded 
supercoiled [form I] DNA (figure 1.28). The supercoiling of this 
molecule places it under torsion. If one of the strands is nicked the 
strands unwind to give relaxed open circular [form II] DNA. If the 
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Form I (supercoiled) DNA 
Form II (open circular or nicked) DNA 
Form III (linear) DNA 
Figure 1.28 The forms of pBR322 plasmid DNA. 
80 
complementary strands are both nicked in an adjacent position [double 
strand nick] the result is linear [form III] DNA. These DNA species are 
resolved by submarine gel electrophoresis. 
1.12.3.1 Principles of agarose gel electrophoresis 
Agarose gels consist of a complex network of polymeric molecules and are 
used for separation of DNA fragments ranging from several hundred to 
20,000 base pairs. At neutral or alkaline pH the DNA phosphate groups 
give rise to a uniform negative charge per unit length of the DNA mole-
cule. Therefore in an electric field the DNA moves toward the positive 
pole, at a rate dependent on its size. If the molecules are in a gel 
they have to move through the pores of the gel as they move toward the 
positive pole, their speed depending on their size and shape. Thus the 
three forms of pBR322 DNA travel at different speeds through agarose 
gel. The highly compact form I DNA is the most mobile and travels 
fastest through the gel. This is followed by the rod shaped form III 
DNA which can travel 'end on' through the pores of the gel. The least 
mobile species is the non-rigid open circular form II DNA. 
The separated DNA species in the gel are visualised by staining with the 
intercalating dye ethidium bromide (figure 1.11), as little as 0.05ug 
of DNA in one band can be detected as visible fluorescence upon 
illumination of the gel with ultra violet light (Old and Primrose, 
1985). In order to quantify the DNA species on the gel a photograph is 
taken and the negative image analysed by scanning laser densitometry. 
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1.13 Development of the anthracyclines 
In the 1950's Farmita1ia research laboratories, Milan initiated a 
programme to study anticancer compounds produced by bacteria isolated 
from soil. By 1957 a colony of Streptomyces caero1eorubidus which 
produced a red pigment was isolated. The antibiotic [daunorubicin] 
isolated from this strain was found to have potent anti leukaemic 
activity. This agent was simultaneously discovered by Rhone Pou1enc SA 
in France. Later the antitumour antibiotic Adriamycin [doxorubicin] was 
isolated from Streptomyces peucetius and found to have more potent 
antitumour activity and a wider spectrum of activity than daunorubicin. 
Both of these anthracyc1ine antibiotics are characterised by a planar 
anthraquinone chromophore attached to an amino sugar- daunosamine [see 
figure 1.29]. By 1974, doxorubicin was on the market and has since 
been one of the most used anti tumour agent in a wide range of human 
neoplasms [reviewed by Goodman, 1986] including leukaemia, lymphoma, 
multiple myeloma as well as solid tumours including breast tumours. 
However the use of doxorubicin has been associated with a cumulative 
dose limiting cardiotoxicity as well as myelosuppression. In 
consequence anthracyc1ines based on doxorubicin have been synthesised to 
investigate whether modifying the structural and stereochemical 
properties alleviate the toxic effects of and improve the therapeutic 
activity of this agent which is inactive in the treatment of melanoma, 
colon and renal carcinoma. New generation anthracyclines, which have 
promising antitumour activity but reduced cardiotoxicity, are currently 
undergoing clinical trials. These include anthracyc1ines modified at 
the aglycone moiety such as idarubicin, esorubicin, menogari1 and 
epirubicin [see figure 1.30]. Epirubicin is the most promising of these 
analogues due to similar potency but reduced cardiotoxicity compared to 
doxorubicin (Johnston and Glazer, 1984». Other anthracyc1ines, 
modified at the sugar moiety have been developed. Of these 4'-
demethoxy-4'-O-methy1odoxorubicin has proven to have a very high 
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Figure 1.29. Structure of doxorubicin and daunorubicin 
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Figure 1.31 Structure of 4-demethoxy-4-0-methylodoxorubicin 
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1.14 Development of the anthraquinone antitumour agents 
1,4-dihydroxy-S,8-bis«-[(2-hydroxyethy1)amino]ethy1)amino»-9,10-
anthracenedione dihydroch10ride [mitozantrone] (figure 1.32) is an 
anthraquinone anti tumour agent which was discovered simultaneously by 
researchers at American Cyanid Company (Murdock et al., 1979) and 
American Midwest Research Institute (Johnson et al., 1979). 
Mitozantrone originated from a molecule designed to have structural 
features predicted to favour DNA intercalation (planar tricyclic 
chromophore). Mitozantrone was the best compound out of hundreds of 
anthraquinones synthesised. Mitozantrone maintains the N-O-O triangular 
pharmacophore which exists between the oxygens of the aglycone and the 
nitrogen of the amino sugar found in drugs such as doxorubicin. This 
feature was found to be required for antitumour activity (Zee Cheng and 
Cheng, 1983). However, the amino sugar of doxorubicin was considered to 
be associated with side effects such as cardiotoxicity [Traganos, 1983). 
The removal of the aminosugar and the use of basic side chains in 
mitozantrone was intended to diminish cardiotoxicity without altering 
the N-O-O triangle. The structural modification in mitozantrone which 
was found to have the greatest effect on anti tumour activity was the 
presence of the aromatic hydroxyl groups on the 5 and 8 positions of the 
aromatic ring and the presence of the hydroxyethyl groups on the basic 
side chains. 
Mitozantrone was found to be cytotoxic both to proliferative and non-
proliferative tumour cells and had reduced cardiotoxic effects in animal 
systems (Smith, 1983). Clinical studies began in 1979 and since then 
mitozantrone has found to be useful in the treatment of breast 
carcinoma, acute leukaemia and lymphoma. However, side effects include 
myelosuppression and mucositis, although it has reduced gastrointestinal 
and cardiotoxic effects compared to doxorubicin (Lenk et al., 1987). 




Figure 1.32. The structure of mitozantrone 
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Mitozantrone has produced a 33% response rate as a first line agent in 
advanced breast cancer (Saleton, 1987, Bennett et a1., 1988), a 9-64% 
response rate in patients with acute refractory leukaemia (Hiddemann, 
1987) and up to a 43% response rate in acute lymphocytic leukaemia 
(reviewed by Shenkenberg and Von Hoff, 1986). It has also been 
successfully used in acute non-lymphocytic leukaemia (Vorobiof et a1., 
1987), in treatment of lymphoma (Hansen et a1., 1988) and in epithelial 
ovarian cancer (Lawton et a1., 1987). Reviews on recent progress with 
mitozantrone therapy are given by Schenkenberg and Von Hoff (1986) and 
Bonadonna (1987). 
1.15 The development of anthrapyrazole antitumour agents 
Mitozantrone has a reduced cardiotoxicity but a reduced spectrum of 
activity compared to doxorubicin. In attempts to produce a non-
cardiotoxic anthraquinone with a wider spectrum of activity the 
anthrapyrazoles have been developed (Leopold et a1., 1985; Showalter et 
a1., 1987). The cardiotoxicity induced by anthracyclines and 
anthraquinones has been associated with oxygen free radical generation 
[see section 1.16.4]. The rationale behind the development of the 
anthrapyrazoles was to render the electron deficient quinone chromophore 
of anthracyclines and anthraquinones more resistant to enzymic reduction 
whilst retaining the planar chromophore and basic side chains required 
for antitumour activity (Showalter et a1., 1986). The quinone moiety in 
the anthraquinone chromophore was modified to a quasi imino quinone with 
an extra ring incorporated. CI941 (see figure 1.33) the most active of 




Figure. 1.33. Structure of CI941 
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1.16 The mechanism of action of anthracyc1ine antitumour 
agents 
The mechanisms of action of the anthracyclines will be discussed mainly 
with reference to doxorubicin [figure 1.29] as this is the most 
investigated and most clinically useful of this class of agents to date. 
Despite being categorised into distinct divisions there is considerable 
overlap between these mechanisms. 
1.16.1 DNA binding 
The anthracyclines doxorubicin and daunorubicin [figure 1.29] are taken 
up by cells and rapidly locate in the nucleus. These drugs have been 
shown to bind to DNA with physico-chemical characteristics consistent 
with intercalation [Lown, 1983; Aubel-Sadron et al. 1984; Arcamone 
1984] [see section 1.6.2.1]. The anthraquinone chromophore is 
inserted between adjacent base pairs with reciprocal overlap and the 
amino sugar is situated in the major or minor groove with .its charged 
amino group close to the second phosphate anion away from the 
intercalation site. The chromophore lies perpendicular to the base pair 
hydrogen bonds, ring A projects through the intercalation site, rings B 
and C overlap with adjacent base pairs and ring D projects through the 
intercalation site opposite to ring A (reviewed by Gianni et al., 1983). 
The chromophore forms hydrogen bonds between the hydroxyl groups and the 
DNA phosphate groups or the nitrogen atoms of the DNA bases [Wang, 
1987). The amino sugar has been found to be essential for stable DNA 
complex formation. A negative c90perativity model has been proposed for 
anthracycline intercalation in which binding of one drug molecule alters 
the conformation of the neighbouring binding site, preventing drug 
binding [reviewed by Gianni et al., 1983]. At high drug:nucleotide 
ratios an alternative mode of binding is seen in which the amino sugar 
is bound by electrostatic interaction to the phosphate groups of the DNA 
backbone. This external binding results in the chromophore being 
available for other interactions such as iron binding or DNA 
crosslinking. DNA binding is associated with formation of a highly 
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condensed and compacted DNA structure and an overall thickening of the 
DNA fibre in isolated chromatin (Waldes and Center, 1982). The 
intercalation model for doxorubicin refers to isolated DNA. The 
situation in vivo is likely to be far more complex and will depend on 
the conformation of DNA [see section 1.3], presence of binding proteins 
and extent of methylation [see section 1.3.1]. Doxorubicin shows weaker 
affinity for isolated nucleosomal DNA with a higher affinity for linking 
regions (Fritsche et al., 1987; Skalka et al., 1982). 
Daunorubicin shows preference for the bent DNA helices found in 
nucleosomes and unfolds the nucleosome to some degree (Pearlman and 
Simpkins, 1985). 
The base specificity of the anthracyclines has been extensively 
investigated but no consensus of opinion has been reached (reviewed by 
Gianni et al., 1983). Generally there has been good correlation between 
the affinity for DNA of anthracycline derivatives and their cytotoxicity 
(Molinier-Jumel et al ., 1978), however the poor DNA binder N-
trifluoroacetyl adriamycin-14-valerate (AD32) is an exception to this 
rule (reviewed by Gianni et al., 1983). 
DNA binding has been found to be associated with inhibition of DNA and 
RNA synthesis [Kriebardis et al., 1987] and by inhibition of template 
activity of DNA and RNA polymerase [Chuang et al., 1987]. However no 
correlation has generally been found between inhibition of DNA synthesis 
and cytotoxicity of doxorubicin (Siegfried et al., 1983). Furthermore, 
the doxorubicin derivative AD32 inhibits DNA and RNA synthesis but does 
not bind with high affinity to DNA, suggesting DNA binding is not 
critical in this inhibition (Israel, et al., 1987). 
1.16.2 Membrane binding 
The cell membrane is the first barrier encountered by anthracyclines, 
hence membrane effects have been extensively studied. Anthracyclines 
bind avidly to cellular membranes due to their amphipathic nature. 
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Doxorubicin has been found to bind to the negatively charged 
phospholipids cardiolipin (Goormaghtigh et al., 1980) and phosphatidyl 
serine (reviewed by Gianni et al., 1983). Cardiolipin is an important 
constituent of the inner mitochondrial membrane which is involved in 
enzyme function and is found extensively in heart mitochondria and 
tumour cell membranes. Tritton, et al. (1983) propose that this offers 
an explanation for anti-tumour and cardiotoxic effects, as the affinity 
of doxorubicin for cardiolipin is similar to that for DNA. Binding to 
cardiolipin occurs via the protonated amino group on the daunosamine 
moiety (Goormaghtigh et al., 1987). 
An alternative mechanism of binding for uncharged doxorubicin is by 
partition into the hydrophobic areas of the membrane. Burke et al. 
(1988) propose the existence of a low affinity binding site involving 
surface binding via electrostatic interaction of amino group to 
cardiolipin and a high affinity site with the amino group bound as above 
but the aglycone hydrophobically associated with the lipid bilayer. 
Doxorubicin has been found to change the surface charge properties of 
membranes (Kessel, 1979), to perturb lipid structure and fluidity of 
membranes in euoxic (Deliconstantinos, 1987) and hypoxic (Siegfried et 
al., 1983) cells and to alter the permeability of the mitochondrial 
membrane (Croce et al., 1986). 
Structural perturbation by doxorubicin is associated with effects on 
membrane components. Doxorubicin inhibits cytochrome c oxidase, 
coenzyme Q dependent NADH dehydrogenase and succinate dehydrogenase in 
mitochondrial membranes (Goormaghtigh and Ruysschaert, 1984). In 
addition, doxorubicin and its metabolite doxorubicinol inhibit the Na/K 
pump of cardiac sarcolemma, the calcium pump in heart muscle (Boucek, et 
al., 1987) and Na/K ATPase in heart microsomes (Gosalvez et al., 1979, 
Miwa et al., 1986). A specific calcium binding protein has also been 
proposed as a doxorubicin binding site (Canada et al., 1988). 
Doxorubicin also inhibits oxidative phosphorylation, decreases ATPase 
activity and affects the redox state of redox carriers in tumou~ liver 
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and heart mitochondria (Bianchi et a1., 1987). These effects suggest a 
role for membrane effects in cytotoxicity and cardiotoxicity. 
Several workers have shown that doxorubicin, immobi1ised on 
microspheres, is more cytotoxic than free drug without entering cells 
[Tritton et a1., 1983; Rogers et a1., 1983; Wingard et a1., 1985]. 
Moreover, recently agarose bound doxorubicin has been found to be active 
in vivo and in vitro (Hacker et a1., 1989). This suggests membrane 
effects are important in this system. The amino group was not available 
for interaction with the membrane in this system, however the aglycone 
was available for iron binding or redox cycling. Alterations in 
membrane properties have also been shown to be intimately involved in 
resistance of cells to doxorubicin (Montaudon et a1., 1986; Marsh and 
Center, 1987). 
1.16.3 Inhibition of DNA topoisomerase II 
Topoisomerase II is a nuclear enzyme that is involved in control of the 
topology of DNA [see section 1.7.1]. Topoisomerase activity is 
associated with the proliferative status of the cell (Sullivan et a1., 
1987; Markovits et a1., 1987). Doxorubicin was first noticed to 
inhibit this enzyme when single and double strand breaks mediated by 
doxorubicin in L1210 cells were shown to be associated with covalently 
bound protein molecules at the 3' and 5' termini of the breaks (Zwelling 
et a1., 1981). Doxorubicin was found to produce double strand breaks in 
end labelled plasmid pBR322 DNA in the presence of purified 
topoisomerase II and inhibit the strand passing activity of the enzyme 
in the P4 DNA unknotting activity (Tewey et a1., 1984). Strand breaks 
occur due to doxorubicin 'trapping' a cleavable enzyme complex, which 
after denaturation with strong protein denaturants reveals double strand 
breaks [see section 1.7.2]. 
Doxorubicin has been shown to produce mainly protein associated strand 
breaks in many cell lines including human colon adenocarcinoma cells 
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(Johnston et a1., 1983; Broggini et a1., 1988), rat mammary tumour cells 
(Evans et a1., 1986), P388 leukaemia cells (Capranico et a1., 1986; 
Maniar et a1., 1988), human lung fibroblasts and V79 chinese hamster 
lung cells (Lawrence, 1988) and human leukaemic cells (Mcgrath et a1., 
1989). 
Topoisomerase II has also been shown to participate in resistance of 
tumour cells to doxorubicin. Potmesil et a1. (1988) found human 
leukaemic and normal lymphocytes were resistant to DNA cleavage by 
doxorubicin due to possession of low topoisomerase II activity. A 
similar finding was made by Deffie et a1. (1989) who found a direct 
correlation between topoisomerase activity and doxorubicin cytotoxicity 
in doxorubicin sensitive and resistant P388 leukaemic cells. Glisson et 
a1. (1986) found an epipodophyllotoxin [a topoisomerase II inhibitor] 
resistant cell line to be cross resistant to doxorubicin. In addition 
Davies et a1. (1988) found doxorubicin hypersensitive cells were also 
sensitive to the topoisomerase II inhibitors VP16 and mAMSA. 
Clinical evidence for a role of topoisomerase II in cytotoxic action of 
doxorubicin includes the resistance to doxorubicin of tumours such as B 
cell chronic lymphocytic leukaemia which express a low level of 
topoisomerase activity and the sensitivity of other cancers to 
doxorubicin such as lymphoma and acute lymphoblastic leukaemia which 
express high levels of topoisomerase. In epipodophyllotoxin and 
anthracycline hypersensitive cells that express high topoisomerase II 
activity, doxorubicin produced more strand breaks than in normal cells 
(Robson et a1., 1987). 
1.16.4 Free radical formatiom 
1.16.4.1 Formation of free radicals by enzymic reduction of 
anthracyc1ines 
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As described in section 1.8.2 antitumour quinones including 
anthracyc1ines can undergo one or two electron reduction by flavin 
reductase enzymes. Doxorubicin has been found to be one electron reduced 
to form a semiquinone free radical (Sato et a1., 1977, Ka1yanaraman et 
a1., 1980). The semiquinone autoxidises in the presence of molecular 
oxygen [rate constant 4.4xl07M- 1S- 1 ] resulting in formation of 
superoxide anion and consumption of oxygen. This redox cycling process 
has been found to occur in rat (Kalyanaraman et a1., 1980) and human 
liver microsomes (Basra et a1., 1985), in the presence of reducing 
agents such as sodium borohydride (Lawn and Chen, 1981) and in purified 
enzyme systems including NADPH-cytochrome P450 reductase (Bachur et a1., 
1979) and xanthine oxidase (Schreiber et 81., 1987). Additionally, 
semiquinone formation and superoxide generation was detected in heart 
tissues (Thayer, 1977). Other enzymes that can carry out the reduction 
of doxorubicin include nitrate reductase, NADPH-cytochrome c reductase 
and lipoamide dehydrogenase (see section 1.8.2). A general mechanism 
for the mechanism of quinone activation was proposed by Bachur et a1. 
(1978), in which superoxide anion formation leads to a damaging free 
radical cascade involving iron, hydrogen peroxide and hydroxyl radical 
production [see section 1.8.3] resulting in cell damaging processes such 
as DNA damage and lipid peroxidation [section 1.9]. 
The enzymes required for reductive activation of doxorubicin have been 
found in the nuclear envelope, proximal to the DNA a possible site for 
free radical damage (Bachur, 1982, Romano et a1., 1982). Sinha and 
Chigna1l (1979) and Sinha and Gregory (1986) found that one and two 
electron products of doxorubicin and daunorubicin were covalently bound 
to DNA. Addition of DNA to semiquinone generating system results in a 
quenching of the esr signal, indicating that the drug can not be reduced 
when bound to DNA (Peters et a1., 1986). The semiquinone has also been 
found to bind covalently to BSA and microsomal protein in a system of 
liver and heart NADPH-microsomes (Scheu1en et a1., 1982). 
Further evidence for an involvement of reactive oxygen species in 
doxorubicin cell kill comes from investigations on the effect of 
glutathione depleting agents on doxorubicin cytotoxicity. These agents 
95 
reg buthionine sulphoxamine] have been found to enhance doxorubicin 
cytotoxicity in EHp3 carcinoma cells (Lee et a1., 1988), A2780 ovarian 
cancer cells (Hamilton et a1., 1985) and rat hepatocytes (Lavelle and 
Patterson, 1987). Furthermore, Russo and Mitchell (1985) showed that 
doxorubicin was preferentially toxic to V79 cells with depleted 
glutathione levels compared to cells with elevated glutathione levels. 
GSH levels were found to be reduced in doxorubicin treated cells 
indicative of doxorubicin induced oxidative stress (Meijer et a1., 
1987), including HeLa cells (Al-Kabban et a1., 1988). Additionally, 
exogenous glutathione reductase protected hepatocytes from oxidative 
challege by doxorubicin (Babson et a1., 1981). The removal of GSH 
reduces the capacity of glutathione peroxidase to scavenge hydrogen 
peroxide and other peroxides produced by doxorubicin redox cycling. 
Bozzi et a1. (1981) showed that daunomycin cytotoxicity was related to 
the ability of the cells to detoxify hydrogen peroxide by glutathione 
dependent mechanisms. A role for oxygen in doxorubicin mediated cell 
kill is further supported by doxorubicin being selectively toxic to well 
oxygenated tumour cells (Tannock et a1., 1982) and less toxic in hypoxic 
tumour cells (Smith et a1., 1980). 
A role for iron in the cytotoxicity of doxorubicin, possibly via the 
Haber-Weiss reaction (section 1.8.3), is supported by the partial 
inhibition of doxorubicin mediated MCF-7 cell kill by membrane permeable 
iron che1ating agents (Doroshow, 1986a). 
Further evidence for reductive activation and redox cycling by 
doxorubicin comes from studies on lipid peroxidation and DNA strand 
breakage. 
96 
1.16.4.2 Lipid peroxidation 
Polyunsaturated fatty acids in membranes are a vulnerable target for 
attack by oxygen radicals [section 1.9.1]. Lipid peroxidation produced 
by doxorubicin could account for many of the effects associated with 
membrane binding [section 1.16.2]. Doxorubicin has been shown to 
stimulate NADPH dependent lipid peroxidation in mouse heart and liver 
microsomes whilst oxygen radical scavengers and iron chelators diminish 
this activity (Mimnaugh et a1., 1983), in rat liver and heart 
mitochondria and microsomes (Griffin-Green et a1., 1988, Mimnaugh et 
a1., 1982) and isolated rat liver nuclei (Mimnaugh et a1., 1985). Lipid 
peroxidation products from nuclear membranes may also participate in DNA 
damage (Vaca, 1988). 
It has been proposed that lipid peroxidation is more important in 
doxorubicin-mediated cardiotoxicity than antitumour activity as alpha-
tocopherol blocked cardiotoxicity in mice but did not alter cytotoxicity 
in mouse P388 ascites tumour (Myers, 1977). Mimnaugh et a1. (1982) found 
a direct correlation between stimulation of heart and liver microsomal 
lipid peroxidation and the cardiotoxic effects of anthracycline deriva-
tives in animal models. Doxorubicin also produced increased lipid 
peroxidation in mouse heart in vivo (Patterson et a1., 1983). 
1.16.4.3 DNA strand breakage 
The majority of evidence for doxorubicin mediated DNA strand breakage 
comes from plasmid DNA strand breakage assays. In a system of cytochrome 
P450 reductase NADPH and end labelled DNA , doxorubicin mediated strand , 
cleavage in double and single stranded DNA, demonstrating that 
intercalation was not an essential requirement for strand breakage. 
Additionally in the absence of oxygen no strand breakage occurred 
(Berlin and Haseltine, 1981). 
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Lown et a1. (1982) found a correlation between stimulation of 
microsomal oxygen consumption and DNA nicking in a system of 
doxorubicin, plasmid DNA and sodium borohydride. Sugar modified 
anthracyc1ines which were less easy to reduce and produced less strand 
breakage in this assay had reduced cardiotoxicity (Lown et a1., 1982). 
Similarly, in this assay the less cardiotoxic anthracyclinp. 5-
iminodaunorubicin produced less strand breakage (Lown et a1., 1979). 
Doxorubicin and daunorubicin were found to bind to PM2 supercoiled DNA 
and induce nicks in the presence of sodium borohydride. This process 
was inhibited by SOD, catalase and sodium benzoate indicating 
involvement of superoxide anions, hydrogen peroxide and hydroxyl 
radicals [Lown et a1., 1977]. A similar result was found by Mong et a1. 
(1980), drug a~one causing conformational changes but no nicking in PM2 
DNA. In the presence of sodium borohydride, NADPH cytochrome P450 reduc-
tase or NADH dehydrogenase doxorubicin nicked supercoiled PM2 DNA 
(Haidle and Hunter Mckinney, 1985 and 1986). Xanthine oxidase was found 
to reduce doxorubicin to a semiquinone which reacted with hydrogen 
peroxide to produce DNA strand scission under anaerobic conditions. 
This process was inhibited by superoxide dismutase (Bates and 
Winterbourn, 1982). 
Doxorubicin has been shown to cause non-protein associated DNA strand 
breakage [see section 1.9.2] in some cellular systems. This non-protein 
associated strand breakage is possibly related to oxygen radical 
formation whereas protein associated strand breaks are related to 
inhibition of topoisomerase II activity [see section 1.7.2]. Goldenberg 
et a1. (1986) showed that the cytotoxic action of doxorubicin was 
closely associated with double strand break formation in P388 leukaemia 
cells. Resistant cells had a lower level of single and double strand 
breaks than sensitive cells. In mouse leukaemic L1210 cells treatment 
with low doxorubicin concentrations produced protein associated strand 
break formation whereas treatment with high concentrations produced non-
protein associated strand breaks (Potmesi1 et a1., 1984). Ross and 
Smith (1982) also found doxorubicin to cause single and double strand 
breaks and DNA protein crosslinks in L1210 cells. Pommier et 81. (1983) 
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investigated the effect of oxygen radical scavengers on doxorubicin 
induced strand breakage in Ll210 cells. DMSO and thiourea inhibited 
strand breakage by ionising radiation. In contrast, thiourea inhibited 
single strand break formation and DMSO stimulated strand break formation 
by doxorubicin. These effects were proposed to be due to different 
effects on DNA conformation. Non-protein associated strand breaks could 
be detected in doxorubicin treated V79 chinese hamster cells [Iliakis 
and Lazar, 1987] and daunorubicin treated rat hepatocytes and mammary 
epithelial cells (Capranico et al., 1989). However, Capranico et al. 
(1986) found no correlation between redox potentials of sugar-modified 
anthracyc1ines and DNA strand breakage in P388 leukaemia cells. 
Similarly Potmesi1 et al. (1983) showed equivalent strand breakage by 
doxorubicin and the redox-inactive 5-iminodaunorubicin. 
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1.16.4.4 The role of doxorubicin free radical formation in 
cellular resistance 
The development of drug resistance by tumour cells is a major problem in 
cancer treatment. To investigate the mechanisms involved, resistant 
cell lines have been characterised in vitro. The results of these 
studies have contributed indirect evidence for doxorubicin free radical 
involvement in cell kill. Mungikar et al. (1981) showed a decreased 
level of mixed function oxidase enzymes in doxorubicin-resistant P388 
cells, particularly cytochrome bS and cytochrome P4S0. The resistant 
cells were also resistant to ascorbate induced lipid peroxidation. 
These results indicate a possible role for MFO activation and lipid 
peroxidation in the action of doxorubicin. Doxorubicin resistance has 
been associated in many cell lines with an increase in glutathione 
dependent enzymes. Glutathione-S-transferases are a group of enzymes 
involved in the detoxification of xenobiotics. Additionally, this enzyme 
has peroxidase activity [see section 1.10.1]. Glutathione-S-transferase 
activity was increased in mouse tumour cells (Dahllof et al., 1987) and 
in P388 leukaemic cells (Deffie et al., 1988) relative to sensitive 
cells. Batist et al. (1986) found that doxorubicin resistant MCF-7 human 
breast cancer cells overexpressed glutathione-S-transferase and 
glutathione peroxidase. In doxorubicin resistant MCF-7 cells an 
increase in phase I (cytochrome P450) and phase II metabolising enzymes 
(glutathione-S-transferase and glucuronyl transferase) was observed by 
Cowan et al. (1986). Depletion of glutathione in doxorubicin resistant 
MCF-7 human breast cancer cells using buthionine sulphoxamine [BSO], an 
inhibitor of GSH synthesis, potentiated doxorubicin mediated hydroxyl 
radical formation and cytotoxicity. 
In contrast to the above studies, Yusa et al. (1988) did not indicate 
that increase in glutathione S-transferase altered the sensitivity of 
Hattori and MCF-7 human breast cancer cells. Furthermore, Capranico et 
al. (1986) found no increase in cytotoxicity or DNA strand break 
formation by doxorubicin in glutathione depleted cell lines. In 
addition, Ramu et al. (1984) found no significant difference in the 
levels of enzymic detoxification systems in P388 murine leukaemia cells, 
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sensitive and resistant to doxorubicin. 
Yeh et al. (1987) found reduced activity of the pentose phosphate shunt 
in doxorubicin resistant MCF-7 cells. This pathway provides NADPH for 
the maintenance of reduced glutathione via glutathione reductase and for 
flavin based oxidoreductases. These authors suggest reduced activity of 
the pentose phosphate shunt may limit cytochrome P450 reductase mediated 
doxorubicin activation [see section 1.8.2] in the resistant cells. 
Mimnaugh et al. (1989) showed that doxorubicin -resistant MCF-7 cells 
were cross resistant to other oxygen free radical generating systems reg 
xanthine/xanthine oxidase and hydrogen peroxide]. Hyperoxia was found 
to potentiate cytotoxicity in resistant and sensitive cells. Resistant 
cells also had increased SOD and glutathione peroxidase activities. In 
a doxorubicin resistant human small cell lung cancer line cross 
resistant to radiation, an increased rate of DNA repair was suggested 
to playa role in the resistant mechanism (Meijer et al., 1987). Lower 
reduced glutathione pools in doxorubicin treated sensitive cells were 
indicative of drug induced oxidative stress (Meijer et al., 1987). 
1.16.4.5 Free radical formation by anthracyciine-metal complexes 
Hydroxyquinones have been shown to form metal complexes with the metal 
ion coordinated by the quinone carbonyls and adjacent hydroxyl groups to 
form a six membered chelate (reviewed by Gianni et al., 1983). 
Doxorubicin has been to shown to form complexes with a variety of metal 
ions (reviewed by Garnier-Suillerot, 1988), this chelation giving rise 
to an intramolecular charge transfer to the hydroxyanthraquinone moiety 
(Myers et aI, 1982). Doxorubicin forms a 1:3 complex with iron (III) 
(Beraldo, 1985) which has a similar stability constant to the 1:1 
complex of iron (III) with desferrioxamine (reviewed by Gianni et al., 
1983). Doxorubicin has also been shown to form 1:1 and 1:2 complexes 
with eu (II). Both Fe and Cu been proposed to be involved in binding of 
doxorubicin to DNA [Eliot et al., 1982; Spinelli and Dabrowiak, 
1982]. This occurs via formation of a doxorubicin-Fe-DNA ternary 
complex involving a mordant bond (reviewed by Garnier-Suillerot, 1988). 
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Doxorubicin-Fe3+ has also been shown to catalyse transfer of electrons 
from glutathione to oxygen (Myers et a1., 1982). Since this complex can 
bind to membrane cardiolipin (Hasinoff et a1., 1989) and DNA (reviewed 
by Garnier-Suillerot, 1988) this mechanism is possibly involved in 
membrane lipid damage and DNA strand breakage. Indeed a system of 
glutathione and doxorubicin-iron complex caused DNA cleavage (Eliot et 
a1., 1984; Muindiet a1., 1985) and destruction of erythrocyte 
membranes (Myers et a1., 1982) by mechanisms involving oxygen free 
radicals. In addition, Muindi et 81. (1984) showed that doxorubicin-
Fe(III) produced hydroxyl radicals in the presence of hydrogen peroxide 
which resulted in DNA strand cleavage. Doxorubicin-iron or -copper 
complexes have also been shown to inactivate cytochrome c oxidase 
(Hasinoff et a1., 1989) and protein Kinase C (Hannun et a1., 1989). 
Doxorubicin can also form an doxorubicin-iron-ADP complex which can take 
place in the initiation of lipid peroxidation. It is thought that this 
and the doxorubicin-iron complex can redox cycle due to reduction by 
cytochrome P450 reductase leading to production of superoxide anions, 
hydrogen peroxide and hydroxyl radicals (Gianni et a1., 1985). However 
daunorubicin and doxorubicin iron complexes were not found to redox 
cycle in the presence of NADH dehydrogenase (Beraldo et a1., 1985). It 
has also been proposed that the reduction of drug-bound iron is 
brought about by oxidation of the Ketoa1dehyde group on C9 of 
doxorubicin (Gianni et a1., 1985). Once reduced the doxorubicin-Fe(II) 
complex can cata1yse hydroxyl radical formation via the iron catalysed 
Haber-Weiss reaction [see section 1.8.3]. Gianni et a1. (1988) found 
that oxygen free radicals were not involved in initiation of lipid 
peroxidation by the doxorubicin-iron complex. This is in agreement with 
the mechanism of initiation proP9sed by Minotti and Aust, 1987 [see 
section 1.9.1]. It may not always be possible to distinguish between 
drug redox cycling and drug-bound iron redox cycling in a particular 
system as iron is a ubiquitous contaminant of laboratory reagents. 
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1.16.4.6 Bioreductive alkylation by doxorubicin 
Under anaerobic conditions the formation of the doxorubicin semiquinone 
by enzymic reduction has been proposed to result in the formation of an 
alkylating species (reviewed by Gianni et a1., 1983). The semiquinone 
undergoes a rearrangement in which the unpaired electron migrates to the 
C7 position with resulting cleavage of daunosamine [see figure 1.34]. 
This leaves a C7 aglycone radical which is proposed to be an alkylating 
species. It is this radical that is thought to be involved in covalent 
binding of doxorubicin to DNA (Sinha and Chignall, 1979). If this free 
radical abstracts a hydrogen atom the product is a 7-deoxyaglycone. The 
7-deoxyglycone of daunorubicin has been shown to be metabolically 
reduced (Oldcorne and Patterson, 1987). 
An alternative proposal for formation of a doxorubicin alkylating 
species involves the formation of a two electron reduction product the 
hydroquinone (Moore, 1977; Moore and Czerniak, 1981). Formation of the 
hydro quinone results in the amino sugar becoming a stable leaving group. 
The loss of the C7 amino sugar results in the formation of a quinone 
methide intermediate. This is envisaged to act as a nucleophile to give 
a C7 functionalised quinone or as an electrophile to give a C7 
functionalised hydro quinone [see figure 1.34]. This latter product may 
re-form the quinone methide unless oxidised to the more stable quinone 
state. Alternatively the quinone methide will react with a hydrogen 
atom to form the 7-deoxyaglycone or with itself to form a 7-7'-dimer 
(reviewed by Gianni et al., 1983; Powis, 1989). However, there is no 
direct evidence to suggest doxorubicin can undergo this mechanism since 
no doxorubicin dimers have been isolated. 
Either pathway could lead to the alkylation of critical cellular 
macromolecules including membranes and DNA. These mechanisms could be 
particularly prevelant in the hypoxic areas of tumours (reviewed by 
Kennedy et a1., 1980) and have been proposed to be involved in the 
cardiotoxic effects of doxorubicin (Cummings et a1., 1987). 
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Figure 1.34. Pathways for formation of alkylating species from doxorubicin 
(I) by one electron reduction to the semiquinone radical (ll) and a 
postulated C-7 carbon centred radical (m), or by two electron reduction to 
the hydroquinone (IV) and a postulated quinone-methide (V). Nu is a 
nucleophile, E is an electrophile. 
(Powis, 1989) 
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1.16.5 Mechanisms of doxorubicin cardiotoxicity 
As described previously the clinical use of doxorubicin has been 
associated with a dose limiting cardiotoxicity (reviewed by Unverferth 
et a1., 1982; Sinha, 1982). The cardiotoxicity of doxorubicin can be 
divided into acute effects and chronic effects. Acute cardiovascular 
effects include hypotension, tachycardia and various arrhythmias. The 
chronic effect is cardiomyopathy leading to congestive heart failure 
(reviewed by Singa1, 1987). Thirty five percent of patients 
treated with a cumulative dose greater than 600 mg/m2 experienced 
chronic effects. Morphological changes in the myocardium include 
dilation of myocyte sarcoplasmic reticulum, dissolution of contractile 
protein and changes in mitochondria (reviewed by Gianni et a1., 1983). 
The consensus of opinion is that reductive activation of doxorubicin 
with concomitant formation of oxygen free radicals in heart tissue leads 
to the cardiotoxicity observed. Myocardial cells have been found to 
have a limited capacity to detoxify oxygen free radicals due to low 
levels of SOD and catalase. In addition doxorubicin has been found to 
suppress glutathione peroxidase activity in heart tissue (Doroshow et 
a1., 1980). Doxorubicin has been shown to be capable of redox cycling 
in cardiac sarcosomes (Doroshow and Reeves, 1981), rat heart subcellular 
fractions (Doroshow, 1983), cardiac sarcoplasmic reticulum and 
submitochondrial particles (Doroshow and Davies, 1983), heart 
mitochondria and microsomes (Nohl and Jordan, 1983) and cardiac myocytes 
(Doroshow, 1987). The doxorubicin metabolite doxorubicinol has also 
been shown to redox cycle in cardiac tissue (Gervasi et a1., 1986) and 
has been proposed to be involved in cardiotoxicity (Danesi, 1987). A 
heart specific mitochondrial NADH-oxidoreductase has been proposed to be 
the site of doxorubicin activation in the heart tissue (Nohl, 1988). 
Doxorubicin has also been found to deplete glutathione levels (Olson et 
a1., 1980) and initiate lipid peroxidation in heart tissue Lavelle et 
a1., 1985). Furthermore, Julicher (1985) found that rat heart cells 
were more sensitive to doxorubicin when glutathione levels were 
depleted. Further support of free radical involvement in cardiotoxicity 
are several studies which have found that anthracyclines shown to be 
105 
less cardiotoxic than doxorubicin are associated with reduced propensity 
for reductive activation. These include 5-iminodaunorubicin (reviewed 
by Gianni et al., 1983), epirubicin (figure 1.30) [reviewed by Johnston 
and Glazer, 1984; Goodman and Laughner, 1986] and 4'-demethoxy-4'-4'-O-
methylodoxorubicin (figure 1.31) [Arcamone, 1984). The substituent 
groups of the aglycone and daunosamine have been found to be critical in 
relation to redox cycling capability of anthracyclines and their 
relative cardiotoxicity (Lown et al., 1982). In addition, Free radical 
scavengers such as alpha-tocopherol, cysteamine and N-acetyl cysteine 
have been shown to lessen the cardiotoxic effects of doxorubicin (Olson 
et al., 1981). More recently, two components to doxorubicin 
cardiotoxicity have been proposed. These involve oxidative and non-
oxidative mechanisms of inactivation of mitochondrial electron transport 
chain components, including NADH dehydrogenase, succinate dehydrogenase, 
succinate oxidase and cytochrome c oxidase (Marcillat et al., 1989). 
The doxorubicin-iron complex has also been proposed to be involved in 
doxorubicin cardiotoxicity [see section 1.16.4.5]. The EDTA derivative 
1,2-bis-(3,5-dioxo-piperazinyl-l-yl)propane (ICRF-187) was found to 
protect against doxorubicin cardiotoxicity in rabbits (Herman and 
Ferrans, 1987) and is currently undergoing clinical trials as a 
protectant during doxorubicin therapy. 
Cardiotoxicity has also been proposed to be due to interaction of 
doxorubicin with cardiolipin, an important lipid located in the 
mitochondrial membrane which is involved in the function of several 
enzymes [see section 1.16.2]. Association constants of a series of 
anthracyclines with cardiolipin was found to correlate with their 
relative cardiotoxicity (Goormaghtigh et al., 1980). 
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1.17 Mechanism of antitumour action of mitozantrone 
As previously described (section 1.14) mitozantrone (figure 1.33) is an 
anthraquinone anti tumour agent that was developed with a view to 
producing a less cardiotoxic agent than doxorubicin or daunorubicin 
(White and Durr, 1985). The mechanism of action of mitozantrone is 
reviewed by Durr et a1. (1983) and Durr (1984). DNA is thought to be 
the major target of mitozantrone as has been shown for the 
anthracyclines [section 1.16.1]. Two binding sites have been proposed, 
a high affinity partial intercalation site and a lower affinity external 
electrostatic interaction with the sugar phosphates. The 
hydroxyethylamino side chains are proposed to partially preclude 
incorporation of mitozantrone into the double helix hydrophobic interior 
and hence part of the molecule lies in the minor groove (Foye et a1., 
1982; Kapuskinski et a1., 1981; Lown et a1., 1984; Lown et a1., 1985; 
Krishnamoorthy, 1986; and Chen et a1., 1986). Mitozantrone has been 
proposed to bind mainly to specific DNA regions by a mechanism which 
involves nearest neighbour exclusion (Rosenberg et a1., 1986). It has 
also been proposed that mitozantrone binds by a mechanism that favours 
binding of other mitozantrone molecules (positive cooperativity) to some 
DNA regions (Rosenberg et a1., 1986). Mitozantrone molecules have been 
shown to stack when they are externally bound to DNA (Kapuscinski et 
a1., 1984). Mitozantrone DNA binding has been proposed to responsible 
for its potent inhibition of DNA and RNA synthesis which has been found 
in mouse L cells (Nishio and Uyeki, 1983), T47D breast tumour cells 
(Safa et a1., 1983) and MDA-MB-23l breast tumour cells (Chegini and 
Safa, 1987). Furthermore mitozantrone has been shown to inhibit RNA 
polymerase (Foye et a1., 1982). Mitozantrone has also been shown to 
condense nucleic acids (particularly RNA) [Kapuscinski and 
Darzynkiewicz, 1984 and 1986]. 
As described in section 1.16.5 doxorubicin mediated cardiotoxicity has 
been associated with free radical generation (redox cycling). 
Consequently the free radical chemistry of the less cardiotoxic [see 
section 1.14] mitozantrone has been widely investigated. Mitozantrone 
has been found to produce cardiotoxicity in patients pretreated with 
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anthracyclines (reviewed by Shenkenberg and Von Hoff, 1986). 
Substantially less redox activity was found with mitozantrone in rabbit 
heart microsomes, purified NADPH cytochrome P450 reductase and NADH-
dehydrogenase compared to doxorubicin (Kharasch and Novak, 1983a and 
1985). This was also found in human liver microsomes (Basra et a1., 
1985) and rat liver and heart microso~es (Basra, 1986). In addition 
Doroshow and Davies (1983) found mitozantrone did not significantly 
enhance oxygen metabolism in cardiac sarcoplasmic reticulum and 
submitochondrial particles. Mitozantrone inhibited base rate NADPH 
dependent lipid peroxidation in rabbit liver microsomes and rabbit 
cardiac sarcosomes, inhibited NADH dependent lipid peroxidation in 
cardiac mitochondria and inhibited iron stimulated lipid peroxidation in 
rabbit liver microsmes (Kharasch and Novak, 1983b and 1985). In 
addition mitozantrone did not initiate lipid peroxidation in mouse liver 
and heart fractions (Patterson et a1., 1983). Doxorubicin, in contrast, 
stimulated lipid peroxidation in all the above systems. Mitozantrone 
was also found to inhibit doxorubicin stimulated lipid peroxidation and, 
to a lesser extent, superoxide formation (Kharasch and Novak, 1982). 
Other effects of mitozantrone include inhibition of platelet aggregation 
and prostaglandin and thromboxane biosynthesis (Frank and Novak, 1986) 
and inhibition of tumour angiogenesis (Polverini and Novak, 1986). 
The mechanism of action of anthraquinone anti tumour agents such as 
doxorubicin and mitozantrone is clearly not fully understood. The 
absence of a systematic study on the role of reductase mediated redox 
cycling of these agents in their anti tumour activity is strikingly 
apparent. Furthermore, more information is required on the 
relationships between cellular DNA damage by these agents, their 
propensity to redox cycle and their cytotoxicity. The next section sets 
out the aims of the present study. 
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1.18 Aims 
(1) The suitability of the MCF-7 human breast cancer cells as a model 
cell line for the investigation of antitumour drug redox cycling 
will be investigated using doxorubicin as a reference system. 
(2) The propensity to redox cycle by mitozantrone, CI941 and a series 
of alkylaminoanthraquinones (figure 1.35) based on mitozantrone 
will be investigated in the MCF-7 cell line. This will allow the 
relationship between side chain substitution pattern and redox 
cycling propensity to be assessed. 
(3) The propensity of the above agents to mediate plasmid DNA strand 
breakage in the presence of purified reductase enzymes will be 
investigated. Doxorubicin will be used as a reference system. 
This will provide further information as to the relative 
propensities of these agents to redox cycle. 
(4) DNA strand breakage produced by the above agents will be determined 
in the MCF-7 cell line. This will allow the relationship between 
DNA strand breakage and the propensity to redox cycle of these 
agents to be ascertained. 
(5) The cytotoxicity of these agents will be determined in the MCF-7 
cell line. Cytotoxicity of these agents will be related to their 
relative propensity to redox cycle and produce cellular DNA strand 
breakage in MCF-7 cells. 
(6) Cellular uptake of the above agents will be determined in MCF-7 
cells. This will determine whether differences in uptake can 
account for any differences in DNA strand breakage and cytotoxicity 
observed for these agents. 
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(7) The effect of the above agents on MCF-7 cell topoisomerase activity 
will be determined. This will reveal whether topoisomerase-DNA 
cleavable complex formation contributes to the cellular DNA strand 
breakage and cytotoxicity of these agents in MCF-7 cells. 
(8) The ability of the above agents and a series of anthrapyrazole 
antitumour agents based on CI941 (figure 1.36) to mediate plasmid 
DNA strand breakage in the presence of iron and reduced glutathione 
will be investigated. This will determine whether iron binding is a 

















Figure 1.35 The structure of alkylaminoanthraquinones 
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Figure 1.36. Structure of anthrapyrazoles 
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CHAPTER 2 
An investigation of redox cycling by quinone antitumour 
agents in MCF-7 human breast cancer cell fractions 
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CHAPTER 2 
An investigation of redox cycling by quinone antitumour 
agents in MCF-7 human breast cancer cell fractions 
2.1 Introduction 
As described in section 1.8.2 one of the proposed mechanisms of action 
of quinone containing antitumour agents is reductase mediated redox 
cycling, resulting in the production of cell damaging reactive oxygen 
species [see figure 1.19]. Section 1.8.3 shows the series of reactions 
which can result from superoxide anion formation. From figure 1.19 it 
can be seen that there are several lines of evidence which are 
indicative of drug redox cycling in a biological system:-
1. Oxidation of NADPH. 
2. Formation of drug semiquinone free radicals. 
3. Formation of superoxide anions. 
4. Formation of hydroxyl radicals. 
In this chapter redox cycling by the quinone antitumour agents of the 
present study is investigated in MCF-7 human breast cancer cells. This 
cell line is particularly relevant for these studies since doxorubicin 
and mitozantrone are used in the treatment of advanced breast cancer 





Determination of the rate of NADPH oxidation in 
cellular 59 homogenates 
This was measured by following the decrease in NADPH absorbance at 
340nm. All measurements were made using an uv/vis scanning 
spectrophotometer [552 spectrophotometer, Perkin Elmer] fitted with a 
temperature controlled Pelte cell [Perkin Elmer]. The reaction mixture 
[lml] , consisting of sodium phosphate buffer [lBOmM, pH 7.4], potassium 
chloride [225mM], nicotinamide [7.5mM] and MCF-7 S9 fraction [lOOul, 
O.2-0.4mg S9 protein] was incubated at 37C for 5 minutes before the 
reaction was initiated by the addition of NADPH [O.lmM]. NADPH 
oxidation was followed for 3 minutes to give a base rate. Then, an 
appropriate volume of drug was added to give the desired final 
concentration and the reaction followed for a further 3 minutes. The 
rate of NADPH oxidation was calculated using the extinction coefficient 
of 6.22mM cm- l [Handa and Sato, 1976] at 340nm and the results expressed 
as nmole min- l mg- l protein. 
2.2.2 Determination of superoxide generation 
2.2.2.1 Reduction of acetylated cytochrome C 
Superoxide generation was determined by following the reduction of 
acetylated cytochrome C at 550nm (see section 1.12.1). All measurements 
were carried out on the spectrophotometer described above. The reaction 
mixture consisted of potassium chloride [150mM]-Tris [50mM, pH7.4], 
acetylated cytochrome C [0.07mM] (see appendix A3.0 for details of 
preparation) and NADPH [l.OmM]. After prewarming to 37C for 5 minutes, 
the reaction was initiated by the addition of S9 fraction (25ul, 0.05-
0.15mg 59 protein) and the reduction of acety1ated cytochrome C followed 
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for 3 minutes. To determine the effect of drug on superoxide generation 
a separate incubation was set up with the appropriate concentration of 
drug. To establish that the reaction rate observed was due to 
superoxide generation the reaction was repeated in the presence of 
superoxide dismutase [300ug ml- l ] or bovine serum albumin [300ug ml- l ]. 
BSA was added to ensure that the superoxide dismutase inhibition 
observed was not due to addition of protein. The rate of acetylated 
cytochrome C reduction was determined using the extinction coefficient 
of 19.6mM cm- l at 550nm [Azzi et al., 1975]. The results were expressed 
as nmoles acetylated cytochrome C formed min-lmg-lprotein. 
2.2.2.2 Formation of adrenochrome from adrenaline. 
This assay is dependent on the conversion of adrenaline to adrenochrome 
by superoxide and the measurement of adrenochrome formation (see section 
1.12.1) spectrophotometrica11y at 480nm [as described in section 
2.2.2.1]. The incubation [lml] mixture consisted of potassium 
phosphate buffer [lOOmM, pH7.4], EDTA [lmM], adrenaline bitartrate [2mM 
in 0.02M HCl], NADPH [l.OmM] and an appropriate volume of drug to 
produce the concentration required. The above mixture was incubated at 
37C for 3 minutes prior to the initiation of the reaction by addition of 
S9 fraction [SOul, 0.1-0.3mg S9 protein], the reaction being followed 
for 5 minutes. Appropriate controls were carried out in the absence of 
drug or S9 fraction. The reaction was repeated in the presence of 
superoxide dismutase [900 units, 560ug protein] or BSA [560ug] to 
ensure the observed adrenochrome formation was due to superoxide, since 
hydrogen peroxide can also mediate the conversion of adrenaline to 
adrenochrome. BSA was added for the reasons described in section 
2.2.2.1. 
The rate of 
coefficient 
results were 
adrenochrome formation was quantitated using an extinction 
of 4.02mM cm- l at 480nM (Peterson et al., 1979). The 
. -1 -1 i expressed as nmoles adrenochrome formed m1n mg prote n. 
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2.2.3 Determination of oxygen consumption in MCF-7 cells. 
Oxygen consumption was measured using a metabolic oxygen meter [SEA] 
with a polarizable Clark type electrode linked to a chart recorder 
[PM8251, Phillips]. The instrument was calibrated between 0 and 100% 
dissolved oxygen using sodium dithionite [lOmg m1- 1 ] solution and air 
saturated distilled water respectively. 
The reaction mixture [lm1] consisted of potassium chloride [lSOmM]-Tris 
[50mM, pH7.4] buffer, magnesium chloride [10mM], MCF-7 cells (106ml -l) 
and NADPH [O.lmM]. The above mixture was placed in the sample well 
[37C] of the oxygen meter and a magnetic stir bar and electrode 
inserted. Oxygen consumption was followed for 8 minutes. A separate 
incubation was set up with the required drug concentration and treated 
as above. 
The rate of oxygen consumption was determined using the datum that lml 
distilled water at 25C contains 0.237 umoles of oxygen [Lessler, 1978]. 
2.2.4 Investigation of drug semiquinone free radical formation using 
electron spin resonance spectrometry [esrJ 
Esr spectrometry (see section 1.12.2) was carried out using a Varian 
E109 X-band esr spectrometer at room temperature [typically 20-23C]. 
Studies were carried out on samples loaded into a quartz flat cell 
[1.5ml]. 
The reaction mixture [lm1] consisted of potassium phosphate buffer 
5 
[100mm, pH7.4], S9 fraction [1.7 mg_~rotein] or MCF-7 cells [3.5xlO ], 
NADPH [O.lmM] and drug. The above mixture was placed in septum sealed 
crimped vial and deaerated for 15 minutes with oxygen-free nitrogen 
[BOC] by means of a fine cannula [inserted via a 19 gauge needle]. 
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After deaeration the sample was taken up into a syringe [lml] and 
injected into the top of the quartz flat cell which had been flushed 
with nitrogen. Prior to stoppering, the flat cell was again flushed 
with nitrogen. 
The flat cell was clamped into the cavity and the instrument tuned. 
The required operating parameters were set on the instrument, typically 
microwave power SmY, field set 3371 Gauss, field sweep +40 Gauss, time 
constant 1 second, modulation amplitude 4 Gauss, receiver gain 104 and 
scan time 4 minutes. 
If an esr signal was detected 4 minute scans were repeated for 30 
minutes to determine the intensity and duration of the spectrum. In some 
experiments the esr spectra were accumulated using a Nicolet data 
accumulator [model 1170, Instrument Corp] using ten, two minute scans. 
2.2.5 Determination of oxygen free radical formation in MCF-7 S9 
fraction or MCF-7 cells by spin trapping 
The principles of this technique are fully described in section 1.12.2. 
The spin trap S,S-dimethyl-l-pyrroline N-oxide [DMPO] was used in these 
studies. Esr was carried out as described in section 2.2.4. 
Each incubate was made up of the following components in the order of 
addition:- Phosphate buffer [200mM, pH7.4] (bubbled with oxygen for 
five minutes), MCF-7 S9 fraction [0.68 mg protein ml- l ] or MCF-7 cells 
[3.SxlOS], Desferrioxamine [lmMJ, DMPO [lOOmM], NADPH [O.SmM) and drug 
[400uM). 
To confirm that the spin adducts produced were drug and S9 fraction 
dependent the above incubate was repeated in the absence of S9 fraction 
or drug. 
In order to confirm that the esr signal obtained was due to oxygen 
118 
radical formation, the above incubate was repeated in the presence of 
DMSO [200mM], catalase [300 units ml- l ] or SOD [1000 units], 
Esr measurements were determined in a quartz flat cell with the upper 
stopper removed. Typically the following parameters were used:-
Microwave power 10mW, microwave frequency 9.467 GHz, modulation 
amplitude 2.0G, time constant 0.25 seconds, scan time 4 minutes, field 
set 3381, scan range 100G, receiver gain 8xl04, temperature 20-23C. 
Esr data was accumulated on an Archimedes data acquisition system using 
a kinetic programme [Brivati, J., Leicester University]. This programme 





Investigation of free radical formation by doxorubicin in HCF-7 
cells 
MCF-7 S9 fractions were chosen for these and subsequent experiments 
because it has been shown previously that this cell line contains the 
necessary enzymology for reductive activation of doxorubicin including 
NADPH-cytochrome c reductase, NAD H-cytochrome bS reductase and xanthine 
oxidase (Sinha et al., 1987). These enzymes have been shown to be 
present in S9 fraction which is composed of the cellular microsomal and 
cytosolic components (Beaune and Guengerich, 1988). This fraction is 
free from interference from drug-DNA interactions [doxorubicin and 
other quinone containing agents bind strongly to DNA (reviewed by Gianni 
et al., 1983)] [see section 1.16]. Preparation of MCF-7 S9 fraction is 
described in appendix A7.0. 
2.3.1.1 Effect of doxorubicin on NADPH oxidation in HCF-7 S9 
cell fraction. 
The effect of doxorubicin on NADPH oxidation in MCF-7 S9 fraction was 
investigated in order to determine whether doxorubicin was metabolised by 
reductase enzymes that require NADPH as a cofactor [section 1.8.2]. 
NADPH oxidation was determined as described in section 2.2.1. 
It can be seen from figure 2.1 that doxorubicin stimulated base rate 
NADPH oxidation in a concentration dependent manner. Doxorubicin 
[100uM] produced a ten fold stimulation of the base rate. 
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Figure 2.1 The effect of doxorubicin on NADPH oxidation in 
HCF-7 59 cell fraction. 
Base rate NADPH oxidation was 72 + 18 pmo1 min- 1mg- 1 protein. 
Each data point is the mean + standard deviation of three determinations. 
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2.3.1.2 Effect of doxorubicin on superoxide anion formation 
in HCF-7 S9 cell fraction. 
Having determined that doxorubicin stimulated NADPH oxidation in MCF-7 
cell S9 fraction, which is evidence in part for reductive activation of 
the drug, the effect of doxorubicin on superoxide anion formation in 
this system was determined. Figure 2.2A shows doxorubicin stimulated 
superoxide anion formation as determined by reduction of acetylated 
cytochrome c in a concentration dependent manner. The effect of 
superoxide dismutase [SOD] on the rate of doxorubicin [100] stimulated 
acetylated cytochrome c reduction was determined. Doxorubicin [lOOuM] 
in the absence of SOD produced a rate of reduction of acetylated 
cytochrome c of 20.9 + 1.9 nmole min- l mg- l S9 protein whilst in 
presence of SOD (900 units) produced a rate of 13.36 + 0.84 nmole min- l 
mg- l S9 protein [base rate]. This demonstrated that 7.54 nmoles 
superoxide anion min- l mg- l S9 protein was produced by doxorubicin 
(lOOuM). When bovine serum albumin [BSA] was used instead of SOD (at an 
equivalent concentration) no inhibition of doxorubicin stimulation of 
acetylated cytochrome c reduction was seen. This demonstrated that the 
inhibition produced by SOD was not simply due to the addition of protein 
to the system. 
Doxorubicin mediated superoxide formation in MCF-7 cell S9 fraction was 
also determined using the adrenochrome assay. Figure 2.2B shows SOD 
inhibitable adrenochrome formation in this system. It can be seen from 
this figure that doxorubicin stimulated superoxide anion formation in a 
concentration dependent manner. BSA had no effect on doxorubicin 
stimulated superoxide formation. 
These results combined with those described in section 2.3.1 were 
consistent with doxorubicin undergoing reductive activation in a redox 
cycling process with resultant oxidation of NADPH and concomitant 
formation of superoxide anions. To determine whether these events were 
associated with formation of a doxorubicin semiquinone, the central 
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Figure 2.2 Effect of doxorubicin on superoxide anion generation in 
HCF-7 S9 cell fraction as determined by SOD inhibitable 
reduction of acetylated:cytochrome c tA} and adrenochrome 
formation [B}. 
Data points are the mean + standard deviation of three determinations. 
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2.3.1.3 Formation of doxorubicin free radicals in HCF-7 S9 
cell fraction 
Figure 2.3 shows the first derivative esr spectrum observed upon incubation 
of doxorubicin [200uM] with NADPH fortified MCF-7 S9 fraction under 
anaerobic conditions. This signal had a peak to peak width of 4.2 Gauss 
and a g value of 2.00461, both parameters·characteristic of an organic 
free radical (reviewed by Foster, 1984). No esr signal was obtained in 
the absence of drug, absence of S9 fraction or presence of air. 
To further investigate doxorubicin free radical formation in MCF-7 cell 
S9 fraction, the effect of drug concentration on the esr signal 
intensity was investigated. Figure 2.4 shows that the intensity of 
the signal increased in a concentration dependent manner up to 300uM. A 
doxorubicin concentration of 50uM was the minimum that allowed detection 
of the free radical. 
2.3.1.4 Detection of doxorubicin free radical in viable 
intact HCF-l cells. 
Doxorubicin free radical formation was investigated in a whole cell 
system. Doxorubicin [300uM] and MCF-7 cells [3.5xl06] were incubated 
under anaerobic conditions at room temperature and measured by esr. 
Figure 2.5 shows the first derivative esr spectrum observed. The peak 
to peak width, 3.4 Gauss and g value, 2.00384 of this spectrum were 
typical of an organic free radical (reviewed by Foster, 1984). No 
signal was obtained in the absence of drug, MCF-7 cells or in the 
presence of air. Figure 2.6 shows the effect of time on the esr signal 
obtained in this system. The signal first appeared 25 minutes into the 
incubation and the intensity increased with time up to 85 minutes. 
These results and those described in sections 2.3.1.1, 2.3.1.2, 2.3.1.3 
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Figure 2.3 Doxorubicin free radical in NADPH fortified HCF-7 59 cell 
fraction detected by electron spin resonance spectrometry. 
Figure shows the first derivative esr spectrum obtained from an 
incubation of MCF-7 59 fraction with NADPH [O.lmM] and doxorubicin 
[200uMJ. A: under anaerobic conditions. B: in the presence of oxygen 
and C: in the absence of drug. 
Operating parameters were microwave frequency 9.465 GHz, microwave power 
5mY, modulation amplitude 4g, time constant 1 second, scan time 4 
minutes, receiver gain 2xlO and scan range 40G. Arrow indicates DPPH g 
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Figure 2.4 Free radical formation by doxorubicin in NADPH fortified 
HCF-7 59 cell fraction as determined by electron spin 
resonance spectrometry. 
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Figure 2.5 Free radical formation by doxorubicin in HCF-7 cell 
suspension as determined by electron spin resonance 
spectrometry. 
Doxorubicin [300uM] was incubated with MCF-7 cells [3.Sxl06ml- l ] in 
RPMI-1640 medium (serum supplemented) at room temperature under 
anaerobic conditions [A], under aerobic conditions [B] and in the 




. Operating parameters were microwave frequency 9.465 GHz, microwave power 
5mW, m~dulation amplitude 4G, time constant 2 seconds, receiver gain 
1.6xlO , scan time 16 minutes, and scan range 20G. Arrow indicates DPPH 
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Figure 2.6 Effect of time on free radical formed by doxorubicin in HCF-
7 cells as determined by electron spin resonance 
spectrometry. 
For experimental conditions and operating parameters see figure 2.5. 
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superoxide anion formation and formed a free radical in MCF-7 S9 
fraction and whole cells providing evidence for reductive activation of 
doxorubicin by MCF-7 cells. To further investigate the formation of 
oxygen radical species formed by doxorubicin in this system, spin 
trapping experiments were undertaken. 
2.3.1.5 Spin trapping of oxygen radicals formed by 
doxorubicin in HCF-7 59 cell fraction 
The use of S,S-dimethyl-l-pyrroline N-oxide [DMPO] as spin trap is 
detailed in section 1.12.2. 
Figure 2.7A shows the first derivative esr spectrum obtained on 
incubation of doxorubicin [400uM] with NADPH fortified MCF-7 S9 
fraction, desferrioxamine [lmM] and DMPO [lOOmM]. The hyperfine 
splitting constants for this spectrum which consisted of a 1:2:2:1 
quartet were; AN - 14.0G and AH - 14.SG. The peak height ratios and 
splitting constants of this spectrum were consistant with the DMPO-
hydroxyl radical spin adduct [DMPO-OH]. The calculated splitting 
constants for this adduct are AN - AH - 14.87G [Britigan et al., 1987]. 
To further ascertain whether this esr spectrum was due to doxorubicin 
dependent hydroxyl radical formation, the effect of catalase and 
dimethyl su1phoxide [DMSO] on the formation of the spectrum were 
investigated. In the absence of drug the signal intensity was reduced 
by 80% (figure 2.7B). In the pr~sence of DMSO [16mM] and catalase [83 
units] the signal intensity was reduced by 40% and 30% respectively 
[figure 2.7B]. Figure 2.8 shows the effect of DMSO and superoxide 
dismutase on the spin adduct generated by doxorubicin in MCF-7 S9 
fraction. In the presence of SOD there was an increase [20%] in the 
peak height of the esr signal obtained. In the presence of DMSO (200mM) 
the 1:2:2:1 signal characteristic ot the DMPO-OH adduct was replaced by 
a 1:1:1:1:1:1 sextet [see figure 2.8B] with hyperfine splitting 
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Figure 2.7 A: Esr spectrum obtained from spin trapping studies of 
oxygen free radical formation by doxorubicin in NADPH 
fortified MCF-7 59 ·cell fraction. 
The system consisted of doxorubicin [400uM], NADPH [O.lmM], 
desferrioxamine [lmM] and DMPO [lOOmM]. 
Operating parameters were microwave frequency 9 . 535 GHz, microwave power 
10mW, ~odulation amplitude 0.5G, time constant 1 second, receiver gain 
8.0xlO , scan time 2 minutes and scan range 100G. 
B: The effect of oxygen free radical scavengers on the 
intensity of the esr signal obtained above. 
1: no drug, 2: doxorubicin [400uM], 3: doxorubicin [400uM] + catalase 
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Figure 2.8 Effect of oxygen free radical scavengers on the D~PO spin 
adduct formed on incubation of doxorubicin with NADPH fortified 
~CF-7 S9 cell fraction 
A. Intensities are derived from the spectra in figure 2.7. A: no 
drug, B: doxorubicin [400uM), C: doxorubicin + SOD 
[450 units). 
B. The signal produced in the presence of DMSO (200mM) . 
Esr parameters as described in figure 2.BA . 
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tne spectra ot tne DMPO-methyl [DMPO-CH3]] adduct which has calculated 
hyperfine splitting constants of A~lS.3lG and AH- 23.0G [Pou et a1,. 
1989]. This adduct is formed after reaction of hydroxyl radical with 
DMSO to liberate a methyl radical which is then trapped by DMPO to give 
a DMPO-methyl radical spin adduct [see section 1.12.2]. 
2.3.1.6 Spin trapping of oxygen radicals formed by doxorubicin in 
intact, viable HCF-7 cells. 
Section 2.1.4 showed that an organic free radical was detected in an 
incubation of doxorubicin with intact viable MCF-7 cells. In order to 
investigate oxygen free radical formation in this system spin trapping 
studies were carried out with freshly harvested MCF-7 cells. Figure 
2.9A shows the first derivative esr spectrum observed from an incubation 
of MCF-7 cells [2.Sx10Sml- l ] with doxorubicin [400uM] desferrioxamine 
[lmM] and DMPO [100mM]. The 1:2:2:1 quartet spectrum and hyperfine 
splitting constants [AN - 14.0G, AH - l4.SG] of this signal were 
characteristic of the DMPO-hydroxyl radical adduct [see section 
2.3.1.5]. In the absence of drug a signal with reduced intensity (46%) 
was observed [figure 2.9B]. 
To further investigate the nature of the spectrum observed the effect of 
catalase was determined. Figure 2.9B shows that the presence of 
catalase [300 units] reduced the intensity of the spectrum produced by 
41%. 
In an attempt to discriminate whether the esr spectrum was associated 
with intra- or extracellular oxygen free radical formation the cell 
suspension was removed from the flat cell and the cells centrifuged 
[12,000g]. The supernatant was replaced in the flat cell and esr 
measurements continued. An identical spectrum was obtained [figure 
2.9B] which was similar in intensity to that previously observed in the 
presence of cells. 
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Figure 2.9 A: Esr spectrum obtained from spin trapping studies of 
oxygen free radical formation by doxorubicin in intact 
viable HCF-7 cells. 
The incubation was carried out with freshly harvested MCF-7 cells [2.5 
l05ml -l] with doxorubicin [400uM], NADPH [O.5mM], desferrioxamine 
[O.lmM] and DMPO [IOOmM]. 
Esr operating parameters were as described in figure 2.7A . 
B: The effect of oxygen free radical scavengers on the 
signal intensity of the esr spectrum obtained above. 
A: No drug, B: doxorubicin [300uM], C: doxorubicin + catalase 
[300units] and D: MCF-7 cell supernatant . 
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radicals by doxorubicin in this system the effect of doxorubicin on 
oxygen consumption by MCF-7 cells was investigated. 
2.3.1.7 Effect of doxorubicin on oxygen consumption in 
intact, viable HCF-7 cells 
These studies were carried out as described in section 2.2.3. 
Figure 2.10 shows that doxorubicin stimulated oxygen consumption by MCF-
7 cells in a concentration dependent manner. 
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o 100 200 300 
doxorubicin concentration ruM] 
Figure 2.10 Effect of doxorubicin on oxygen consUmption by 
!1CF-7 cells. 
Cell concentration was l06ml -1. Data points are mean + standard 
deviation of three determinations. 
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2.3.2 Investigation of free radical formation by 
mitozantrone and CI94l in HCF-7 cells 
These studies were carried out in MCF-7 S9 fraction. In most of the 
following studies a single drug concentration of 100uM was used. This 
represented a concentration at which stimulation of NADPH oxidation and 
superoxide formation were observed for doxorubicin [see sections 2.3.1.1 
and 2.3.1.2]. 
2.3.2.1 Effect of mitozantrone and CI94l on NADPH oxidation, superoxide 
anion generation, drug free radical formation and 
hydroxyl radical formation in HCF-7 59 cell fraction. 
NADPH oxidation was determined as previously described [section 2.2.1]. 
Table 2.1 demonstrates that mitozantrone and CI941 [both 100uM] 
inhibited basal rate NADPH oxidation in MCF-7 S9 fraction by about 30%. 
Table 2.2 shows the effect of mitozantrone and CI941 on superoxide 
generation in MCF-7 S9 fraction as determined by SOD inhibitable 
reduction of acetylated cytochrome c or adrenochrome formation [see 
sections 2.2.2 and 2.2.3]. These drugs produced a negligible amount of 
superoxide anion formation in this system. The effect of mitozantrone 
on reduction of acetylated cytochrome c in MCF-7 S9 fraction is shown in 
figure 2.11. No significant superoxide formation could be detected in 
the presence of mitozantrone. 
Esr studies were carried out to determine if mitozantrone or CI941 
formed a free radical species in NADPH fortified MCF-7 S9 fraction using 
identical experimental conditions as described for doxorubicin [see 
section 2.2.3]. Figure 2.12 shows that no esr signal could be detected 
for these drugs [300uM]. 
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Table 2.1 Effect of mitozantrone and CI941 on NADPH 
oxidation in MCF-7 59 fraction. 
Drug [lOOuM] NADPH oxidation 
[pmole min-1mg-1 S9 protein] 
----------------------------------------
none 72+ 18 
mitozantrone 49.7 + 2.2 
CI941 48.96 + 2.9 
. 
Values are mean + sd of three determinations. 
Table 2.2 Effect Of mitozantrone and CI941 on superoxide anzon 




Reduction of acetylated 
cytochrome c nmole 
min -lmg-l S9 protein 
0.98 + 2.09 
1.71 + 0.95" 
adrenochrome 
formation 
nmole Imin Img 
S9 protein 
6.93+0.51" 
4.42 + 1.9" 
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Figure 2.11 Effect of mitozantrone on superoxide anion formation in 
HCF-l 59 cell fraction as determined by reduction of 
acetylated cytochrome c. 





Figure 2.12 Esr studies on free radical formation by mitozantrone and 
CI941 in NADPH fortified HCF-7 S9 cell fraction 
Spectra are:- A: mitozantrone [400uM) and B: CI941 [400uM). 
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Figure 2.13 Esr spectra from spin trapping studies of oxygen free 
radical formation by mitozantrone and CI941 in NADPH 
fortified HCF-7 59 cell fraction. 
Incubations contained MCF-7 S9 fraction, NADPH [0.5mM], desferrioxamine 
[lmM] and DMPO [100mM) with A: no drug, B: mitozantrone [400uM) and C: 
CI941 [400uM). Esr parameters were as described in figure 2.7. 
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Mitozantrone and CI941 mediated oxygen free radical formation in NADPH 
fortified MCF-7 cell S9 fraction was further investigated by esr using 
the spin trap DMPO [see section 2.2.5]. Figure 2.13 shows that no esr 
signal was observed in the presence of mitozantrone or CI941 in this 
system. 
2.3.3 Investigation of free radical formation by 
alkylaminoanthraquinones in HCF-7 cells 
2.3.3.1 Effect of alkylaminoanthraquinones on NADPH 
oxidation in MCF-7 59 cell fraction. 
Effect of a series of a1ky1aminoanthraquinones [AQ's] on NADPH oxidation 
in MCF-7 S9 fraction was determined as described in section 2.2.1. 
Figure 2.14 shows the effect of the AQ's on NADPH oxidation and 
demonstrates that 1AQ and 1,8AQ significantly stimulated base rate NADPH 
oxidation, whilst 1,4AQ and 1,SAQ produced no significant effect. 
Since 1AQ produced the largest stimulation of base rate NADPH oxidation 
[440%], this compound was investigated further. Figure 2.15 shows that 
1AQ stimulated MCF-7 S9 base rate NADPH oxidation in a concentration 
dependent manner. 
2.3.3.2 Effect of alkylaminoanthraquinones on superoxide anion 
formation in MCF-7 59 cell fraction. 
In order to substantiate further whether the AQ's could undergo 
reductive activation in MCF-7 S9 fraction, superoxide anion formation by 
these compounds was investigated by the methods described previously 
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Figure 2.14 Effect of alkylaminoanthraquinones on NADPH 
oxidation in HCF-7 S9 cell fraction. 
A~ ~~nc~rtration was 100uM. Base rate NADPH oxidation was 72 + 18 prnole 
m1n mg S9 protein. Data points are the mean + standard deviation of 
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Figure 2.15 Effect of lAQ on NADPH oxidation in HCF-7 59 
cell fraction. 
Base rate NADPH oxidation was 81 pmo1e min- 1mg- 1S9 protein. 
Data points are the mean + standard deviation of three determinations. 
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lAQ and l,8AQ both stimulate superoxide anion formation in MCF-7 S9 
fraction as determined by reduction of acetylated cytochrome c, however 
l,4AQ and l,5AQ produced no significant effect (figure 2.l6A). lAQ 
stimulated superoxide anion formation in a concentration dependent 
manner in this system (figure 2.17). AQ mediated superoxide formation 
was also investigated using the adrenochrome ·assay. Figure 2.l5B shows 
that using this assay lAQ, 1,4AQ and 1,8AQ were observed to 
significantly stimulate superoxide anion formation in MCF-7 S9 fraction, 
whilst 1,5AQ produced no significant effect. 
2.3.3.3 Detection of alkylaminoanthraquinone free radical 
formation in NADPH fortified HCF-7 S9 fraction 
Esr studies were carried out under anaerobic conditions to determine 
whether stimulation of NADPH oxidation and superoxide anion formation by 
AQ's was associated with semiquinone formation. Experimental conditions 
as previously described for doxorubicin were used [section 2.2.3]. 
Figure 2.18 shows the first derivative esr spectra obtained for AQ's in 
NADPH fortified MCF-7 S9 fraction. It can be seen from this figure that 
esr spectra were detected for 1,5AQ and l,8AQ whereas no spectra were 
obtained for lAQ or 1,4 AQ. The spectrum observed for l,5AQ had a peak 
to peak width of 4.85G and a g value of 2.00455. whilst the spectrum 
observed for 1,8AQ had a peak to peak width of 4.2G and a g value of 
2.00461. The parameters of these spectra are characteristic of organic 
free radicals [reviewed by Foster, 1984)]. The esr spectra obtained 
from these compounds were dependent on the absence air. 
2.3.3.4 Spin trapping of oxygen free radicals formed by 
alkylaminoanthraquinones in HCF-7 S9 cell fraction 
Studies were carried out in NADPH fortified MCF-7 S9 fraction as 
described in section 2.2.5. Figures 2.19, 2.20 and 2.21 show that spin 
adducts could be detected for all four AQ's in this system. The peak 
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Figure 2.16 Effect of alkylaminoanthraquinones on superoxide anion 
formation in HCF-7 59 cell fraction as determined by 
reduction of acetylated cytochrome c [A) and adrenochrome 
formation [B). 
AQ concentration was lOOuM. 
Data points are the mean + standard deviation of three determinati ons . 
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Figure 2.17 Effect of lAQ on superoxide anion formation in HCF-7 S9 
cell fraction as determined by reduction of acetylated 
cytochrome c. 
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Figure 2.18 Free radical formatIon by alkylaminoanthraquinones in NADPH 
fortified HCF-l 59 cell fraction as determined by electron 
spin resonance spectrometry. 
No Drug [A], LAQ [B], 1,4AQ [e), 1,5AQ [D], or 1,8AQ [E] 
(300uM) were incubated with NADPH fortified MCF-7 S9 cell fraction under 
anaerobic conditions at room temperature. 
The operating parameters were: micro~ave frequency 9.455 GHz, microwave 
power 5mW, modulation amplitude 4G, time constant 2 seconds, scan time 
16 minutes, scan range 20G and receiver gain 2.5xl05 [except for 1,8AQ 
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Figure 2.19 Esr spectra from spin trapping studies of oxygen free 
radical formation by lAQ in NADPH fortified HCF-7 59 cell 
fraction 
The system consisted of S9 fraction, NADPH [O.5mM], desferrioxamine 
[lmM] and DMPO [100mM] with: A: no drug, B: 1AQ [400uM](-S9 
fraction), c: 1AQ [400uM], D: lAQ + DMSO [200mM]. 
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Figure 2.20 Esr spectra from spIn trappIng studies of oxygen free 
radIcal formatIon by 1,4AQ In NADPH fortIfIed HCF-7 59 cell 
fractIon 
The system consisted of S9 fraction, NADPH [O.5mM], desferrioxamine 
[lmM] and DMPO [lOOmM} with: A: no drug, B: 1,4AQ [400uM}, C: l,4AQ 
[400uM]-S9 fraction. Esr parameters were as described in figure 2.7. 
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Figure 2.21 Esr spectra from spIn trappIng studIes of oxygen free 
radIcal formatIon by l,5AQ In NADPH fortIfIed HCF-7 59 cell 
fractIon 
The system consisted of S9 fraction, NADPH [O.SmM]. desferrioxamine 
[lmM] and DMPO [lOOmM] with: A: no drug, B: 1,SAQ [400uM]-S9 
fraction, c: 1,SAQ [400uM] D: 1,SAQ + DMSO [200mM]. 









Figure 2.22 Esr spectra from spin trapping studies of oxygen free 
radical formation by l,BAQ in NADPH fortified HCF-7 59 
cell fraction 
The system consisted of S9 fraction, NADPH [O.smM), desferrioxamine 
[lmM) and DMPO [lOOmM) with: A: no drug, B: l,8AQ [400uM), C: l,8AQ 
+ S9 fraction, D: l,8AQ + catalase [300 units ml- l ) and E: l,8AQ + 
DMSO [200mM). Esr parameters were as described in figure 2.7. 
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given in table 2.3 are consistent with the DMPO-OH adduct [see section 
2.3.1.5]. In the absence of S9 fraction LAQ, l,5AQ and l,8AQ produced 
similar but less intense esr signals. However, a signal of greater 
intensity was detected for l,4AQ in the absence of S9 fraction. The net 
intensities of the spectra obtained attributable to the presence of S9 
are shown in figure 2.23. 
To further investigate whether the spectra obtained by the AQ's in MCF-7 
S9 fraction were due to drug mediated hydroxyl radical formation, the 
incubations were repeated in the presence of DMSO [200mM]. Table 2.3 
shows the hyperfine splitting constants for the esr spectra obtained. 
In each case a 1:1:1:1:1:1 signal was produced with hyperfine splitting 
constants consistent with the DMPO-CH3 adduct (Pou et a1., 1989) [see 
figures 2.19, 2.20, 2.21 and 2.22]. 
The nature of the spectra obtained in the presence of 1AQ and 1,8AQ were 
investigated in more detail. Figure 2.24 shows that catalase [83 units] 
and DMSO [16mM] reduced the intensity of the spectrum obtained for LAQ 
Figure 2.22 shows the spectrum obtained for 1,8AQ in the presence of 
catalase [300 units m1- 1 ]. Catalase abolished the drug dependent esr 
signal, as shown in figure 2.22. The relative intensities of the 
spectra obtained for 1,8AQ in MCF-7 S9 fraction in the presence of DMSO 





Table 2.3 Spin adducts obtained from spin trapping experiments with 
alkylaminoanthraquinones in NADPH fortified MCF-7 S9 fraction. 
Hyperfine splitting constants Signal description 
alkylamino- -DMSO +DMSO 
an thraquinone AN AH AN AH -DMSO +DMSO 
lAQ 15.0 15.0 16.25 22.75 1:2:2:1 1:1:1:1:1:1 
.. 1,4AQ 14.75 15.0 16.25 23.0 II II 
1,SAQ 15.0 15.0 16.25 23.0 II II 
1,8AQ 15.0 15.0 16.25 23.0 .. II II 
Drug concentration was 400uM. DMSO concentration was 200mM. 
Esr parameters were as described in section 2.2.5. 
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Figure 2.23 Signal intensities of esr spectra obtained from spin 
trapping studies of oxygen free radical formation by 
alkylaminoanthraquinones in NADPH fortified HCF-7 S9 cell 
fraction 
Incubations were carried out in MCF-7 S9 fraction in the presence of 
NADPH [O.5mM], desferrioxamine [lmM] , DMPO [lOOmM] and drug [400uM ] . 
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Figure 2.24 Signal intensities of the esr spectra obtained from spin 
trapping studies of oxygen free radical formation by IAQ in 
NADPH fortified HCF-7 S9 cell fraction. 
Figure 2 . 19 shows the spectra obtained . 
A: no drug, B: lAQ [400uM], c: lAQ + catalase [83 units] and D: lAQ 
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Figure 2.25 Signal intensities of esr spectra obtained from spin 
trapping studies of oxygen free radical formation by I , BAQ 
in NADPH fortified MCF-l S9 cell fraction 
Intensities were derived from figure 2.22. 
A: no drug, B: 1,8AQ [400uM] minus S9 fraction C: drug [400uM ] D: 
drug + catalase [300 units ml- l ]. 
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2.4 Discussion 
2.4.1 Redox cycling by doxorubicin in HCF-7 cells 
Studies were carried out in order to determine if MCF-7 cells were 
capable of reductively activating doxorubicin to a free radical species 
by a redox cycling mechanism [see section 2.3.1]. This has widely been 
reported to occur in animal and human liver and heart tissues [see 
section 1.16.4.1] but no comprehensive studies have been carried out in 
human tumour tissue. As discussed in section 1.16.5 redox cycling has 
been implicated in the cardiotoxicity of doxorubicin, more so than in 
the antitumour activity. MCF-7 human breast cancer cells, originally 
isolated from a female patient with metastatic breast cancer (Seoule et 
al., 1973), is a particularly relevant cell line for these 
investigations as doxorubicin (and mitozantrone) are used in the 
chemotherapy of advanced breast cancer (see sections 1.13 and 1.14). 
Doxorubicin was found to stimulate in a concentration dependent manner 
both NADPH oxidation and superoxide anion formation in MCF-7 S9 cell 
fraction [see figures 2.1 and 2.2]. This indicated that doxorubicin was 
being metabolised by NADPH requiring enzymes with concomitant reduction 
of molecular oxygen. Furthermore, these events were associated with 
formation of an organic free radical species observed by esr [figure 
2.3]. The dependence of this esr signal on the presence of doxorubicin, 
NADPH-fortified MCF-7 S9 cell fraction and absence of oxygen indicated 
that this was a metabolically generated doxorubicin semiquinone free 
radical. Moreover, the intensity of this esr signal was dependent on 
the concentration of doxorubicin. The doxorubicin semiquinone free 
radical is the one electron reduction product of doxorubicin following 
reduction by NADPH requiring flavin reductase enzymes. The esr signal 
has a g value similar to that of the chemically generated doxorubicin 
semiquinone (Lown and Chen, 1981). The broadline esr signal produced 
[figure 2.3] has been proposed to be due to hindered rotation of the 
doxorubicin free radical as a consequence of membrane binding 
(Ka1yanaraman et al., 1980). The esr signal observed did not appear 
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until thirty minutes into incubation, this is likely to be due to 
residual oxygen in the incubate which needs to be reduced [see figure 
1.19] during metabolic activation of doxorubicin before a steady state 
esr signal for the semiquinone free radical can be detected. 
The above findings are consistent with doxorubicin undergoing one 
electron reduction by NADPH requiring flavoprotein oxidoreductases such 
as cytochrome P450 reductase as has been previously shown (Bachur et 
a1.,1979). These enzymes have been shown to be present in mammalian S9 
fraction (Beaune and Guengerich, 1988) and MCF-7 cells (Sinha et a1., 
1987). Other enzymes are also present in MCF-7 S9 fraction which have 
been shown to metabolically activate doxorubicin. These include 
xanthine oxidase (Bates and Winterbourn, 1982; and section 1.8.2) 
NADH-dehydrogenase (Haidle and Hunter McKinney, 1985) and NADH 
cytochrome b5 reductase (reviewed by Powis, 1989). One electron 
reduction of doxorubicin results in formation of a semiquinone free 
radical which is transient under aerobic conditions because it reacts 
with molecular oxygen at a diffusion controlled rate (3.0 + 0.2 x 108M-
ls-l, Butler and Hoey, 1987) resulting in formation of superoxide 
anions. Formation of superoxide anions can lead to a cell damaging free 
radical cascade beginning with dismutation of the superoxide anion 
either spontaneously [5xl05M- 1s- 1 ] or enzymically [2xl09M- l s- l ] by 
superoxide dismutase [SOD] [Cu-Zn SOD present in the cytoplasm or Mn-SOD 
in the mitochondrial matrix (see section 1.10.1) [equation (1)]. The 
hydrogen peroxide resulting from dismutation of superoxide anions, in 
the presence of trace amounts of transition metals, can lead to the 
formation of hydroxyl radicals [equation (2)] via the iron cata1ysed 
Haber-Weiss reaction. As discussed in section 1.9 hydroxyl radicals are 
highly reactive species and will damage DNA, proteins and lipids. The 
formation of reactive oxygen species in NADPH fortified MCF-7 S9 
fraction mediated by doxorubicin was investigated using the technique of 
spin trapping [section 1.12.3]. No DMPO-superoxide anion spin adduct 
[DMPO-OOH] formation was observed in this system which appears 
contradictory to the. results obtained using biochemical indicators of 
superoxide anion formation. However, a DMPO-hydroxy1 radical [DMPO-OH] 
spin adduct was observed in this system [figure 2.7]. This is because 
the superoxide anion reacts very slowly with DMPO (10 M- l s- 1) whereas it 
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dismutates [equation (1)] spontaneously at 5xl05M- l s-l and enzymically 
2 109M-l -1 [ . at x s revlewed by Pou et al., 1989]. Hydrogen peroxide can be 
further reduced to form hydroxyl radicals by the iron catalysed Haber-
weiss reaction [equation (2)]. 
(1) 
(2) 
where M is a transition metal [see section 1.8.3]. The metal ion may 
be reoxidised by the superoxide anion [equation (3)] or by the 
semiquinone radical under anaerobic conditions [equation (4)] (reviewed 




The hydroxyl radical reacts much faster than the superoxide anion with 
DMPO (2x109M- 1s- 1) [reviewed by Pou et al., 1989]. Furthermore, the 
DMPO-OOH adduct formed by superoxide anions is rapidly converted to 
DMPO-OH either chemically or enzymatically [reviewed by Pou et al., 
1989] (eg by glutathione peroxidase, Samuni et al., 1989). This may 
explain why in the present study:a DMPO-superoxide anion spin adduct was 
not observed. It was necessary in the present study to ensure that 
DMPO-OH formation was not due to decomposition of DMPO-OOH. This was 
achieved by the use of catalase (300 units) which decomposes hydrogen 
peroxide (section 1.10.1) and DMSO (16mM) which scavenges hydroxyl 
radicals (reviewed by Pou et a1., 1989). Inhibit~on of doxorubicin 
. -
mediated DMPO-OH formation in NADPH:fortified MCF-7 S9 fraction in the 
presence of these scavengers indicates that hydroxyl radical formation 
was responsible for the DMPO-OH adduct observed [see figure 2.7]. At 
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higher DMSO concentrations (200mM) a spin adduct characteristic of the 
DMPO-methyl radical [DMPO-CH3] spin adduct was produced in a system of 
doxorubicin and NADPH-fortified MCF-7 S9 cell fraction (figure 2.8). 
This is formed by the reaction of hydroxyl radical with DMSO to generate 
a methyl radical, which reacts with DMPO to give a DMPO-CH3 adduct (see 
figure 2.26). This provides further evidence for hydroxyl radical 
formation in NADPH-fortified MCF-7 cell S9 fraction in the presence of 
doxorubicin. During spin trapping studies a small DMPO-OH adduct signal 
was observed even in the absence of drug or S9 fraction [figure 2.8]. 
This was likely to be due to either 02'or trace iron mediated oxidation 
of DMPO. The presence of the iron chelator desferrioxamine in the 
incubate should have cancelled the effect of iron on DMPO. However, 
desferral has recently been shown to form a nitroxide free radical 
species in the presence of a hydroxyl radical generating system 
(Morehouse et a1., 1987) and systems that generate superoxide anions 
(Davies et a1., 1987; Li et a1., 1989). In summary, these spin 
trapping studies support the redox cycling of doxorubicin in MCF-7 S9 
cell fraction giving rise to the highly reactive hydroxyl radical. Spin 
trapping was also used to investigate redox cycling by doxorubicin in 
intact viable MCF-7 human breast cancer cells. As indicated by the 
formation of doxorubicin free radical species (figure 2.6) [as discussed 
above], formation of a catalase and DMSO sensitive DMPO-OH adduct 
(figure 2.9) and doxorubicin concentration dependent stimulation of 
oxygen consumption (figure 2.10) in an MCF-7 cell suspension, redox 
cycling would appear to be occurring. By analogy to the results 
obtained in MCF-7 S9 cell fraction it is likely that a doxorubicin 
semiquinone is being formed enzymatically which consumes molecular 
oxygen by reducing it to superoxide anions. Formation of this species 
is likely to give rise to the hydroxyl radical by the reactions 
previously described [equations (1-3)]. The findings of the present 
study are supported by the work of other researchers who have 
investigated free radical formation by doxorubicin in tumour cells. 
Doxorubicin has been shown to stimulate oxygen consumption and form a 
semiquinone free radical species in Chinese hamster ovary cells (Keizer 
et a1., 1988), rat hepatocytes (Lavelle et a1., 1985) and Hela cells 
(Partridge, 1987). Daunomycin has also been shown to generate a 
semiquinone free radical in rat hepatocytes, yoshida ascites cells and 
Ehrlich ascites cells (Bozzi et a1., 1981). Sato et a1. (1977) and 
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Figure 2.26 Diagram of DMPO spin-trapped adduct formation 
following the interaction of DMPO with superoxide and 
hydroxyl radical in the presence of DMSO. 
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Doroshow (1986a and 1986b) have shown that Ehrlich ascites tumour cells 
and MCF-7 human breast cancer cells, in the presence of doxorubicin , 
generated increased amounts of reactive oxygen species as determined 
using spin trapping. Also, using esr spin trapping techniques Sinha et 
al. (1987a and 1987b) demonstrated that doxorubicin increased hydroxyl 
radical formation in doxorubicin sensitive MCF-7 cells. Dusre et al. 
(1989) showed that buthionine sulphoxamine (BSO), an inhibitor of 
glutathione synthesis, potentiated doxorubicin mediated DMPO-hydroxyl 
radical spin adduct formation and cytotoxicity in doxorubicin-resistant 
MCF-7 cells. Indirect studies using doxorubicin resistant tumour cell 
lines have indicated doxorubicin redox cycling to be important in 
mediating cell kill [see section 1.16.4.4]. Moreover, modulation of 
cellular protection systems against reactive oxygen formation has been 
found to influence doxorubicin cytotoxicity, indicating a role for redox 
cycling in the mechanism of action of doxorubicin [see section 1.16.4.1]. 
However, the studies carried out by other workers have not 
systematically investigated each line of evidence for doxorubicin redox 
cycling in a cell line as has been undertaken in the present study. 
In the present study the DMPO-OH adduct produced in viable MCF-7 cells 
in the presence of doxorubicin appeared to be located extracellularly, as 
indicated by the diminuition of this signal in the presence of catalase, 
an enzyme which is unlikely to cross the cell membrane. In addition, 
persistance of the esr signal in the cellular supernatant after the 
cells have been removed indicates an extracellular site of hydroxyl 
radical formation. DMPO is lipid soluble so it is capable of permeating 
the cell membrane (Pou et al., 1989). This finding would appear to agree 
with the proposal of Tritton et al. (1983) that doxorubicin can be 
metabolically activated enzymatically at the cell surface and does not 
need to enter the cell to express cytotoxicity. Sinha et al. (1987b) 
also showed that 60-65% of the DMPO-OH adduct was produced 
extracellularly in doxorubicin treated MCF-7 cells as indicated by the 
use of chromium oxalate as a line broadening agent. Furthermore SOD 
inhibited DMPO-OH formation and exogenous NADPH stimulated hydroxyl 
radical formation. This might be explained if the DMPO-OH adduct or 
hydrogen peroxide produced during doxorubicin redox cycling diffused out 
of the cell. Furthermore, despite its lipophilicity, DMPO has been 
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proposed by Samuni et al. (1989a) to be unsuitable for use for spin 
trapping in cellular systems due to its rapid metabolism. As discussed 
previously DMPO-OOH can decompose to DMPO-OH and other products 
chemically or by enzymes such as glutathione peroxidase (reviewed by Pou 
et al .• 1989). Recent evidence has shown that DMPO-OH is degraded by 
superoxide anions (Samuni et al .• 1989b). From the results of the 
present study it is clear that hydroxyl radicals are produced in MCF-7 
cells when they are treated with doxorubicin. However. due to the 
difficulties associated with intracellular spin trapping studies it is 
not possible to locate the site of doxorubicin activation in MCF-7 
cells. 
The formation of reactive oxygen species by doxorubicin redox cycling in 
MCF-7 cell fraction and whole cells as determined in the present study 
would appear to correlate with similar studies in MCF-7 human breast 
cancer cells and other cell lines. Doxorubicin redox cycling would 
appear to occur in tumour cells with production of the potentially 
damaging hydroxyl radical. The overall consequence of this will 
ultimately depend on the site of generation of this reactive species and 
how well the cell protective systems (section 1.10) can cope with this 
oxidative insult. Possible biological end points of doxorubicin redox 
cycling in MCF-7 cells. namely DNA damage and cytotoxicity and are 
investigated in chapters 3 and 4. The findings reported in this section 
have also confirmed that the MCF-7 cell line has the enzymes required to 
mediate metabolic reductive activation of doxorubicin in the process of 
redox cycling. Therefore. this cell line appears suitable for 
investigation of redox cycling by other quinone containing antitumour 
agents. 
2.4.2 Comparison of redox cycling by mitozantrone, CI-94l and 
doxorubicin in HCF-7 cells 
Mitozantrone and CI941 are structurally related anti tumour agents which 
have been developed in order to produce agents with reduced 
cardiotoxicity in comparison to doxorubicin. As described previously 
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their structural features were designed to favour DNA intercalation but 
reduce their interaction with flavin reductase enzymes and hence reduce 
their ability to undergo redox cycling, the mechanism proposed to 
mediate doxorubicin cardiotoxicity [see section 1.16.5]. Studies have 
been carried out to compare doxorubicin with mitozantrone and CI941 
redox cycling in both animal and human tissues [Basra et a1., 1985; 
Graham et al., 1987). However, no studies have yet been reported on the 
relative propensity of these agents to redox cycle in human tumour 
tissue. 
Mitozantrone and CI941 inhibited base rate NADPH oxidation, produced 
negligible superoxide anion formation, did not form semiquinone free 
radicals and did not generate hydroxyl radicals in MCF-7 cell S9 cell 
fraction [tables 2.1 and 2.2; figures 2.11, 2.12 and 2.13]. This 
indicates that these compounds have little propensity to undergo redox 
cycling in MCF-7 cells in comparison to doxorubicin. Tables 2.4a and 
2.4b compare NADPH oxidation and superoxide anion formation by these 
three compounds. Basra et a1. (1985) found that mitozantrone stimulated 
base rate NADPH oxidation, superoxide formation and generated an esr 
signal attributed to semiquinone formation in human liver microsomal 
tissue, but at considerably lower levels than doxorubicin. Similar 
findings were found in mouse and rat liver and heart tissue (Basra, 
1986). However, Vile and Winterbourn (1989) found that mitozantrone did 
not stimulate superoxide anion formation in rat liver microsomes. CI941 
has also been found to have reduced propensity for metabolic activation 
in rat tissue compared to doxorubicin, no free radical being detected by 
esr (Graham et a1., 1987). Consistent with the inhibition of NADPH 
oxidation in this study, mitozantrone has also been shown to inhibit 
base rate NADPH dependent lipid peroxidation in rabbit liver and heart 
tissue (Kharasch and Novak, 1983a and 1985) and inhibit doxorubicin 
stimulated lipid peroxidation and superoxide formation. Similar 
findings were reported for CI941 in rat tissues (Graham et a1., 1987). 
In addition mitozantrone did not initiate lipid peroxidation in mouse 
liver and heart fractions (Patterson et a1., 1983) or rat liver 
microsomes (Vile and Winterbourn, 1989). The absence of enzymic 
reduction of mitozantrone and CI941 compared to doxorubicin in the 
present study correlates well with their one-electron reduction 
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Table 2.4a Comparison of the effect of doxorubicin, 
mitozantrone and CI941 on NADPH oxidation in 
MCF-7 59 fraction. 
Drug [lOOuM] NADPH oxidation 
pmole min-1mg-1 59 protein 
Base 72.0 + 18.0 
mitozantrone 49.7 + 22 
0941 48.96 + 29 
doxorubicin 830.74 + 0.1 
Table 2.4b Comparison of superoxide anion formation in 





Reduction of acetylated 
cytochrome c nmole 
min-1mg-1 S9 protein 
0.98 + 2.09 
1.71 + 0.95 








Values represent mean + sd of three determinations. 
* (p<O.Ol) _ 
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potentials at pH7.0 (E17) [see table 2.5]. Both mitozantrone (E17
; _ 
527+5mV) and CI941 (E17 ; -538+10mV{Graham et a1., 1987}) have 
considerably more negative reduction potentials than doxorubicin (E1
7
; _ 
328+5mV). However, the rates for the reaction of the respective 
semiquinones with molecular oxygen are all very fast [table 2.5]. As 
described previously [section 1.8.1] subsequent reactions of the 
superoxide anion are very rapid. This indicates that the rate limiting 
step for the activation of these agents and formation of reactive oxygen 
species is the step involving one electron enzymic reduction. The more 
negative reduction potentials of mitozantrone and CI941 means they are 
more difficult to reduce than doxorubicin. Furthermore, they are also 
likely to be poorer substrates for reductases than doxorubicin due to 
steric hinderance between these compounds and the flavin component of 
the reductase, the proposed site of interaction of quinone containing 
antitumour agents. Flavin adenine dinucleotide (FAD) and flavin 
mononucleotide (FMN) mediate electron transfer from NADPH to cytochrome 
P450 (Vermilion, et a1., 1981). Both doxorubicin and mitozantrone have 
been shown to bind to FMN and FAD with high affinity, an interaction 
that has been proposed to be involved in electron transfer from the 
reductase to quinone containing drugs (Kharasch and Novak, 1981 and 
1983c). In addition, the MCF-7 S9 cell fractions used in this study had 
lower NADPH cytochrome P450 reductase activity [1.19 nmo1es min- 1 mg- 1 
S9 protein] than human liver [166.1+49:4 nmo1es min- 1mg- 1 protein] and 
mouse liver microsomes [222.3+4 nmo1es min- 1mg- 1 protein] (figures 
indicate rate of reduction of cytochrome c, derived from Basra et al .. 
1985). The cytoso1ic enzyme xanthine oxidase was found not to be 
involved in activation of mitozantrone or CI941 [see section 3.3.1.2]. 
The lack of detectable radical formation in the case of CI941 and 
mitozantrone can therefore be explained by a very low rate of 
semiquinone formation. The rate of doxorubicin semiquinone formation is 
typically measured as nmo1e NADPH oxidised min- 1 , this will rapidly 
react with oxygen (3.0x108M- 1s-l) to produce superoxide anions which 
will rapidly dismutate (2xl09M- l s- l ) in the presence of SOD or 
spontaneously (5x105M- l s- l ) [see section 1.8.1]. From the above 
reaction rates it can be seen that high concentrations of semiquinone 
free radical need to be produced before it can be detected. For 
example, the lowest doxorubicin concentration at which semiquinone 
formation detected in MCF-7 S9 fraction was 50uM (figure 2.4). 
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Table 2.5 Reduction potentials and rates of reaction for the semiquinone 





















lAQ -469+8 1.9+0.1x109 1.6+0.8x109 
1,4AQ nd nd nd 
1,5AQ -495+5 2.0+0.15x109 1.5+0.6x10
9 
l,8AQ -497+8 1.9+0.1x109 1.9+0.3x10
9 
Derived from Basra (1986) except "'derived from Butler and Roey (1987) 
nd=not determined 
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The main concern about the drug concentrations used in these assays is 
as to whether these concentrations are physiologically relevant. Basra 
et al. (1985) suggest that despite the peak plasma concentration of 
doxorubicin and mitozantrone being approximately luM, it is likely that 
intracellularly higher local concentrations are attained due to the high 
binding affinities of these drugs for cellular membranes and DNA 
(reviewed by Gianni et al., 1983). Given that the DNA binding 
affinities of the quinone antitumour agents are in the region of 106-107 
(see table 3.3) the nuclear concentration of these agents could be 106 
fold higher than other regions of the cell. 
2.4.3 Redox cycling by alkylaminoanthraquinone anti tumour agents 
A series of hydroxyethylaminoethylamino substituted anthraquinones with 
structures based on the requirements for DNA intercalation by 
doxorubicin and mitozantrone were synthesised by Murdock et al. (1979) as 
part of the screening programme to find less cardiotoxic anti tumour 
agents and later by Gandecha (1985). These compounds (figure 1.35) 
have identical side chains to mitozantrone but do not have the aromatic 
hydroxyl groups on the A ring of the anthraquinone chromophore. By 
analogy with doxorubicin, due to the possession of the anthraquinone 
moiety these compounds are candidates for metabolic activation by flavin 
reductase enzyme systems [see section 1.16.4.1]. Therefore the ability 
of these compounds to undergo redox cycling in the MCF-7 human breast 
cancer cell line was investigated in this study [see section 2.3.3.4]. 
All four AQ's showed some evidence for redox cycling in MCF-7 S9 cell 
fractions. The LAQ strongly stimulated NADPH oxidation [figure 2.15], 
superoxide anion formation [figure 2.17] and the formation of hydroxyl 
radicals [figure 2.19] in this system. This provides evidence for the 
occurrence of a redox cycling process involving flavin reductase one 
electron reduction to a semiquinone free radical intermediate as 
previously described for doxorubicin [section 2.4.1]. However, no esr 
signal could be detected for lAQ to indicate drug semiquinone formation 
[figure 2.18]. As described in section 2.4.2, this is likely to be due 
to the slow rate of formation of this species enzymically and its 
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sensitivity to the presence of residual oxygen. The 1,8AQ also 
stimulated NADPH oxidation [figure 2.14], superoxide anion formation 
[2.16], hydroxyl radical formation and produced a free radical species 
detectable by esr (figure 2.lS). These results are consistent with this 
compound undergoing redox cycling in MCF-7 S9 cell fraction as described 
for doxorubicin [section 2.4.1]. 1,sAQ was found to have no significant 
effect on base rate NADPH oxidation (figure 2.14) and produced 
negligible superoxide anion formation (figure 2.16) suggesting only a 
small level of e~zymic activation of this compound. However, these 
results are contradicted by the detection of a free radical species for 
1,sAQ by esr in MCF-7 cell S9 fraction, consistent with semiquinone 
formation (figure 2.lS). Furthermore 1,sAQ also generated hydroxyl 
radicals in MCF-7 cell S9 fraction [figure 2.21]. This would suggest 
that despite 1,sAQ having no significant effect on base rate NADPH 
oxidation that the 1,sAQ is possibly being activated by a non-NADPH 
requiring enzyme system. However, 1,sAQ was found not to be activated 
by the cytosolic enzyme xanthine oxidase [see section 3.3.1.3]. Finally 
1,4AQ also stimulated NADPH oxidation in MCF-7 S9 fraction (figure 
2.14) but formed negligible superoxide anions (figure 2.16) as 
determined by the reduction of acetylated cytochrome c. However, no 
hydroxyl radical formation or drug free radical species could be 
detected in MCF-7 cell S9 fraction for this compound (figures 2.lS and 
2.20). This indicates that in contrast to the other AQ's this compound 
does not redox cycle in the MCF-7 cell line. 
The weak semiquinone free radical esr signals obtained for the AQ's in 
MCF-7 S9 cell fraction (figure 2.lS) can be explained by the slow rate 
of enzymic formation of the one electron reduced drug intermediate 
compared to the rate of its decay [as discussed in section 2.4.2]. A 
strong esr signal could be consistently obtained for doxorubicin 
semiquinone irt an identical system [figure 2.4]. Considering the levels 
of NADPH oxidation and superoxide formation produced by lAQ and 1,SAQ 
which are of similar level to that stimulated by doxorubicin it is 
surprising that measurable esr signals could not be obtained for the 
semiquinones of these compounds. However, due to AQ's having more 
negative reduction potentials [table 2.5] than doxorubicin they are 
likely to be more difficult to reduce by reductases and are therefore 
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likely to be reduced more slowly. These reduction potentials are still 
sufficiently negative to reduce molecular oxygen to the superoxide anion 
[reduction potential for 1 Molar 02/02-- -lssmV]. In addition, the 
reaction rates for the interaction of the AQ semiquinones with oxygen 
[see table 2.5, Basra, 1985] are approximately six times faster than 
that obtained for doxorubicin (O.3+O.2x109M- 1s-1 ]. The esr signal 
intensity is dependent on the equilibrium between rate of formation and 
rate of decay of the semiquinone. This means in the presence of 
residual oxygen the semiquinone is not likely to build up in intensity 
due to its slow rate of formation and fast rate of decay. Contributing 
to the rate of decay of this species is the interaction of two 
semiquinone radicals [reaction rates table 2.5] (equation 1) which for 
anthrasemiquinones is a diffusion controlled process. This mechanism 
for the loss of semiquinone will predominate under anaerobic conditions. 
However the semiquinone free radical may be reformed by 
comproportionation if sufficient fully reduced quinone is present 
(hydroquinone) [equation 2]. 
AQH· + AQH· ;.==~. AQH2 + AQ (1) 
AQH2 + AQ •• ===~. 2AQH· (2) 
Considering the five parameters of redox cycling investigated in this 
study a rank order of propensity to undergo this process can be 
constructed for the AQ's:- 1AQ - 1,8AQ > 1,sAQ > 1,4AQ. Overall, it 
would appear that doxorubicin has a greater propensity than lAQ, 1,sAQ 
and 1,8AQ to redox cycle whereas mitozantrone, CI941 and 1,4AQ do not 
redox cycle in MCF-7 cells. The results obtained in this study are 
consistant with the previous findings of Basra (1986) who studied redox 
cycling by AQ's in mouse liver microsomes. In these studies 1,8AQ was 
found to be the most active redox cycling agent and 1,4AQ the least 
active with 1AQ and 1,sAQ being intermediate between these two 
compounds. However, it is unrealistic to directly compare the results 
of the present study in MCF-7 cells with those obtained from mouse liver 
microsomes. 1,4AQ, (also known as ametantrone) has been found to behave 
in a similar manner to mitozantrone in several systems [see section 
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2.4.2]. Kharasch and Novak (1982, 1983a and 1983b) found l,4AQ 
inhibited base rate lipid peroxidation and doxorubicin-stimulated lipid 
peroxidation in rat and rabbit liver microsomes, cardiac sarcosomes and 
cardiac mitochondria. This effect was proposed to be due to an 
inhibition of hydroperoxide dependent initiation and propagation 
reactions (Kharasch and Novak, 1985). In addition, in rabbit liver 
microsomes ametantrone did not significantly stimulate basal rate NADPH 
oxidation or superoxide anion formation (Novak and Kharasch, 1985). 
These studies support the absence of redox cycling observed with the 
l,4AQ in the present study. 
It would appear that structural alteration of the AQ's by changing the 
position of the side chains on the anthraquinone chromophore [see figure 
1.35] influences the stimulation of NADPH oxidation, superoxide anion 
formation, hydroxyl radical formation and formation of a drug free 
radical species in MCF-7 S9 cell fraction indicating differences in the 
abilty of the AQ's to undergo reductive metabolic activation. This may 
be due the positioning of the side chains steric~lly hindering 
interaction of the anthraquinone chromophore with the flavin component 
of reductase enzymes (as discussed in section 2.4.2). 
In summary, evidence has been accumulated that doxorubicin undergoes a 
redox cycling process in MCF-7 human breast cancer cells with resultant 
production of the potentially cell damaging hydroxyl radical. In 
contrast, mitozantrone and CI941 do not redox cycle in this cell line. 
Furthermore, a series of alkylaminoanthraquinones based on mitozantrone 
have also been shown to redox cycle in MCF-7 S9 cell fractions to 
varying degrees depending on the position of the hydroxyethyl-
aminoethylamino side chains on the anthraquinone moiety. In subsequent 
chapters, biological end points which are possibly caused by redox 
cycling and resultant reactive oxygen formation by the quinone 
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CHAPTER 3 
Studies on the effects of Quinone antitumour agents on DNA 
3.1 Introduction 
As described in sections 1.16.1 and 1.17 anthracyc1ine and anthraquinone 
anti tumour agents bind to DNA by a mixture of interca1ative binding and 
electrostatic interaction with the surface of the DNA helix. Besides 
this characteristic property, chapter 2 has shown that the quinone 
anti tumour agents of the present study have varying propensities to 
undergo metabolic reductive activation during reductase mediated redox 
cycling, resulting ultimately in hydroxyl radical formation. This chapter 
investigates several aspects of DNA interaction by the anti tumour agents 
of the present study:-
1. The ability of these agents to produce DNA damage in a system 
containing purified reductases and plasmid DNA. 
2. The ability of these agents to mediate plasmid DNA strand 
breakage in the presence of iron and reduced glutathione. 
3. The effect of these agents on topoisomerase activity in 
MCF-7 cell nuclear extract. 
4. The ability of these agents to produce DNA strand breakage 





Determination of the effects of quinone anti tumour agents on 
plasmid DNA in the presence of purified NAD(P)H dependent 
reductases. 
This assay was based on the strand breakage of plasmid pBR322 DNA which 
is supercoiled in its native form. Nicking of the DNA results in 
conversion of the supercoiled [form I] DNA to relaxed [form II] DNA or 
linear [form III] DNA (see section 1.12.3 for full details). Open 
circular and linear DNA present after incubation of the native 
supercoiled DNA with drug/enzyme were separated by submarine agarose gel 
electrophoresis. The DNA species were quantitated by staining with 
ethidium bromide, photographing the gel [using UV transillumination] and 
determining the intensity of the DNA bands on the negative by laser 
densitometry. Appendix figure A3 shows that the DNA concentration used 
was in the linear region of a plot of DNA concentration against band 
intensity, which enabled maximum sensitivity for detection of changes in 
DNA concentration. 
The components of each incubate were dispensed into plastic eppendorf 
tubes (2m1) in the following order to produce a total volume of lOOul: 
Tris buffer [100mM, pH8.0], MgC12 [3mM] , NADH [O.4mM] or NADPH [lmM] , 
xanthine oxidase [2.5 units] or cytochrome P4S0 reductase [23.4 units], 
drug [10-100uM] and finally plasmid pBR322 DNA [300ng]. Plasmid DNA was 
added last to minimise DNA damage during the preparation of each 
incubate. The contents of the control and test tubes are summarised in 
table 3.1. 
On addition of the plasmid DNA, the tubes were capped and mixed by 
centrifugation for five seconds in a microcentrifuge [Hema-C, Jouan] and 
then incubated in the dark at 37C for thirty minutes. At the end of the 
incubation, NaC1 [sM, 100ul] was added to each tube, following which the 
drug was extracted using water-saturated n-butanol [200ul aliquots]. 
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Table 3.1 Experimental table for a typical plasmid assay 
component control A control control C experimental 
MgCl2 
enzyme 













control A = DNA only, control B = DNA + enzyme and 










Upon addition of the solvent the tubes were gently agitated to mix, then 
spun in a microcentrifuge for five seconds and the n-butanol layer 
removed and discarded. This procedure was repeated until drug 
colouration of the aqueous phase was no longer evident [2-4 extractions]. 
In order to precipitate the DNA, pre-chilled ethanol [-20C] was added to 
the samples and the tubes placed in a freezer (-20C) for one hour. 
Following this the samples were spun [12,000g, 10min] on a 
microcentrifuge to pellet the DNA. The caps of the tubes were cut off 
and the ethanol decanted carefully so as to avoid disturbing the DNA 
pellet. The tubes were then inverted and any remaining ethanol removed 
using a capillary tube. The samples were then dried by placing under a 
vacuum for five minutes. Following drying, TE buffer [Tris-HCI (IOmM) 
EDTA (lmM), SuI, pHS] was added and the bottom of the tubes 'flicked' 
once to dislodge the DNA pellet. The tubes were centrifuged for five 
seconds and then incubated at 37C for fifteen minutes to redissolve the 
DNA pellet. Following incubation, loading buffer [bromophenol blue 
(0.25%), sucrose (1.17M), SuI] was added to the samples and the tubes 
centrifuged (12,000g, 5 seconds) to mix. Aliquots (IOul) of the samples 
were loaded onto a pre-prepared agarose gel [agarose (1%) in Tris base 
(39.6mM), glacial acetic acid (lS.3mM), EDTA (lmM), {TAE buffer}] 
containing 16 sample wells (see appendix A4). The gel was placed in an 
electrophoresis tank and submerged in electrophoresis buffer [TAE] and 
twenty volts [35 mAmps] applied overnight (or l50V for one hour), the 
DNA moving in the direction of the anode. 
After electrophoresis the gel plate was placed in ethidium bromide 
[2ug/ml, in TAE] for fifteen minutes in order to stain the DNA, excess 
stain being removed by placing the gel plate in descaining buffer [TAE] 
for thirty minutes. The gel was then photographed. 
Photography was carried out using a Land camera [MP-4, Kodak] by 
illuminating the gel from underneath with uv light at 300nm using a 
transilluminator [UVP inc]. The film used was Kodak professional 
(Pe1ica T max 100 4052), with an exposure time of twenty seconds, two 
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orange filters in series (Wratten orange filter 23A) being used to 
enhance the contrast. The negative was developed in total darkness using 
developer [ID11, I1ford] (time of developing dependent on temperature of 
developer) and fixed for seventeen minutes using fixer [Hypam, Ilford). 
Quantitation of negatives was carried out using a U1troscan laser 
densitometer [Model 2202, LKB Bromma] with Ge1scan interface and 
software package [LKB 2190-001] run on an Apple II computer. The 
accumulated data was analysed using the programme 'Ge1scan' which 
presented the results in the form of densities and relative percentages 
of the DNA species in each sample. The recorded density of supercoiled 
plasmid DNA was corrected at this stage using the correction factor of 
1.22, since ethidium bromide has reduced binding affinity for this form 
of DNA [Hertzberg and Dervan, 1982]. 
3.2.2 Determination of the effect of quinone anti tumour agent . 
iron complexes on plasmid DNA in the presence of reduced 
glutathione. 
3.2.2.1 Preparation of anthraquinone-iron complexes 
Complexes between iron and doxorubicin, CI941 or mitozantrone were 
prepared as a 2:1 iron:drug ratio in the following manner. 
Drug [3mM] , in HC1 [pH 2.0] was mixed with ferrous ammonium sulphate 
[3mM] in HC1 [pH 2.0] in a 1:2 r~tio. The mixture was diluted (1:5) 
using tris buffer [200mM, pH 7.4] to give a final concentration of 0.2mM 
drug: 0.4mM iron(II) at pH 7.4. Solutions containing iron or drug only 
were prepared for use as controls by replacing either ferrous ammonium 
sulphate or drug with HC1 [pH 2.0] in the above protocol. 
Anthrapyrazo1e-ferric iron complexes were prepared in an identical 
: 
manner using ferric chloride. 
177 
3.2.2.2 Plasmid assay 
This assay was essentially the same as that described above [section 
3.2.1] except the incubate contained the following: 
Tris buffer [lOOmM, pH7] , glutathione (reduced form) [25mM, in Tris 
buffer], drug-iron complex [O.s-sOuM, 1:2 drug:iron ratio] and DNA 
[300ng]. The controls consisted of samples containing iron (ferrous 
ammonium sulphate, 2-l00uM) or drug (O.s-sOuM). 
To aid the extraction of the drug iron complex from the DNA 
desferrioxamine [smM, SuI] was added prior to extraction with water-
saturated n-butanol. 
3.2.3 Determination of the effect of quinone antitumour agents on 
MCF-7 cell topoisomerase activity 
This assay involved the use of supercoiled [form I] pBR322 plasmid DNA 
as a substrate for a topoisomerase containing nuclear extract from MCF-7 
cells. Topoisomerase I and II activity can be separated by including 
adenosine 5'-triphosphate (ATP) , which is required for topoisomerase II 
activity only (reviewed by Yang, 1985). In this system topoisomerase 
activity unwinds or relaxes the supercoiled DNA producing various 
relaxed DNA forms or topomers including open circular (form II) DNA. 
The DNA species are resolved by submarine gel electrophoresis. Two 
types of drug effect on topoisomerase activity can be determined in this 
assay system:-
a) Inhibition of the relaxing activity of topoisomerase 
b) Formation of topoisomerase cleavable complex by the presence of 
drug. The cleavable complex consists of an enzyme complex 'trapped' 
on the DNA. On treatment of this complex with proteinase K, single 
or double strand breaks are revealed. Thus, in this assay drug-
mediated cleavable complex formation would be indicated by the 
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presence of open circular or linear DNA (see section 1 12 3 . .) . 
3.2.3.1 Preparation of a crude nuclear extract from HCF-7 
cells 
This was prepared using the method described by Minford et a1. (1986). 
Firstly MCF-7 cells [107-109] in exponential growth phase were harvested 
and suspended in nucleus buffer [MgC12 (SmM), KH2P04 (lmM) , EGTA (lmM) , 
dithiothreitol (O.lmM), glycerol (10%), NaCl (O.lSM), pH 6.5]. The 
cells were washed twice in nucleus buffer by centrifuging [lOmin, 
l200rpm, 4C] using a refrigerated bench centrifuge [CR122, Jouan]. In 
order to permeabilise the cells the cell pellet was resuspended in 
nucleus buffer (lOml, 4C) and the volume made up to 100ml with lysis 
buffer [MgC12 (SmM) , KH2P04 (lmM) , EGTA (lmM) , dithiothreitol (O.lmM), 
glycerol (10%), triton X-IOO (0.35%) and phenylmethanesulphonyl fluoride 
(O.lmM), pH 6.5]. The cell suspension was rotated at low speed [15min, 
4C] using a mixing device [Heidolph]. The suspension was then divided 
into two centrifuge tubes (SOml) and centrifuged [lOmin, l400rpm, 4C] in 
order to spin down the released nuclei. The nuclear pellet was washed 
once with nucleus buffer by centrifuging [lOmin, l400rpm, 4C] and the 
resulting pellet resuspended in extraction buffer [nucleus buffer 
containing NaCl (0.35M)]. The suspension was gently rotated [30min, 4C] 
in order to extract nuclear protein. The suspension was then 
centrifuged [20min, l800rpm, 4C] and the resulting supernatant removed 
and further centrifuged [lOmin, l2,000g, 4C] in a microcentrifuge [Hema-
C, Jouan]. The supernatant [nuclear extract] was stored in aliquots 
[lOOul] under liquid nitrogen until required. 
3.2.3.2 Determination of topoisomerase relaxing activity in 
HCF-7 cell nuclear fraction 
The basic components of the incubate [lOOul] were topoisomerase buffer 
[KCl (lOOmM), MgC12 (lOmM), EDTA (O.SmM), BSA (30ug/ml) and 
dithiothreitol (5mM) in tris buffer (lOOmM), pH 7.4], nuclear extract 
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(l-lsug protein) and plasmid DNA (SOOng). Each extract concentration 
was incubated in the presence or absence of ATP (lmM). Control 
incubates consisted of DNA only and DNA plus ATP. The incubation was 
carried out for 15-30 minutes at 37C, and the reaction terminated by the 
addition of sodium dodecyl sulphate [2%] and proteinase K (O.OSmg) [20 
Anson units/g, BDH], mixing by centrifugation [ssec] and incubating [30 
min, 37C). NaCl [sM, 100ul) and pre-chilled ethanol [400ul] were added 
to the incubates and the protocol described in section 3.2.1 was 
followed. 
3.2.3.3 Determination of the effect of quinone antitumour 
agents on topoisomerase DNA relaxing activity in HCF-7 cell 
nuclear extract 
The basic incubate was as described in section 3.2.3.2. Incubations were 
carried out with nuclear extract [lug] in the presence or absence of 
drug and in the presence or absence of ATP [lmM). Control incubate 
consisted of DNA only and DNA plus ATP. The incubation was carried out 
for fifteen minutes at 37C. The reaction was terminated by the addition 
of SDS [2%] followed by a further incubation [4Smin, SOC]. The protocol 
subsequently followed was as described in section 3.2.1. 
3.2.3.4 Determination of topoisomerase cleavable complex 
formation by quinone antitumour agents. 
This assay was carried out as described in section 3.2.3.3. However the 
reaction was terminated using SDS [2%] and proteinase K (0.05 or O.lmg). 
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3.2.4 Determination of quinone antitumour agent induced DNA 
strand breakage in HCF-7 cells by alkaline elution. 
This technique, developed by Kohn et a1. (1976) utilises filters to 
determine DNA strand breaks in mammalian cells produced by cytotoxic 
drugs or radiation. The filters are used as a mechanical barrier to the 
passage of large DNA strands (see section 1.11.1). In this study this 
technique was used to determine DNA single strand breaks after treatment 
of MCF-7 cells with radiation or quinone antitumour agents. 
3.2.4.1 Preparation of filter assembly 
Firstly ten filter systems were assembled as fol1ows:-
A po1ycarbonate membrane filter [0.8uM, 2smm diameter, Nucleopore (USA), 
obtained from Steri1in Ltd (UK)] was placed in a pre-cooled swinnex 
filter holder [2smm diameter, Mi11ipore] fitted with a rubber gasket. 
The top male Luer connection of the swinnex was connected via a threeway 
tap [type 875.00, Vygon] to a syringe with a concentric luer lock 
connector [sOm1, Fisons]. The bottom connector of the swinnex was 
connected to another threeway plastic tap [type 875.00, Vygon]. The 
filter assembly was clipped vertically onto an especially constructed 
rack which enabled drainage of the assembly into a perspex channel, 
leading to a waste container. Using a syringe (sOml), connected to a 
threeway tap, the syringe was filled with ice cold phosphate buffered 
saline (PBS) (10m1, pH7.2) via the bottom tap. The PBS was passed 
upwards and downwards through the swinnex several times whilst tapping 
the swinnex in order to remove all air bubbles. With the upper tap in 
the closed position, the syringe was filled from above with a further 
40m1 of ice cold PBS. The PBS was then allowed to drip through the 
filter assembly until the meniscus reached the apex of the syringe. The 
swinnex was left at this stage (1 hour) in order for the filter to cool 
prior to loading of cells. 
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3.2.4.2 Treatment of cells 
a) Radiation 
MCF-7 cells were harvested and dispersed as described in section to 
provide a concentration of 0.5-2.0 x 106 cells ml- l . Aliquots (lml) of 
cell suspension were placed in ten screw cap plastic vials (2ml, Nunc) 
and placed on ice. The vials were exposed to gamma radiation, by 
placing in a pre-cooled lead block [ave. thickness 35mm] and inserting 
this into an automated 60Co gamma source (Vickrad). The vials were 
exposed to the gamma source for varying time lengths (46, 92, 184 secs) 
to give doses of radiation corresponding to 2,4 and 8 Grays (Elsy, D., 
Leicester University, personal communication). Duplicate vials were 
treated at each dose, whilst dupicate vials were left untreated to serve 
as controls. After irradiation the vials were immediately placed on ice 
to prevent DNA repair (Kohn et al., 1981). The cells were then ready 
for lysis. 
b) Antitumour agents 
MCF-7 cells were harvested and dispersed as described in appendix Al.2 
and section 4.2.1, suspended in RPMI-1640 growth medium at a 
concentration of 5xl06ml- 1 . Aliquots of cell suspension (lml) were 
placed in plastic centrifuge tubes (12ml, Sterilin) and transferred to a 
water bath (37C). A volume of drug solution was added to the cell 
suspension so as to give the desired final drug concentration. The 
cells were incubated with drug for one hour, following which the cells 
centrifuged (900rpm, 10min, 4C) using a refrigerated bench centrifuge 
(CR422, Jouan). The drug supernatant was discarded and the cell pellet 
resuspended in ice cold PBS (2ml). The cells were centrifuged as above 
to wash the cells free of drug. Finally, the pellet was resuspended in 
ice cold PBS (lml) and placed on ice. The cells were then ready for 
lysis. 
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3.2.4.3 Loading and lysis of cells 
With the upper tap in the closed position the syringe was filled with a 
further volume of ice cold PBS (4Oml). MCF-7 cells (0. Sxl06 , in lml 
PBS) were mixed with the PBS in the syringe. The cells were loaded onto 
the filter by allowing the suspension to drip through the swinnex until 
the meniscus reached the apex of the syringe. The cells on the filter 
were then washed with a further aliquot of PBS (2Oml). Lysis solution 
(sodium dodecyl sarkosine (sodium sarkosyl) (0.2%), dis odium EDTA 
(0.04M), NaCl (2M), pHlO, 2ml) containing proteinase K [BDH, 0.01 Anson 
units ml- l (O.Smg ml-l)] was placed in the syringe and allowed to drip 
through into the swinnex until the meniscus reached the apex of the 
syringe. At this point the filter assemblies were covered with foil to 
protect the DNA from light mediated strand breakage. The cells were 
left in contact with the lysis solution for one hour to allow complete 
digestion of cellular and DNA associated protein. After one hour 
cellular debris, remaining protein and RNA was washed through the filter 
with an EDTA wash solution (tetrasodium EDTA (0.02M), pHlO.O, 10ml). 
The EDTA wash was allowed to reach the apex of the syringe. At this 
point the filters could be left for up to one hour before elution of the 
DNA was started. 
3.2.4.4 Elution of DNA 
Once the EDTA wash was complete the lower taps of the filter assemblies 
were connected via a needle (19 gauge, stainless steel, with sawn off 
point, BDH) and transmission tub~ng (0.02mm internal diameter, Chem Lab) 
to a ten channel peristaltic pump (HR flow inducer type MHRE 300, Watson 
Marlowe Ltd) set to give a flow rate of 0.03Sml min- l . The collection 
side of the pump led, via transmission tubing (0.02mm), to a ten channel 
fraction collector (modified Minirac fraction collector, LKB) set to 
collect eleven fractions per channel at fortyfive minute intervals in 
z 
graduated sample cups (4m1, Chern Lab). 
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When the fraction collecting apparatus was assembled, single strand 
eluting solution [EDTA free acid (O.02M), Tetraethyl ammonium hydroxide 
(O.1M), pH12.3, 2Sml] was placed in the syringes with the upper tap 
closed. The taps were opened and the peristaltic pump switched on. 
When the eluted solution reached the first sample cups, the fraction 
collector was switched on. Elution of DNA was carried out with the 
filter assemblies protected from light by an aluminium foil covering. 
3.2.4.5 Treatment of filters 
When all the fractions were collected the swinnex and lower tap were 
disconnected from the syringe and upper tap and inverted onto a glass 
Universal vial (30ml). The transmission tubing connected to the 
fraction collector was disconnected, the end placed in a beaker of 
eluting solution and the peristaltic pump switched on [in reverse, O.lml 
min-I] in order to flush through and wash the tubing. After thirty 
minutes the pump was switched off, and the filter assembly disconnected 
from the pump. The transmission tubing was immediately washed by 
pumping distilled water through it for one hour. The swinnex was tapped 
firmly on the neck of the vial to dislodge any residual DNA. The 
swinnex was then flushed through with eluting solution (Sml) [via a 
syringe from the top] and gently unscrewed above the vial so as to 
collect residual DNA. The filter was removed using a pair of fine 
tweezers and placed in the vial. The two halves of the swinnex and 
rubber gasket were thoroughly rinsed with a further aliquot of eluting 
solution (Sml) using a Pasteur pipette. Screw caps were placed on the 
vials and the vials transferred to a water bath (60C) for one hour to 
denature the remaining DNA. After one hour the vials were removed and 
the filter/eluting solution sonicated at full power for one minute using 
a sonic probe (Model KT100, Kerrys Ultrasonics Ltd). 
3.2.4.6 Determination of DNA content in eluted fractions 
Firstly a calibration graph using denatured [single stranded] calf 
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thymus DNA [see appendix AS.O] was prepared for the fluorescent dye 
binding assay. Denatured calf thymus DNA standards (O-lOug ml- l ) were 
prepared in eluting solution. 
In order to neutralise the pH of each standard and quantitate the DNA 





potassium phosphate buffer (O.05M, pH 7.0), standard saline citrate 
(O.15M, pH 7.0), 2ml)] was added to DNA standard (lml) in a quartz 
fluorimetric cuvette and mixed using a plastic spatula. The 
fluorescence of the sample was measured using a Luminescence 
spectrometer (LS-5, Perkin Elmer) with an excitation wavelength of 
340nm, an emission wavelength of 440nm and excitation and emission slit 
widths of lOnm. Background fluorescence was subtracted from all 
readings and a calibration curve constructed (see section A15 for a 
typical calibration curve). 
The fluorescence of the eluted fractions was determined as follows:-
Firstly, the volume of each eluted fraction was measured visually from 
the graduated vials (to the nearest O.lml). An aliquot of each fraction 
(lml) was transferred to a clean sample cup. H3325Sjbuffer solution 
(see above) was added to each aliquot, mixed and the fluorescence 
determined as described above. The amount of DNA in each fraction was 
calculated taking into account the volume of the fraction and the DNA 
concentration (ug ml- l ) as determined from the calibration curve. 
The amount of DNA retained on the filter was determined by measuring the 
fluorescence of an aliquot (lml) of the filter wash/sonicate as 
described above. The volume of each filter wash was determined using a 
measuring cylinder (25ml). 
3.2.4.7 Presentation of results 
Results were plotted semi-logarithmically as the log of the proportion 
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of DNA remaining of filter against cumulative volume eluted (m1). From 
this graph the Strand Scission Factor (SSF) can be derived using the 
following equation:-
Where Fx is the fraction of DNA retained on the filter of the treated 
sample at the midpoint volume of the total volume eluted, and Fc is the 
corresponding value for the control sample. SSF is used to relate drug 
induced DNA strand scission to that caused by radiation in the same 
system. Drug induced strand scission can therefore be expressed as 
radiation (Rad or Gray) equivalents. This enables direct comparison of 
the DNA strand scission caused by different drugs in either the same 





Effect of quinone anti tumour agents on plasmid DNA in 
the presence of purified reductase enzymes. 
3.3.1.1 Effect of doxorubicin on strand breakage of plasmid 
DNA in the presence of xanthine oxidase and 
cytochrome P450 reductase. 
Studies were carried as described in section 3.2.1. 
It can be seen from figure 3.1A and photograph 3.1 that doxorubicin, in 
the presence of xanthine oxidase and NADH, produced strand breakage of 
plasmid DNA in a concentration dependent manner. As the doxorubicin 
concentration was increased the proportion of both open circular and 
linear DNA increased, indicating a dose dependent formation of single 
and double strand breaks. No significant strand breakage was seen in 
the absence of drug or when NADH was removed from the system [see figure 
3.2A], indicating strand breakage was doxorubicin and NADH dependent. 
Figure 3.lB shows that doxorubicin produced a concentration dependent 
increase in strand breakage in the presence of cytochrome P4S0 reductase 
and NADPH. However double strand breakage was only seen at the highest 
drug concentration. Enzyme and NADPH alone caused no significant strand 
breakage. When NADPH was removed from the system [see figure 3.2B] 
there was no significant strand breakage by doxorubicin [lOOuM], 
indicating this cofactor was required for strand breakage. 
For subsequent studies drug concentrations of SOuM [for xanthine 
oxidase] and lOOuM [for cytochrome P450 reductase] were used as 
doxorubicin at these concentrations produced strand breakage. 
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Photograph 3.1 Th e effect of doxor/l[Jicill 011 
plasmid DNA in the prese ll ce of ,Yalltllille oxidI7S L'. 
Plasmid DNA (300ng) [lanes 1+2] was incubated 
(37C, 30min) with xanthine oxidase (2 .5units) and 
NADH (O.4mM) [lanes 3+4], and doxorubicin 
(10IlM) [lanes 5-7], (50IlM) [lanes 8-10], and 
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Figure 3.1 Effecc of doxorubicin on scrand breakage of plasmid DNA in 
che presence of xanchine oxidase and cycochrome P450 
reduccase. 
Doxorubicin was incubated with plasmid DNA [300ng] and A: xanthine 
oxidase [2.5 units] and NADH [4.0mM] or B: cytochrome P450 reductase 
[23.4 units] and NADPH [l.OmM] for 30 minutes at 37C [controls were DNA 
(A), DNA + cytochrome P450 reductase (B)]. DNA species resolved by gel 
electrophoresis were supercoiled [~], open circular [0] and linear 
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Figure 3.2 Effect of doxorubicin, mitozantrone, CI941 and alkylamino-
anthraquinones on strand breakage of plasmid DNA in the 
presence of xanthine oxidase [A} and cytochrome P450 
reductase [B}. 
Incubations were carried out as described in figure 3.1 but in the 
absence of NADH or NADPH. Control incubation consisted of DNA only 
[Ctrl]. DNA species resolved by gel electrophoresis were supercoiled 
[~] and open circular [0]· 
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3.3.1.2 Effect of mitozantrone and CI941 on plasmid DNA in 
the presence of xanthine oxidase and cytochrome P450 reductase 
Figure 3.3A shows that CI941 [50uM] had no significant effect on plasmid 
DNA strand breakage in the presence of xanthine oxidase and NADH. 
Mitozantrone [50uM] produced a small increase in open circular DNA 
relative to controls [enzyme and NADH only]. This indicated some single 
strand breakage by mitozantrone. Figure 3.3A shows that in the absence 
of NADH, mitozantrone produced no significant increase in open circular 
DNA relative to control. 
Figure 3.2B and 3.3B show that CI941 produced a similar level of plasmid 
DNA strand breakage both in the presence and absence of NADPH in a 
system containing cytochrome P450 reductase suggesting strand breakage 
was not enzyme cofactor dependent. Mitozantrone, in this system [figure 
3.3B] produced single and double strand breakage which was 
concentration dependent. At lOOuM mitozantrone all the plasmid DNA 
contained single or double strand breaks. In the absence of 
mitozantrone or NADPH (figure 3.2B) no strand breakage was observed in 
this system. 
3.3.1.3 Effect of alkylaminoanthraquinones on plasmid DNA in 
the presence of xanthine oxidase and cytochrome P450 reductase 
No significant strand breakage was detected for the AQ's in the presence 
of xanthine oxidase and NADH [fi&ure 3.5A]. 
Figure 3.5B shows that lAQ [4.4 fold], 1,5AQ [5.3 fold] and 1,8AQ [4.8 
fold] at lOOuM all produced a large increase in the amount of open 
circular DNA in a system containing cytochrome P450 reductase and NADPH. 
Cytochrome P450 reductase and NADPH alone produced no significant 
increase in strand breakage. In the absence of NADPH [figure 3.2BJ IAQ, 
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Figure 3.3 Effect of mitozantrone and CI941 on strand breakage of 
plasmid DNA in the presence of xanthine oxidase 
Drugs [50uM] were incubated [37C, 30min] with plasmid DNA [300ng], 
xanthine oxidase [0.25 units] and NADH [4.0mM]. Control A:- DNA only, 
Control B:- DNA, xanthine oxidase and NADH. DNA species resolved by 
gel electrophoresis were supercoi1ed [~], open circular [0] and 
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Figure 3.4 Effect of mitozantrone [A] and CI941 [B] on strand breakage 
of plasmid DNA in the presence of cytochrome P450 
reductase. 
Drugs [100uM] were incubated [37C, 30min] with plasmid DNA [300ng], 
cytochrome P450 reductase [23.4 units] and NADPH [1.0mM]. DNA species 
resolved by gel electrophoresis were supercoi1ed [~], open circular 
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Figure 3.5 Effect of alkylaminoanthraquinones on strand breakage of 
plasmid DNA in the presence of xanthine oxidase and 
cytochrome P450 reductase. 
A: AQ's [50uM] were incubated with xanthine oxidase as described in 
figure figure 3.4,B: AQ's [lOOuM] were incubated with cytochrome P450 
reductase as described in figure 3.5. Control consisted of DNA + enzyme 
and NAD(P)H. DNA species resolved by gel electrophoresis were 
supercoiled [ELl] and open circular [D]. Values are the mean + sd of at 
least three determinations. 
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DNA relative to DNA alone. These results indicated that DNA strand 
breakage in the presence of cytochrome P450 reductase by these AQ's was 
drug and NADPH dependent. The l,4AQ produced no significant strand 
breakage in this system. 
3.3.2 Effect of quinone anti tumour agent iron complexes on 
strand breakage of plasmid DNA in the presence of 
glutathione. 
3.3.2.1 The effect of doxorubicin and mitozantrone iron 
complexes on strand breakage of plasmid DNA in the presence of 
reduced glutathione. 
A doxorubicin-iron complex was formed using ferrous ammonium sulphate 
(1:2 drug:iron ratio) as described in section 3.2.2.1. The effect of 
this complex on plasmid DNA in the presence of reduced glutathione is 
shown in figure 3.6. The relative intensities of DNA species in the 
presence of glutathione only were. supercoiled 69.4 + 14.1 and open 
circular 14.75 + 3.1. In the presence of ferrous iron (lOOuM) and 
glutathione the intensities of supercoiled and open circular DNA were 
typically 5l.B and 74.0 respectively. Doxorubicin-iron complex produced 
a concentration dependent decrease in the total amount of supercoiled 
and open circular DNA due to frank double strand breakage. The complex 
at 5:10 and 25:50 uM (drug:iron) produced some double strand breaks and 
at 50:100 uM destroyed all the DNA present. This did not occur in the 
presence of drug only. 
A mitozantrone-iron complex was prepared using ferrous ammonium sulphate 
at a 1:2 drug: iron ratio. Photograph 3.2 shows the result when the 
effect of this complex on plasmid DNA in the presence of reduced 
glutathione was investigated. It can be seen that mitozantrone-iron 
complex SO:100uM (drug:iron) produced double strand breakage of the DNA. 
A blue precipitate was observed following the DNA ethanol precipitation 
step despite carrying out five n-butano1 extractions. The DNA treated 
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with complex was seen to 'streak' rather than run in discrete bands as 
seen in the other lanes. This suggested that the mitozantrone-iron 
complex did not extract from the DNA as efficiently as drug alone. The 
lanes of this photograph were quantitated and are shown in figure 3.7. 
This clearly shows that mitozantrone-iron complex caused double strand 
breaks in this system whilst iron or drug alone at equivalent 
concentrations produced no such effect. 
3.3.2.2 The effect of CI941 and related anthrapyrazole iron 
complexes on strand breakage of plasmid DNA in the presence of 
reduced glutathione 
A CI94l-iron complex was prepared as described in section 3.2.2.1 using 
ferric chloride with a drug:iron ratio of 1:2. The complex formed showed 
no significant effect on plasmid DNA in the presence of reduced 
glutathione relative to controls [figure 3.8]. 
Ferric chloride was used to prepare anthrapyrazole [APZ] iron complexes 
for CI941 and related anthrapyrazoles [APZ's] shown in figure 1.36. 
Figure 3.9 and photograph 3.3 shows that the 7,lO-H-APZ iron complex 
produced no significant DNA strand breakage in the presence of reduced 
glutathione relative to controls. However the 7,lO-OH-APZ and lO-OH-APZ 
iron complexes produced single and double strand breaks both in the 
presence and absence of oxygen. In the absence of glutathione these 
complexes produced no effect on the DNA. Ferric iron and glutathione 
alone also showed no effect. 
3.3.2.3 The effect of alkylaminoanthraquinones on the strand 
breakage of plasmid DNA in the presence of iron and reduced 
glutathione. 
Mixtures of AQ's and ferrous iron (1:2 drug:iron ratio) were prepared as 
described in section 3.2.2.1 and the effect of these mixtures on plasmid 
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Figure 3.6 Effect of doxorubicin-iron complex on strand breakage of 
plasmid DNA in the presence of reduced glutathione. 
Graphs are A: supercoi1ed DNA and B: open circular DNA. 
Plasmid DNA [300ng] was incubated (30min, 37C) with doxorubicin-ferrous 
iron complex [@] or doxorubicin [0]. Values are mean + sd of three 
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Photograph 3.2 The ef/ect of mitoza7ztrone-iroll 
complex on strand breakage of plasmid DNA in the 
presence of reduced glutathio71e. 
Plasmid DNA (300ng) was incubated (37C, 15min) with 
glutathione (2.5~lM) [lanes 1-3], glutathione and 
iron(II) (100~lM) [lanes 4-5], glutathione and 
mitozantrone (50pM) [lanes 7-9] and glutathione and 
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Figure 3.7 The effect of mitozantrone-iron complex on strand breakage 
of plasmid DNA in the presence of reduced glutathion e . 
Plasmid DNA [300ng] was incubated [37C, 30min] with glutathione (2 . SuM ) 
[A], glutathione and ferrous iron (lOOuM) [B] , glutathione and mitozantrone 
(SOuM) [C] and glutathione and mitozantrone-ferrous iron compl ex (50:100 
uM) [D] . The DNA species resolved by gel electrophoresis were [~J 
supercoiled , [[]] open circular and [~] linear . Values are mean + sd 
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Figure 3.8 Effect of CI941-iron complex on strand breakage of plasmid 
DNA in the presence of reduced glutathione. 
Plasmid DNA (300ng) [A] was incubated (30min, 37C) with glutathione 
(2.SmM) [B], glutathione and ferric iron (lOOuM) [e], CI94l-ferric iron 
complex (SO:lOOuM) [D], glutathione and CI94l-ferric iron complex 
(SO:lOOuM) [E], and glutathione and CI94l-ferric iron complex (SO:lOOuM) 
deaerated with nitrogen [F]. The DNA species resolved by gel 
electrophoresis were [~] supercoiled and [()] open circular. Values 
are the mean + sd of three determinations. 
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Photograph 3.3 Effect of APZ-iron complexes on strand 
breakage of plasmid DNA in the presence of reduced glutathione 
Plasmid DNA (300ng) was incubated with glutathione 
(2.5mM) and Fe(III) (100~M) [lanes 1-3], 7,10-H 
APZ+Fe(III) (50:100~M) [lanes 4-6], 10-0H APZ + Fe(III) 
(50:100~M) [lanes 7-9], 7,10-0H APZ + Fe(III) (50:100~M) 
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Figure 3.9 Effect of anthrapyrazole-iron complexes on strand breakage 
of plasmid DNA in the presence of reduced glutathione . 
Plasmid DNA (300ng) was incubated with glutathione (2.5mM) [A), 
glutathione and ferric iron (lOOuM) [B), complex (50:100 uM ferric 
iron: drug) [C], glutathione and complex [D) and glutathione and complex 
deaerated with nitrogen [E) . The DNA species resolved by gel 
electrophoresis were [0) supercoiled, [0] open circular and [e) 
linear. Values are mean + sd of three determinations. 
202 
DNA in the presence of reduced glutathione determined. Figure 3.10 
shows that in the presence of ferrous iron and glutathione the AQ's 
produced no significant DNA strand breakage relative to controls 
containing glutathione and drug only. 
3.3.3 Effect of quinone anti tumour agents on topoisomerase 
activity in HCF-7 nuclear extract. 
A nuclear extract was isolated from MCF-7 cells as described in section 
3.2.3.1. Supercoiled plasmid DNA is a substrate for topoisomerase I and 
II activity resulting in the relaxation of the DNA to the open circular 
form. These two types of enzyme can be discriminated by the requirement 
of ATP for topoisomerase II activity. It can be seen from photograph 
3.4 that in the presence of MCF-7 nuclear extract pBR322 supercoiled DNA 
was converted to open circular, relaxed DNA and a further series of 
bands of intermediate mobility between open circular and supercoiled 
DNA. These bands are the result of different degrees of unwinding of 
the supercoiled DNA molecule and are known as concatomers or topomers 
(reviewed by Maxwell and Gellert, 1986), being characteristically 
produced by topoisomerase activity [section 1.7]. There was no 
difference in DNA unwinding in the presence or absence of ATP. It can 
also be seen that the intensity of the topomer banding increases with 
increasing extract protein concentration. Doxorubicin (luM) inhibited 
the unwinding or relaxing activity produced at all concentrations of 
nuclear extract used. From this experiment an extract concentration of 
1.Oug protein was chosen for subsequent studies. 
In order to identify the type of topoisomerase responsible for the DNA 
unwinding activity present in MCF-7 nuclear fraction the effect of the 
topoisomerase II inhibitors mAMSA (Nelson et al., 1984) and 
amiloride (Besterman et al., 1987) and the topoisomerase I inhibitor 
camptothecin (Hsiang and Liu, 1988) [figure 3.18] on this activity was 
investigated. The reaction was stopped with either SDS or SDS and 
proteinase K as described in section 3.2.3. Photograph 3.5 shows the 
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Figure 3.10 Effect of alkylaminoanthraquinones on strand breakage of 
plasmid DNA in the presence of ferrous iron and 
glutathione. 
A drug:ferrous iron concentration of SO : lOOuM was used . Plasmid DNA 
(300ng) was incubated (37C, 30min) with glutathione (2 . SmM) [A], 
glutathione and iron (lOOuM) [B] or glutathione and : - lAQ [E] , lAQ and 
iron [F], 1,4AQ [G], 1,4AQ and iron [H], 1,SAQ [I] , 1 , SAQ and iron [J ]. 
1,BAQ [K] and 1,BAQ and iron [L] . DNA species resolved by gel 
electrophoresis were supercoiled [ ~ ] and open circular [0 ] . Values 
are mean + sd of three determinations. 
204 
100ng/ml inhibited DNA unwinding activity. Formation of topoisomerase 
cleavable complexes is revealed by digestion with proteinase K which 
results in formation of single and double strand breaks hence an 
increase in open circular and linear DNA [see section 1.7]. However, no 
difference in the DNA banding (ie amount of topomers) [photograph 3.SB] 
was seen when the reaction was stopped with SDS and proteinase k. The 
effect of doxorubicin and a higher concentration of mAMSA on DNA 
unwinding activity of MCF-7 nuclear extract was further investigated 
(photograph 3.6). It was found that when the reaction was stopped with 
SDS and proteinase K both doxorubicin (O.luM) and mAMSA (lOuM) showed a 
slight inhibition of topomer formation in the presence and absence of 
ATP. Doxorubicin inhibited topomer formation to an equal extent when 
the reaction was stopped by either method. Subsequently the effect of 
doxorubicin concentration on the DNA unwinding activity of MCF-7 nuclear 
extract in the presence of ATP was determined. Photograph 3.7 shows 
that the inhibition of DNA unwinding activity by doxorubicin was 
concentration dependent as indicated by the reduction of topomer 
formation with increasing doxorubicin concentration. Doxorubicin (SuM) 
totally inhibited DNA unwinding activity. When the reaction was stopped 
with SDS and proteinase K [as described in section 3.2.3] no increase in 
open circular or linear DNA was produced. 
A drug concentration of luM was chosen to investigate the effect of the 
other quinone anti tumour agents used in this study on the DNA unwinding 
activity of MCF-7 nuclear extract (Photograph 3.8). When the reaction 
was stopped with SDS only, mitozantrone and CI941 appeared to be the 
most potent inhibitors of this activity as they totally inhibited 
unwinding of supercoiled DNA. 1,4AQ, 1,5AQ and 1,8AQ produced a similar 
level of inhibition, but less than mitozantrone or CI94l. lAQ showed 
the least inhibition of unwinding activity. When the reaction was 
stopped with SDS and proteinase K no difference in the DNA banding 
pattern was observed. 
3.3.4 The effect of quinone antitumour agents on cellular DNA. 
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Photograph 3.4 Topoiso 111 era se activit y ill MCF- 7 
cell nuclear extract. 
Plasll1id DNA (SOOng) was incubated OSmin) \vith 
extract (1).lg protein + A TP 0 mM) [lane 1], +A TP + 
d oxorubicin O).lM) [lane 2]'-ATP[lane 3J,-ATP+ 
doxorubicin [lane 4]; ex tract (S.O).lg pro tein ) + A TP 
[lane 5], + ATP +doxorubicin [lane 6], -ATP Oane 7], 
-ATP +doxorubicin [lane 8]; ex trac t 0 O.O~l g pro te in ) 
+ ATP [lane 9], +ATP +doxorubicin [lane 10], -ATP 
[lane 11], -ATP +doxorubicin [lane 12]; extrac t 
(20.0).l.g protein) + ATP [laneI3], +ATP +doxorubicin 
[lane 14], -ATP [lane 15], -ATP +doxorubicin [lane 
16] . The reaction was stopped w ith SDS (2 %). 
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Photograph 3.5 Th e effect of amilarid!!, 
crnnptothecin and I1'l AMSA 011 toPOi::;o lll cm::;(' 
activity in MCF-7 cell nuclear extmcf. 
Plasnlid DNA (SOOng) was incuba ted (15min) wi th 
A TP (l nlM) [lanes 1 +2], A TP+ ex trC1ct (1 Pg protei n ) 
[lanes 3+4] I A TP + extract+ ami loride (1 OOng / Ili l) 
[lanes 5+6], ATP + extract + camptothecin 
(lOOng/nil) [lanes 7+8], ex trac t + ATP+ m AMS/\ 
(lOOng/nil [lanes 9+10], 
Photogra ph A , reaction s topped wi th SDS (2 LIc ); 
pho togra ph B I reaction s topped w i th SOS (2 (Ic ) ,I nd 
proteinase K (O .OSnlg). 
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Photograph 3.6 The effect of doxorubicin and 
mAMSA on topoisornerase activity in MCF-7 a /l 
nuclear fraction. 
Plasmid DNA (SOOng) [lanes 1+2] was incubated 
(1Smin) with extract (2~g protein) [lanes 3+4] or 
extract+ATP (1mM) [lanes 5+6], extract + 
doxorubicin (O.1~M) [lanes 7+8], extract + 
doxorubicin + A TP [lanes 9+10], extract + n1AMSA 
(100~g/ml) [lanes 11+12] and extract + mAMSA + 
ATP [lanes 13+14]. 
Photograph A, reaction stopped with SDS (2 %); 
photograph B, reaction stopped with SDS (2%) and 
proteinase K (O.OSn1g). 
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Photograph 3.7 The effect of doxorubicill 011 
topoisomerase activity in MCF- 7 cell J1ucl ea r 
extract . 
Plasmid DNA (500ng) was incubated (15nlin) with 
A TP (1 mM) [lanes 1+2], ATP+extract (1f,1g protein) 
[lanes 3+4] or ATP+extract+doxorubicin (0 .01 f,1M ) 
[lanes 5+6], (O.05f,1M) [lanes 7+8], (O.1f,1M) [lanes 
9+10] and (5f,1M) [lanes 11+12]. 
Photograph A , reaction stopped wi th SDS (2 %); 
photograph B I reaction stopped w ith SDS (2 %) and 
proteinase K (O.1mg). 
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Photograph 3.8 The effect of mitozantrone, 
CI941 and alkylaminoanthraquinones 071 
topoisomerase activity in MCF-7 cell n L1clea r 
extract. 
~ f-ormll 
Plasmid DNA (SOOng) was incubated OSmin) with 
ATP [lanes 1+2], ATP + nuclear extract O)lg 
protein) [lanes 3+4], or A TP + extract + 
n1itozantrone O)lM) [lanes 5+6], CI941 O)lM) 
[lanes 7+8], lAQ O)lM) [lanes 9+10], l,4AQ O)lM ) 
[lanes 11+12], l ,SAQ O)lM) [lanes 13 +14], and 
l,8AQ O)lM) [lanes 15+16]. 
Photograph A reaction stopped w ith SOS (2 %), 
photogra ph B reaction s topped wi th SOS (2 ~ ) Cl nd 
proteinase K (O.lmg) . 
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Alkaline [filter] elution studies were carried out in order to determine 
total strand breakage of DNA caused by quinone antitumour agents in MCF-
7 cells. A one hour exposure was chosen to enable comparison with a 
series of cytotoxicity experiments described in section 4.3.1, in which 
MCF-7 cells [104 ] were exposed to drug for one hour then washed and 
incubated for a further six days before assessing cell survival rates. 
In addition a one hour exposure time has been widely used by other 
workers to determine cytotoxicity (see tables 4.7 and 4.8) and DNA 
• 
strand breakage (see section 1.16.4.3). Figure 3.11 shows that the 
viability of MCF-7 cells in suspension does not decrease significantly 
over a one hour period even in the presence of drug. The alkaline 
elution technique is described in section 3.2.4. 
3.3.4.1 The effect of doxorubicin on strand breakage of 
cellular DNA 
Figure 3.l2A shows the elution profile of DNA isolated from MCF-7 cells 
treated with doxorubicin. It can be seen that as the doxorubicin 
concentration increased the rate of DNA elution increased relative to 
untreated controls indicating increasing DNA strand breakage. Figure 
3.l2B shows the DNA strand scission factors derived from the elution 
curves in figure 3.l2A. These values were derived from the relative 
proportions of DNA remaining on the filter after half the total elution 
volume [8ml] had been eluted [see section 3.2.4.7]. This volume was 
used to derive strand scission factors in all subsequent studies. 
3.3.4.2 Effect of mitozantrone and CI941 on cellular DNA 
Figure 3.l3A shows the elution profile of DNA isolated from MCF-7 cells 
which had been treated with CI941 [lOOuM] or mitozantrone [lOOuM] for 
one hour. There was no difference in the elution rate for either drug, 
indicating a similar level of strand breakage. Subsequently, strand 
breakage by these drugs at equitoxic concentrations (ie LDSO values) was 
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3.11 Survival of harvested MCF-l cells in suspension. 
Viability of MCF-7 cells was determined using the trypan blue exclusion 
assay (see appendix A1.9). 
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Figure 3.12 A: Elution rate of DNA isolated from HCF-7 cells treated 
with doxorubicin. 
MCF-7 cells [SxlOSml- l ] were untreated [+] or treated with doxorubicin 
O. luM [0], l.OuM [.], lOuM [0] and lOOuM [e) for one hour at 37C . 
B: Strand scission factors for doxorubicin derived from A: 
SSF - - log (Fx/Fc) where Fx- proportion of DNA remaining on filter 
after midpoint elution volume (8.Srnl) for treated cells and Fc= as Fx 
for untreated cells. 
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cells treated with EDSO concentrations of mitozantrone [SxlO- 9M] or 
CI941 [2xlO-
lO
M] for one hour. Mitozantrone produced a more rapid 
elution rate than CI941 indicative of more strand breakage by 
mitozantrone than CI941 ar equitoxic concentrations. Figure 3.14 
summarises the strand scission factors for mitozantrone and CI941 
derived from figures 3.l3A and 3.l3B. There was no significant 
difference between the amount of strand scission caused by 100uM and 
SxlO- 9M mitozantrone [a 20,000 fold difference in concentration]. In 
contrast, 60% less strand scission was observed after treatment with 
2xlO- 10M compared to 100uM CI94l. 
3.3.4.3 Effect of alkylaminoanthraquinones on cellular DNA 
The elution profile of DNA isolated from MCF-7 cells treated with 
alkylaminoanthraquinones [lOOuM] for one hour is shown in figure 3.lSA. 
The 1AQ, 1,SAQ and 1,8AQ produced a rapid elution of DNA within the 
first 100 minutes, representing up to 80% of the total cellular DNA. 
This was indicative of frank DNA strand breakage such that the DNA 
fragments produced passed rapidly through the filter on denaturation 
with alkali. After 100 minutes, only a small amount of the DNA 
remaining on the filter was further eluted indicating that this DNA was 
undamaged. In contrast, the elution profile for 1,4AQ was not as rapid 
but occurred steadily over the elution period. After 100 minutes the 
amount of DNA eluted from cells treated with 1,4AQ was not significantly 
different to the amount of DNA eluted from untreated cells. 
Strand breakage by the AQ's in MCF-7 cells was further investigated at 
equitoxic concentrations [EDSO concentrations]. Figure 3.16 shows the 
elution profile of DNA isolated from MCF-7 cells treated with lAQ [4uM], 
1,4AQ [1.2uM], 1,SAQ [12.3uM] and 1,8AQ [O.SuM] (EDSO concentrations 
d . d i . 4 3 1 4) A similar elution rate was observed for eterm1ne n sect10n . ., . 
all four AQ's at these concentrations. The strand scission factors for 
the AQ's, derived from figures 3.1S and 3.16 are shown in figure 3.17. 
The lAQ, 1,SAQ and 1,8AQ [100uM] produced a similar amount of strand 
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Figure 3.13 Elution profile of DNA isolated from HCF-7 cells 
treated with mitozantrone or CI941. 
A: MCF-7 cells [5x~05ml-l] were untreated I~] or treated with 
mitozantrone (5xlO- M) [.] or CI941 (2xlO- OM) [~] for one hour at 
37C. 
B: MCF-7 cells [5xl05ml- l ] were untreated [1i] or treated with 
mitozantrone (lOOuM) [.] or CI941 (lOOuM) [~] for one hour at 37C. 


















Figure 3.14 Effect of mitozantrone and CI941 on strand 
scission of HCF-7 cell DNA as determined by alkaline 
elution. 
MCF-7 cells were treated (lhr, 37C) with either lOOuM [~] or EDSO [0] 
concentration of drug. (EDSO mitozantrone - SnM, EDSO CI941 - O.2nM). 
Values are the mean + sd of three determinations. SSF's calculated from 
figure 3.l3A and 3.l3B. 
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significantly less than the other AQ's at this concentration. lAQ, 
1,SAQ and 1,8AQ produced significantly less strand scission at EDSO 
concentrations compared to lOOuM. In contrast, 1,4AQ produced a similar 
level of strand scission at both concentrations. The amount of strand 
scission by all four AQ's was not significantly different after 
treatment with EDSO concentrations, indicating that at equitoxic 
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Figure 3.15 Elution profile of DNA isolated from MCF-7 cells treated 
with alkylaminoanthraq~inones. 
MCF-7 cells [5xl05ml- l ] were treated (lhr, 37C) with lOOuM of lAQ [0]. 
1,4 AQ [.], 1,5 AQ [.] or 1,8 AQ [0]. Data points are the mean + sd 
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Figure 3.16 Elution profile of DNA isolated from HCF-l cells treated 
with ED50 concentrations of alkylaminoanthraquinones. 
MCF-7 cells [Sx10Sml- 1 ] were treated (lhr, 37C) w~th [()] lAQ (4.0xlO- 6 
M), [.] 61 ,4 AQ (1. 2xlO - 6M) , [ .] 1,5 AQ (12. 3xlO - M) or [D) 1,8 AQ 
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Figure 3.17 Effect of alkylaminoanthraquinones on strand scission of 
HCF-7 cell DNA as determined by alkaline elution. 
MCF-7 cells [5x105ml- 1 ] were treated 
or ED50 concentration [0] of drug. 
determinations from two experiments. 
from figures 3.15 and 3.16. 
(lhr, 37C) with either 100uM [0] 
Data points are mean + sd of four 





Effect of quinone anti tumour agents on strand breakage of 
plasmid DNA in the presence of purified reductase enzymes. 
The previous chapter has shown that the antitumour agents in this study 
have different potentials to undergo redox cycling in MCF-7 S9 cell 
fraction. In this chapter, two purified reductase enzyme systems, 
namely NADH xanthine oxidase and NADPH cytochrome P450 reductase, were 
investigated to see if they could reductively activate these agents. 
Furthermore, the potential of this activation process to instigate DNA 
strand breakage was studied. The pBR322 plasmid strand breakage assay 
[described in section 1.12.3] offers a unique opportunity to study both 
enzymic activation of quinone anti tumour agents and whether this 
activation can mediate DNA strand breakage. 
3.4.1.1 Effect of doxorubicin on strand breakage of plasmid DNA in the 
presence of purified reductase enzymes 
Doxorubicin was used to characterise the plasmid strand breakage assay 
with respect to drug, enzyme and DNA concentration. Doxorubicin was 
found to cause a concentration dependent single and double strand 
breakage of plasmid DNA in the presence of NADH xanthine oxidase and 
NADPH cytochrome P450 reductase [see figure 3.18]. This effect was only 
produced in the presence of the complete incubation system. This 
indicates that reduction of doxorubicin by the enzyme is a prerequisite 
for DNA strand scission. The mechanism of strand breakage is likely to 
proceed via one electron reduction of doxorubicin to a semiquinone free 
radical species: 
Q---..... ~Q. 
This reacts in a diffusion controlled manner with molecular oxygen to 
form the superoxide anion and regenerate the parent drug: 
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The parent drug becomes available once again for reductive activation. 
As described previously [ section 1.8.2] this process is known as redox 
cycling. The formation of superoxide anions can lead to the formation 
of hydroxyl radicals by the following series of reactions:-
Firstly the spontaneous dismutation of superoxide anions:-
Followed by the iron driven Haber Weiss reaction: 
-------I~ Fe2+ + 0 
4 2 
-------I OH· + OH-
Iron is likely to be present due to it being a u~iquitous contaminant of 
laboratory agents. The hydroxyl radical, a highly reactive species has 
been shown to cause DNA strand scission and damage to lipids and 
proteins [see section 1.9]. The increase in double strand breaks at 
higher doxorubicin concentrations is supportive of a random hit 
mechanism in which the more hydroxyl radicals formed the higher the 
probability of two single strand breaks occurring on directly opposite 
DNA strands to produce a double strand break. Iron bound to the DNA or 
the drug (see section 1.9.2.1) may lead to 'site specific' DNA strand 
scission [reviewed by Ward, 1987]: 
OH· + DNA ------~.~ DNA-SSB (single strand break) 
DNA-SSB + OH· ______ .~~ DNA-DSB (double strand break) 
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DNA strand breakage could also occur by covalent binding of the 
doxorubicin free radical to the DNA [Sinha and Chignell, 
1979]. Hydroxyl radical attack on DNA has been proposed to be due to 
hydrogen abstraction from the 2', 3' or 4' carbon atoms of deoxyribose 
[see figures 3.19 and 3.20]. This results in formation of a deoxyribose 
radical which may be attacked by molecular oxygen to form a peroxy 
radical. This can abstract a hydrogen atom from a neighbouring DNA 
sugar or base to give a hydroperoxide. Therefore, the radical species 
may be propagated along the DNA molecule. The hydroperoxide can 
decompose in the presence of transition metals to give a hydroperoxide 
free radical, alternatively the hydroperoxide can eliminate water to 
produce breakage of the sugar ring followed by hydrolysis of this 
modified sugar to generate a strand break (Figure 3.20) [reviewed by 
Tanaka, 1984]. Alternatively the carbon-carbon double bond of the DNA 
bases are a target for hydroxyl radical attack resulting in a strand 
break or base modification and base loss (figures 3.21 and 3.22) [see 
section 1.9.2.2] (reviewed by Von Sonntag, 1988). Oxygen free radical 
attack on pBR322 DNA has been shown to result in the formation of 
endonuclease sensitive sites due to the production of thymine glycol 
residues (see figure 3.22) [Denq and Fridovich, 1989]. The findings of 
this present study are supported by the work of other investigators. 
Bates and Winterbourn (1982) also showed that activation of doxorubicin 
by xanthine oxidase could mediate strand breakage of DNA, this being 
inhibited by superoxide dismutase and catalase. DNA strand breakage 
produced in a system of doxorubicin and NADPH cytochrome P450 reductase 
has been shown to be dependent on the presence of molecular oxygen 
(Berlin and Haseltine, 1981). Furthermore, this DNA strand breakage was 
partially inhibited by superoxide dismutase and catalase (Lown et a1., 
1977, Someya and Tanaka, 1979). Furthermore, in the presence of 
cytochrome P450 reductase doxorubicin has been shown to stimulate NADPH 
oxidation and form an esr detectable free radical species (Bachur et 
a1., 1979; Berlin and Haseltine, 1981). 
The results obtained in the present study provide further evidence for 
doxorubicin undergoing reductive metabolic activation, correlating with 
the redox cycling activity of this agent in MCF-7 human breast cancer 





























Figure 3.19 Structure of repairable free radical mediated single 
strand breaks in DNA 
Products are the 3'-phosphoglycolate residue or total 
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Figure 3.20 Postulated mechanism for hydroxyl radical 
mediated cleavage of DNA 
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, 
A. Attock on the bose, resulting in formation of deo[yribose residue. 





B. Attock at pos1fion C-,', resulting in formation of a 2-deo[yribono-t,4,-laclone residue. 
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C. Attack at position C-4', resulting in formation of a 3,5 -dihydro[y-4'olopentonal residue. 
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Figure 3.21 Mechanism of hydroxyl radical mediated formation of 
an apurinicjapyrimidinic site on DNA 
A. Attack on the base results in labilisation of the bond 
and release of the damaged base, leaving a deoxyribose 
residue in the DNA backbone. 
B, C. These are the best characterised residues resulting 
from free radical attack on the sugar moiety. The 
structures within brackets are intermediates thought 
to lead to the final product. 
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Figure 3.22 Hydroxyl radical mediated degradation of 
thymidine. 
A. This reaction sequence results from attack on the 5,6 
ethylenic bond, which in the presence of oxygen, leads to formation 
of hydroperoxides which may be reduced to the repairable thymine 
glycol moiety. 
B. Oxidation and fragmentation of the 5(6)-hydroxy-(6)5-peroxides 
result in formation of formamide and 5-hydroxy-5-methyl hydantoin 
residues both of which are repairable. 
C This reaction sequence illustrates the products derived from 
attack on the exocyclic methyl group leading to formation of the 
repairable 5-hydroxymethyluracil moiety and the 5-formyluracil 
moiety whose repairability is uncertain. 
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cytochrome P450 reductase (a microsomal enzyme) are therefore possibly 
involved in the reductive activation of doxorubicin in this cellular 
system. These results also indicate that activation of doxorubicin in 
this manner can mediate DNA strand breakage. 
3.4.1.2 Effect of mitozantrone and CI941 on strand breakage of plasmid 
DNA in the presence of purified reductase enzymes 
In contrast to doxorubicin, mitozantrone produced only a small amount of 
DNA strand breakage in a system containing NADH xanthine oxidase [figure 
3.3] and CI941 produced no significant effect [figure 3.3]. This result 
indicates that these compounds are poor substrates for reductive 
metabolic activation by this enzyme. In a system of NADPH cytochrome 
P450 reductase, mitozantrone produced a dose dependent single and double 
strand breakage of plasmid DNA whereas CI941 showed no significant 
effect [see figure 3.4]. The inability of CI941 to produce strand 
breakage in the presence of cytochrome P450 reductase is consistant with 
CI941 not being reductively activated by this enzyme as shown by Graham 
et al. (1987). As previously described for doxorubicin [section 
3.4.1.1] the mechanism of mitozantrone mediated strand breakage in this 
system is likely to involve reactive oxygen species. Oldcorne et al. 
(1985) also showed that mitozantrone produced DNA strand breakage in the 
presence of cytochrome P450 reductase. In addition Kharasch and Novak 
(1983a) showed that mitozantrone formed superoxide anions in the 
presence of this enzyme. 
3.4.1.3 Effect of alkylaminoanthraquinones on strand breakage of 
plasmid DNA in the presence of purified reductase enzymes 
A series of mitozantrone related alkylaminoanthraquinones [figure 1.35] 
were also investigated with respect to their propensity to mediate 
plasmid DNA strand breakage in the presence of purified xanthine oxidase 
and cytochrome P450 reductase. This was in order to assess the effect 
of the side chain substitution pattern on their relative propensity for 
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reductive activation. None of the AQ's produced significant strand 
breakage in the presence of NADH xanthine oxidase indicating that these 
compounds are not substrates for reductive activation by this enzyme 
(figure 3.SA). However, the AQ's produced different amounts of DNA 
single strand breaks in the presence of NADPH cytochrome P4S0 reductase 
(figure 3.SB). lAQ, 1,SAQ and 1,8AQ hll produced single strand breakage 
of plasmid DNA though to a lesser extent than doxorubicin or 
mitozantrone. This indicates that these compounds are substrates for 
reductive activation by this enzyme. DNA strand breakage is likely to 
be mediated via production of reactive oxygen species in a redox cycling 
process as described for doxorubicin [section 3.4.1.1]. In contrast, the 
1,4AQ produced negligible strand breakage indicating that this compound 
is a poor substrate for reductive activation by cytochrome P4S0 
reductase. From these results the AQ's can be ranked in order of 
propensity for activation by NADPH cytochrome P4S0 reductase:- lAQ _ 
1,SAQ - 1,8AQ > 1,4AQ. 
To summarise, the results presented in this section show that the 
quinone antitumour agents in this study have markedly different 
propensities to undergo reductive activation by purified flavin 
reductase enzymes. This activation results in the formation of reactive 
oxygen species by the process of redox cycling which mediate DNA strand 
breakage. A role for reactive oxygen in strand breakage is supported by 
the similar profile of plasmid DNA strand scission produced by gamma 
irradiation (appendix figure A4) and hydrogen peroxide (appendix figure 
AS) which are proposed to mediate DNA strand scission via hydroxyl 
radical formation (reviewed by Ward, 1987; Floyd and Lewis, 1983). In 
contrast CI941 was not a substrate for reductive activation by these , 
enzymes. Mitozantrone was not activated by xanthine oxidase but was 
activated by cytochrome P4S0 reductase. Similarly, the AQ's (except 
1,4AQ) were activated by cytochrome P4S0 reductase. The relative 
propensities of mitozantrone, CI941 and AQ's to undergo reductive 
activation correlates well with their one electron reduction potentials 
[table 2.S] but is also likely to be influenced by their structural 
differences, including the positions of the alkylamino side chain on the 
anthraquinone chromophore. As discussed in section 2.4.2 this is 
possibly due to steric hindarance of the interaction between the 
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anthraquinone chromophore and the flavin component of the reductase. 
3.4.2 The effect of anti tumour agent-iron complexes on plasmid DNA. 
Doxorubicin has been shown to bind iron with a high degree of affinity, 
a phenomenon that has only recently gained interest (reviewed by 
Garnier-Suillerot, 1988). As described in section 1.8.3 iron is 
proposed to play an intimate role in the mediation of cell damage by 
drugs that redox cycle, resulting in superoxide anion formation. This 
is due to the involvement of iron in the iron catalysed Haber-Weiss 
reaction (see section 1.8.3) which results in the production of hydroxyl 
radicals from superoxide anions and H202 . Drug bound iron has been 
found to undergo a non-enzymic redox cycle mechanism in the presence of 
cellular thiols [eg reduced glutathione (GSH)] by the following series 
of reactions (reviewed by Myers et al., 1986):-
2Drug-Fe3+ + 2GSH ----~ .. ~ 2Drug-Fe2+ + GSSG (ox1dised GSH) (1) 
Drug-Fe2+ + 02 -... -----I.~ Drug-Fe3+ + 02 - (2) 
02 - + 02 - + 2H+------I.~H202 (3) 
02- + Drug-Fe3+ 
2+ Drug-Fe + H202 
.. • Drug-Fe2+ + 02 (4) 
-----I~~ Drug-Fe3+ + OH- + OH' (5) 
These reactions, analagous to the those that produce hydroxyl radicals 
during reductase mediated quinone redox cycling [section 1.8.3] are 
independent of the potential of the quinone to undergo enzyme mediated 
redox cycling. In this study the ability of a doxorubicin-iron complex 
to cause DNA strand breakage in the presence of reduced glutathione was 
investigated using the plasmid DNA strand breakage assay. 
A doxorubicin-iron complex formed from mixing doxorubicin and ferrous 
iron (1:2), in the presence of reduced glutathione, produced a 
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concentration dependent decrease in DNA recoverable from the incubation , 
as well as some double strand breaks [see figure 3.6]. The absence of 
strand breakage in the presence of ferrous iron only [figure 3.6] would 
suggest that all this iron has been rapidly oxidised to ferric before 
the start of the incubation (Myers et al., 1982). The loss of DNA 
observed was probably due to frank strand breakage resulting in the 
formation of low molecular weight DNA fragments. These are either not 
recovered by the DNA precipitation and centrifugation step during the 
assay procedure or are not resolved by gel electrophoresis. The DNA 
strand breakage observed is likely to take place via a mechanism 
involving the production of reactive oxygen species as described above 
(reactions 1-5). Doxorubicin has been shown to form a 3:1 complex with 
Fe3+ (Beraldo et al., 1985) with stepwise association constants of 1018 , 
1011 and 104 . 4 (May et al., 1980), which can intercalate into DNA 
releasing the iron or produce a ternary drug-Fe3+-DNA complex due to the 
high affinity of Fe3+ for DNA phosphate groups (reviewed by Garnier-
Sui11erot 1988). The doxorubicin-iron complex involves the coordination 
of one phenolate C11 oxygen and one C12 carbonyl from each drug molecule 
to Fe3+ to give a six membered chelate [see figure 3.23]. In agreement 
with the results of this study, a doxorubicin-Fe3+ complex has been 
shown to cause destruction of erythrocyte ghost cell membranes with 
concomitant consumption of oxygen in the presence of glutathione. This 
was process totally inhibited by a combination of SOD and partially 
blocked by the hydroxyl scavenger mannitol or the iron chelator EDTA 
(Myers et al., 1982). This effect was greater when the drug-iron-DNA 
complex was used (Myers et al., 1982). This is presumably due to the 
stabilisation of the iron by this ternary complex. Also, Eliot et al. 
(1984) showed that a doxorubicin-Fe3+ complex caused strand breakage of 
DNA in the presence of glutathione. A role for hydroxyl radical 
involvement in DNA-bound doxorubicin-iron complex mediated DNA damage is 
further supported by the work of Muindi et al. (1984) who found that a 
DNA-Fe3+-doxorubicin ternary complex was more effective than complex 
alone at producing hydroxyl radicals in the presence of glutathione. 
The system used in the present study initially involves formation of a 
doxorubicin-Fe2+ complex. The Fe2+ is likely to be rapidly oxidised to 
Fe 3+ by molecular oxygen with reduction of the oxygen to superoxide 
anions (equation 2). This part of the reaction is glutathione 
independent. However, the doxorubicin-Fe3+ formed becomes available for 
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reduction by glutathione (equation 1). Doxorubicin-Fe2+ can either 
react with molecular oxygen to form superoxide anions or take part in 
the iron-catalysed Haber-Weiss reaction with resultant production of 
hydroxyl radicals from superoxide anions and hydrogen peroxide 
[reactions 2,4 and 5]. It is likely that DNA strand breakage is 
produced by a combination of these processes, the reactive species 
involved being hydroxyl radicals. The reactions shown above [equations 
1-5] are likely to be an over simplification of the mechanisms involved 
as participation of a perferryl radical species (Fe3-02-) cannot be 
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discounted (reviewed by Halliwell and Gutteridge, 1985). Mechanisms of 
reactive oxygen attack on DNA are described in section 1.9.2 and 3.4.1.1 
(see figures 3.19-3.21). 
By analogy with the structural similarity to doxorubicin mitozantrone 
would appear to have structural requirements necessary for iron binding. 
Indeed mitozantrone has been shown to form complexes with copper (II) 
and platinum (II) ions (reviewed by Garnier-Suillerot, 1988). However, 
no studies have been carried out on the interaction of iron with 
mitozantrone, the alkylaminoanthraquinones or the anthrapyrazoles. This 
study has investigated the ability of these agents in combination with 
iron to generate plasmid DNA strand breakage. 
A complex generated from a 1:2 mixture of mitozantrone and ferrous iron, 
in the presence of glutathione, was found to produce double strand 
breakage of plasmid DNA, whilst drug or iron alone produced no effect 
[see figure 3.7]. A 1:2 drug:iron ratio was used as mitozantrone has 
two possible iron binding sites between the aromatic hydroxyl groups and 
the carbonyl groups. The mitozantrone-iron complex proved difficult to 
extract from the DNA incubate despite the presence of desferrioxamine, a 
strong iron chelator. This indicates that the complex is tightly bound 
to DNA, possibly in the form of a ternary complex involving 
mitozantrone-Fe3+-DNA. The absence of DNA strand breakage in the 
presence of Fe 2+ alone shows that the presence of a mitozantrone-iron 
complex is a prerequisite. This is probably due to the strong affinity 
of mitozantrone for DNA (see section 1.17) which targets the iron to a 
site closely adjacent to the DNA strands. In a similar manner to 
doxorubicin, the mitozantrone-Fe2+ complex initially produced is likely 
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Figure 3.23 Schematic diagram of the Fe(doxorubicin)3 complex. 
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to have rapidly oxidised to mitozantrone-Fe3+ with concomitant reduction 
of molecular oxygen (equation 2). The superoxide anion formed in this 
manner could participate in DNA strand breakage via hydroxyl radical 
formation (reactions 3-5). The results of this study indicate that 
mitozantrone forms an iron complex which can mediate DNA damage in the 
presence of reduced glutathione. The likely iron binding sites on 
mitozantrone are between the aromatic hydroxyl groups [Cs and Ca] and 
their adjacent carbonyl groups. The role of these hydroxyl groups in 
iron binding is supported by the lack of DNA strand breakage produced by 
1:2 mixtures of alkylaminoanthraquinones and ferrous iron [see figure 
3.10]. This suggested an absence of iron binding by these agents which 
do not possess Cs and Cs aromatic hydroxyl groups. 
The anthrapyrazoles [APZ] are antitumour agents which have recently been 
developed [see section 1.15]. Structurally they are similar to 
mitozantrone, however, the quinone moiety is replaced by a quasi-
iminoquinone. This modification was carried out to reduce their 
interaction with reductase enzymes, hence diminish their ability to 
redox cycle. Despite this modification it is likely that iron binding 
can occur between the C7 and CIO hydroxy groups and the adjacent imino 
or carbonyl groups. A series of APZ's [figure 1.36] including CI941 
(7-0H APZ) with modified chromophores at the C7 and/or CIO hydroxyl 
groups were investigated with respect to produce DNA strand breakage in 
combination with ferric iron in the presence of glutathione. In these 
studies ferric iron was used to produce APZ-iron complexes in order to 
circumvent direct involvement of Fe2+ oxidation in reactive oxygen 
formation and strand breakage. Therefore, formation of APZ-Fe2+ should 
be anticipated to be primarily as a result of glutathione reduction of 
APZ-Fe3+ in this system. In the presence of glutathione and a 
combination of APZ's and ferric iron, only the CIO hydroxyl group 
substituted 7,lO-OH-APZ and 10-OH-APZ produced single and double strand 
breaks in plasmid DNA [see figure 3.9 and photograph 3.3]. This strand 
breakage is likely to be mediated by the series of reactions [1-5] 
described above with resultant hydroxyl radical formation. No strand 
breakage was observed for these compounds in the absence of glutathione 
or in the presence of iron or drug alone. This indicates that it is the 
ferric iron coordinated at the C10 hydroxyl group and the imino group 
which is participating in glutathione mediated redox cycling of iron. 
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The absence of DNA strand breakage by the 7,lO-H APZ correlates with the 
requirement of the aromatic hydroxyl groups for iron binding. The 
APZ's investigated in the present study have previously been shown to 
bind ferric iron (Graham et al., 1989). However, 7-0H APZ ~I94~ only 
weakly complexed ferric iron and 7,lO-H APZ did not bind ferric iron. 
This would indicate that absence of DNA strand breakage by 7-0H APZ 
(CI94l) in combination with ferric iron is due to it being only a weak 
binder of this iron species. In nitrogen purged incubates the 7,lO-OH 
APZ and lO-OH APZ produced an equivalent amount of DNA strand breakage 
as in the presence of oxygen. Despite making all efforts to remove 
oxygen from the system it is likely that sufficient oxygen was present 
to allow reactive oxygen mediated strand breakage to occur. 
This study has shown that quinone antitumour agents with aromatic 
hydroxyl groups can form iron complexes which produce DNA strand . 
breakage in the presence of glutathione by a mechanism likely to involve 
formation of reactive oxygen species. As discussed in section 3.4.1, a 
role for oxygen free radical species in quinone-iron complex mediated 
plasmid DNA strand breakage is supported by the similar pattern of 
strand breakage of plasmid DNA produced by gamma radiation (appendix 
figure A4) and hydrogen peroxide (appendix figure AS). Iron has been 
implicated in hydrogen peroxide mediated DNA scission (Floyd and Lewis, 
1983). Binding to DNA is likely to be an important contributory factor 
to DNA strand breakage by drug-iron complexes presumably due to the 
glutathione mediated redox cycling of iron and formation of reactive 
oxygen species proximal to DNA. 
The results of this study could have important implications in the 
mechanism of action of these agents. Clinical use of such complexes 
seems unlikely since it has been shown that at physiological pH and at 
clinical drug concentrations doxorubicin would have very little iron 
bound even if it is injected as a complex (Gelvan and Samuni, 1988). In 
neutral aqueous solution the concentration of soluble ferric iron is 
only lO-11_lO-18M (reviewed by Myers et al., 1986). It has been 
proposed that doxorubicin at clinically relevant concentrations will not 
bind adventitious iron. Clinical trials with quelamycin a doxorubicin-
iron chelate produced conflicting results as to its efficacy and 
cardiotoxicity [reviewed by Garnier-Suillerot, 1988]. 
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3.4.3 Effect of quinone antitumour agents on topoisomerase 
activity in MCF-7 cell nuclear extract 
3.4.3.1 The effect of doxorubicin, topoisomerase II and topoisomerase I 
inhibitors on topoisomerase activity in MCF-7 cell nuclear 
extract 
Recently the mechanism of action of some DNA binding agents has been 
related to their ability to inhibit the nuclear enzymes topoisomerase I 
and II [reviewed by Ross, 1985 and Lock and Ross, 1987) [see section 
1.7.1]. These enzymes are involved in controlling the topological state 
of DNA. The topoisomerases catalyse knotting/unknotting, 
relaxation/supercoiling and catenation/decatenation of DNA [see figures 
1.13 and 1.14] (reviewed by Maxwell and Gellert, 1986). The difference 
between the two types of topoisomerase is that topoisomerase I changes 
the linking number of DNA by one whilst topoisomerase II changes it by 
two. These changes are brought about by transient strand breaks either 
single [topoisomerase I] or double [topoisomerase II] which allow 
passage of either a single DNA strand or a double DNA strand 
respectively. Mechanistically, the difference between the two enzyme 
types can be discriminated by the requirement of ATP and magnesium ions 
for topoisomerase II activity. In the present study the ability of 
quinone antitumour agents to inhibit topoisomerase activity isolated 
from MCF-7 human breast cancer cells was investigated. Supercoiled 
pBR322 plasmid DNA was used as a substrate and the topomers formed 
resolved by agarose gel electrophoresis. The assay procedure for 
topoisomerase activity is used to assess two drug induced end points, 
inhibition of relaxing activity ~nd formation of topoisomerase cleavable 
complexes. Topoisomerase cleavable complexes [see section 1.7.2 and 
1.7.3] are formed due to trapping of the enzyme on the DNA duplex by the 
presence of drug and are proposed to consist of DNA and enzyme in a 
conformation which is susceptible to cleavage in the presence of strong 
protein denaturants such as sodium dodecyl sulphate [SDS] and proteinase 
K. Denaturation of the cleavable complex reveals either DNA single 
[topoisomerase I and II] or double [topoisomerase II] strand breaks. In 
the case of topoisomerase I these breaks are associated with 
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topoisomerase attached to the free 3' end of the DNA break by a 3'-
phosphotyrosine linkage, whereas topoisomerase II enzyme subunits are 
associated with the 5' ends of the broken DNA double strands also via 
tyrosyl linkages [reviewed by Wang, 1985]. 
Topoisomerase II activity has been shown to be dependent on the 
proliferative status of the cells with less activity being found in 
quiescent cells (Sullivan et sl., 1987; Markovits et sl., 1987; Hsiang 
et sl., 1988). Cellular content and activity of topoisomerase II also 
varies during the cell cycle (Heck et sl., 1988; Hsiang et sl., 1988). 
In contrast, topoisomerase I levels do not vary between various growth 
states (reviewed by Liu, 1983). A nuclear extract was prepared from 
MCF-7 cells by the method described by Minford et sl. (1986). This 
extract has been reported to contain both topoisomerase I and II 
activity. The supercoiled DNA relaxing activity of this extract was not 
dependent on the presence of ATP [photograph 3.4] suggesting that this 
activity was topoisomerase I. This correlates with the MCF-7 cells used 
to prepare the nuclear extract being in a non-proliferative (confluent) 
stage of growth. In order to identify the topoisomerase type present in 
MCF- 7 nuclear extract, the effect of the topoisomerase II inhibitors 
mAMSA (Nelson et sl., 1984) and amiloride (Besterman et sl., 1987) and 
the topoisomerase I inhibitor camptothecin (Hsiang and Liu, 1988; 
Hertzberg et sl., 1989) on the relaxing activity of MCF-7 nuclear 
extract was investigated [see figure 3.18 for drug structures]. 
In the presence of topoisomerase I or II the supercoiled plasmid DNA is 
relaxed to form open circular DNA and intermediate species (topomers) 
with degrees of unwinding between supercoiled and open circular with 
differences in linking number of 1 or 2 [see photograph 3.5]. The 
reaction was terminated with SDS or SDS and proteinase K. In the 
presence of active topoisomerase I or II inhibitors a reduction in the 
number of topomers and the amount of open circular DNA should be 
observed. However, when the reaction was stopped with SDS only mAMSA, 
amiloride and camptothecin [all lOOng ml- l ] had no effect on the above 
processes [photograph 3.5]. 
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Figure 3.18 The structures of mAMSA, amiloride and camptothecin. 
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When the reaction was stopped with SDS and proteinase K mAMSA, amiloride 
and camptothecin also produced no effect on the DNA relaxing activity of 
MCF-7 nuclear extract [photograph 3.5]. If these drugs produced 
topoisomerase-DNA cleavable complexes an increase in linear 
[topoisomerase II] or open circular DNA [topoisomerase I and II] should 
be observed under these conditions. These results were inconclusive as 
to the identity of the type of topoisomerase activity present in MCF-7 
nuclear extract. The concentations of these agents required to inhibit 
topoisomerase activity vary considerably. between different laboratories 
[see table 3.2] therefore the concentrations used in the present study 
may have been too low. Furthermore, amiloride is reported to be a very 
weak (optimal concentration l15ugml-l) inhibitor of topoisomerase II and 
does not form cleavable complexes (Besterman et sl., 1987). Therefore, 
in a further experiment, the effect of doxorubicin [O.luM] and a higher 
concentration of mAMSA [lOuM, 4.0ugml-l] were investigated on the DNA 
relaxing activity of the MCF-7 nuclear extract. Doxorubicin has also 
been reported to be an inhibitor of topoisomerase II activity (Tewey et 
a1., 1984). When the reaction was stopped with SDS and proteinase K, 
this higher concentration of mAMSA slightly inhibited topomer formation 
and resulted in the formation of mainly open circular DNA [Photograph 
3.6]. This is consistent with topoisomerase 1- DNA cleavable complex 
being formed in the presence of mAMSA, which in the presence of 
proteinase K was being converted to nicked open circular DNA. 
Unfortunately this species cannot be discriminated from unnicked open 
circular in the plasmid assay since both species have identical 
migration rates through the agarose gel. Previously, mAMSA had been 
reported to be a specific inhibitor of topoisomerase II activity 
[Nelson et a1 1984; Rowe et a1., 1986; Minford et a1 1986; Pommier et a1 
1987] with good correlation between protein associated strand breakage 
and its cytotoxicity (Bakic et a1., 1986; Pommier et sl., 1984, 1985, 
1986; Per et sl., 1987). It has recently been reported that mAMSA is a 
potent inhibitor of topoisomerase I isolated from L12l0 cells (Pommier 
et sl., 1987), although, cleavable complex formation was not observed by 
these workers. Thus, it is likely that the DNA relaxing activity in 
MCF-7 nuclear fraction is topoisomerase I due to it being inhibited by 
mAMSA, producing cleavable complex mediated single strand breakage. If 
this activity was topoisomerase II this drug would form topoisomerase II 
cleavable complexes which would be revealed as double strand breaks in 
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Table 3.2 Inhibitory concentrations of mAMSA, camptothecin 
and amiloride on isolated DNA topoisomerase 
activity as determined by other workers. 
Inhibitor concentration (Jlg/ml) reference 
topoisomerase II 
mAMSA 0.1 Rowe et al. (1986) 
0.4 Pommier et al. (1987) 
0.8 Estey et al. (1987) 
amiloride 10.0 Figgitt et al. (1987) 
46.0 Besterman et al. 
(1989) 
topoisomerase I 
camptothecin 0.14 Hertzberg et al. (1989) 
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the form of linear DNA. It is not clear why mAMSA did not appear to 
inhibit MCF-7 topoisomerase I activity when the reaction was stopped 
with SDS alone [see photograph 3.6]. 
Doxorubicin [O.luM] produced a similar level of inhibition of DNA 
relaxing activity when the reaction was stopped with either SDS or SDS 
and proteinase K (see photograph 3.6), resulting in the formation of 
open circular DNA. This is indicative of topoisomerase I-DNA cleavable 
complexes being formed in the presence of drug which are converted to 
single strand breaks in the presence of protein denaturants. It would 
therefore appear that both methods used to stop the reaction are 
denaturing the topoisomerase I cleavable complex to reveal single strand 
breaks [nicked open circular DNA]. Doxorubicin also inhibited topomer 
formation in a concentration dependent manner, with a parallel increase 
in open circular DNA formation [see photograph 3.7]. This effect was 
also independent of which the way in which the reaction was terminated. 
These results further indicate that topoisomerase I activity is 
responsible for the relaxing activity of the MCF-7 nuclear extract. 
Doxorubicin [1 and SuM, photographs 3.4 and 3.7] totally inhibited 
topoisomerase I activity of MCF-7 nuclear extract without formation of 
the single strand breakage associated with cleavable complex formation. 
This is similar to the inhibition of topoisomerase II DNA cleavage 
activity of doxorubicin at high concentrations shown by rewey et al. 
(1984). Previously, doxorubicin has been shown to inhibit topoisomerase 
II activity with production of a cleavable complex and resultant double 
strand breaks (rewey et al., 1984). The absence of double strand break 
production [formation of linear DNA] in this study would therefore 
indicate an absence of topoisomerase II in this nuclear extract from 
MCF-7 cells. The results of this study therefore indicate a role for 
doxorubicin in inhibition of MCF-7 topoisomerase I, formation of 
topoisomerase I cleavable complex and subsequent single strand break 
formation. This could be a contributory factor to the DNA protein 
associated single and double strand breaks produced by doxorubicin in 
cellular systems [see section 1.16.3 and 1.16.4.3]. The results 
described in Chapter 3 of the present study [section 3.3.4.1] show that 
doxorubicin produced a concentration dependent strand breakage of DNA in 
MCF-7 cells which is likely to consist of both protein associated and 
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frank strand breaks. Furthermore, the concentration of doxorubicin 
[O.OSuM] shown to inhibit DNA relaxing activity of MCF-7 nuclear extract 
in the present study are of similar magnitude to those that produce DNA 
strand breakage and a cytotoxic response in the MCF-7 cell line in vitro 
[see section 3.3.4.1]. Doxorubicin has also been found to cause protein 
associated single and double strand breaks in mouse leukaemia L1210 
cells (Zwelling et al., 1981), rat mammary tumour cells (Evans et al., 
1986), human lung fibroblasts and V79 chinese hamster cells 
(Lawrence et al., 1988), human leukaemic cells (McGrath et al., 1989) 
and human colon adenocarcinoma cells (Broggini et al., 1989). A role 
for topoisomerase II in tumour cell resistance and hypersensitivity to 
doxorubicin has also been reported [see section 1.16.3]. 
This section has shown that the supercoi1ed plasmid DNA relaxing 
activity displayed by MCF-7 nuclear extract is likely to be 
topoisomerase I activity. The absence of topoisomerase II activity 
appears to be related to either a naturally low level of enzyme in MCF-7 
cells or due to the growth state of the cells at the time of harvesting. 
MCF-7 topoisomerase I activity was inhibited by doxorubicin, suggesting 
a possible role for this enzyme in protein associated DNA strand 
breakage by doxorubicin in MCF-7 cells. 
3.4.3.2 The effect of CI941, mitozantrone and alkylaminoanthraquinones 
on topoisomerase activity in MCF-7 nuclear extract 
These studies were extended to investigate the effect of other quinone 
containing antitumour drugs on topoisomerase I activity in MCF-7 nuclear 
extract, namely mitozantrone, CI94l and the alkylaminoanthraquinones. 
At a drug concentration of 1uM all these agents inhibited topomer 
formation to varying extents with a corresponding formation of open 
. 1 DNA [ h t h 3 8] The ~Q's produced an increase in Clrcu ar see p 0 ograp . . 
open circular DNA relative to controls when the reaction was stopped 
with both SDS or SDS and proteinase~. This increase in open circular 
DNA is probably due to cleavable complex mediated single strand breakage 
of DNA to produce nicked open circular DNA. This is indicative of 
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topoisomerase I cleavable complex formation by the AQ's. Kitozantrone 
and CI941 were the most potent inhibitors 
I mediated relaxation of supercoiled DNA. 
, preventing any topoisomerase 
This would indicate a total 
inhibition of the enzyme prior to single strand break production (due to 
drug induced cleavable complex formation) as was found for doxorubicin 
at high concentrations [see section 3.4.3.1]. Kitozantrone has 
previously been reported to be a topoisomerase II inhibitor in vitro, 
producing protein associated single and double strand breaks (Ho et 
a1., 1987; Epstein et a1., 1986; Heinemann et al., 1988; Locher and 
Meyn, 1983). Crespi et a1. (1986) [using KCF-7 cells] and Tewey et al. 
(1984) showed that mitozantrone inhibits mammalian topoisomerase II 
activity. However, Crespi et al. (1986) showed that mitozantrone had no 
effect on topoisomerase I activity isolated from KCF-7 cells, although 
the highest concentration tried by these workers was only 0.18uM and a 
higher concentration of substrate pBR322 DNA was used compared to the 
present study. Furthermore, the protein concentration of the extract 
used by these workers is not stated. Protein (topoisomerase) associated 
single and double strand breaks have been shown to be produced by 
mitozantrone in L12l0 cells (Cohen et a1., 1980) and Chinese hamster 
ovary cells (Locher and Keyn, 1983). From the results of this study a 
role for topoisomerase I cleavable complex formation could be involved 
in the mitozantrone mediated DNA strand breakage observed. This is also 
likely for CI941 as this compound was also shown to generate DNA strand 
breakage in KCF-7 cells in the present study [section 3.3.4.2]. The 
alkylaminoanthraquinones inhibited KCF-7 nuclear extract DNA relaxing 
activity in the following order of potency: 1,4AQ - 1,5AQ - 1,8AQ > lAQ. 
However, the AQ's were less potent inhibitors than mitozantrone and 
CI94l. As described above these agents also formed topoisomerase I 
cleavable complexes as indicated by the increased amount of open 
circular in drug treated samples relative to the control treated with 
nuclear extract alone [see photograph 3.8]. 1,4AQ was previously shown 
by Locher and Meyn (1983) to produce DNA protein associated strand 
breaks in Chinese hamster ovary cells to a lesser degree than 
mitozantrone. This correlates with the lower inhibition of 
topoisomerase activity produced by 1,4AQ relative to mitozantrone shown 
in the present study. The results of the present study indicate that 
promotion of MCF-7 topoisomerase I cleavable complex formation may 
contribute to the total DNA strand breakage produced by AQ's in MCF-7 
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cells [section 3.3.4.3]. 
Inhibition of topoisomerase I by quinone antitumour agents could have 
important implications in the mechanism of cytotoxicity of these agents 
in the MCF-7 cell line. An involvement of topoisomerase I has been 
implicated in DNA replication, RNA transcription, chromosome 
condensation and decondensation and genetic recombination (reviewed by 
Liu, 1983). The topoisomerase I inhibitor camptothecin inhibits DNA 
and RNA synthesis (reviewed by Bodley and Liu, 1988). Therefore, by 
analogy, inhibition of topoisomerase I, as indicated by the present 
study, could be implicated in the inhibition of DNA and RNA synthesis 
produced by doxorubicin (reviewed by Gianni et a1., 1983), mitozantrone 
and 1,4AQ (Nishio and Uyeki, 1983) and CI941 (Showalter et a1., 1986) 
and the condensation of nucleic acids by mitozantrone and 1,4AQ 
(Kapuscinski and Darzynkiewicz, 1984 and 1986). 
The mechanism of quinone antitumour agent inhibition of topoisomerase I 
activity isolated from MCF-7 cells is unknown. However it is likely to 
be related to the DNA binding affinity of quinones. Until recently 
inhibitors of topoisomerase were not categorised as DNA binders. 
However, those 'non-binding' inhibitors such as the epipodophyllotoxin 
VM-26 and the anthracycline AD32 have recently been shown to bind to DNA 
(Chow et a1., 1988). Thus DNA binding appears to be a prerequisite for 
inhibition of topoisomerase activity. The order of potency for 
inhibition of topoisomerase activity in the present study [derived from 
photograph 3.8] is mitozantrone = CI941 > 1,SAQ - 1,4AQ - 1,8AQ > lAQ. 
This correlates with the order of DNA binding affinity of these agents 
[see table 3.3]. Furthermore, from table 3.3 it can be see that the DNA 
dissociation rate constants of the AQ's also correlates with their 
potency to inhibit MCF-7 topoisomerase I activity. The weakest 
inhibitor of topoisomerase I, lAQ, having the highest DNA dissociation 
constant. 
There are several possibilities as to how inhibition of topoisomerase I 
occurs due to DNA binding by these agents:-
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Table 3.3 Binding of quinone antitumour agents with DNA. 
Compound DNA affinity constant DNA dissociation 
Kapp M-1 constant sec-1 
doxorubicin **6.Sx106 1.84 
mitozantrone *2.6x108 nd 
CI941 *1.0x108 nd 
lAQ 1.03x106 127 
1,4AQ 2.83x106 3.82 
1,SAQ 3.2x106 1.39 
1,BAQ 2.3Sx106 1.84 
nd=not determined. derived from Gandecha (1985), except 
**Capranico et al (1989), *Hartley et al (1988). 
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1. The intercalation of the quinone [reviewed by Neid1e and Abraham , 
1987] may cause torsional stress within the DNA duplex which induces 
topoisomerase I to form the cleavable complex. This would be 
assisted by the intercalation of drug preventing the enzyme from 
forming its normal interaction with DNA at a particular site. This 
view is supported by the inhibition of cleavable complex formation 
at high concentrations of doxorubicin, mitozantrone and CI941 [see 
photographs 3.6 and 3.8]. This could be due to drug intercalation 
causing unwinding of the DNA so that topoisomerase I cannot bind. 
2. Intercalation may enable the quinones to specifically interact with 
topoisomerases therefore stabilising the cleavable complex. This 
possibly occurs through an interaction between the parts of the drug 
molecule which protrude from the intercalation site and the DNA-
enzyme complex. For example the hydroxyethylethylamino side chains 
of mitozantrone, CI941 and the AQ's, and the amino sugar of 
doxorubicin [see figures 1.32, 1.33 and 1.35]. This is supported by 
the potency of a series of acridine topoisomerase II inhibitors 
being related to the 'bulkiness' of their side chains (Pommier et 
al., 1987). 
3. The quinones may be able to interact directly with topoisomerase I. 
These possibilities are somewhat complicated by the fact that different 
drugs induce topoisomerase II associated strand breaks at different DNA 
sites and the general lack of correlation between protein associated 
strand breaks and cytotoxicity of different drug classes (Rowe et al., 
1986). Furthermore an understanding is required of whether cleavable 
complex formation is important in cell kill per se or whether it is the 
inhibition of topoisomerase function which is important. In addition, 
there is no clear understanding on how cleavable complexes are converted 
to lethal DNA strand breaks in vivo. Avemann et al. (1988) showed that 
camptothecin induced topoisomerase I mediated strand breakage at the 
replication forks of SV40 minichromosomes. Also, Schneider et al. (1989) 
found that mAMSA was maximally cytotoxic in cells undergoing RNA and 
protein synthesis. When RNA and protein synthesis were inhibited mAMSA 
produced no change in the level of cleavable complexes formed, 
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suggesting that an active event is required for conversion of complex 
formation to cell kill (Schneider et al., 1989). 
3.4.4 The effect of quinone anti tumour agents on cellular DNA. 
Cellular DNA strand breakage was determined in MCF-7 human breast cancer 
cells after treatment with quinone containing antitumour agents. This 
was determined in order to relate the propensity for redox cycling and 
the cytotoxic potential of these agents to their ability to produce 
cellular DNA damage. 
3.4.4.1 The effect of doxorubicin, mitozantrone and CI941 on DNA strand 
breakage in MCF-7 cells. 
Doxorubicin produced DNA strand breakage in MCF-7 cells in a drug 
concentration dependent manner [figure 3.12A]. Table 3.4 relates the 
strand scission factors observed for doxorubicin in MCF-7 cells with the 
cell kill produced by doxorubicin following a one hour exposure and 
different periods of further drug-free incubation period [derived from 
figure 3.l2B]. It can be seen from this table that as the post-exposure 
incubation time increases the cell kill observed for a given level of 
DNA strand scission also increases. The low level of strand breakage 
observed for 0.1 and 1.0uM doxorubicin correlated with almost no cell 
kill following a 2.5 or 6 day post-exposure incubation period. 
However, following an 11 day post-exposure incubation both these 
concentrations produced cell kill. This indicates that there is a time 
delay before the DNA strand breakage observed is expressed as cell 
kill. This suggests that although low doxorubicin concentrations 
produced only a low level of DNA strand scission, sufficient numbers of 
these DNA lesions are non-repairable and ultimately lethal to the cell. 
The results of the present study are supported by the work of others who 
also measured doxorubicin strand breakage under deproteinised 
conditions. Doxorubicin has been found to produce strand breakage in 
other human tumour cell lines including human myeloma cells (Bellamy et 
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Table 3.4 Relationship between doxorubicin mediated DNA strand 













% Cell kill 
ABC 
10.1 + 13.0 14.4 + 19.7 58.1 + 12.9 
23.9 + 6.5 "30.0 + 28.4 85.9 + 1.9 
58.0 + 5.1 71.9 + 6.0 88.4 + 10.0 
nd 78.6* 84.0 + 0.6 
A = Ihour exposure + 60 hours drug-free growth 
B = Ihour exposure + 6 days drug-free growth 
C = Ihour exposure + 11 days drug-free growth 
values are mean + sd (except*) 
nd = not determined 
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a1., 1988), CCRF- CEM human leukaemia cells (McGrath et a1., 1989), A549 
human lung adenocarcinoma cells (Lawrence, 1988) and also in other 
mammalian cell lines such as P388 leukaemia cells (Capranico et a1., 
1989; Deffie et a1., 1988) and L1210 mouse leukaemia cells (Potmesil et 
a1., 1988). Many of the above studies do not discriminate between 
~ 
protein associated and non-protein associated (frank) strand breakage. 
Doxorubicin has also been shown to produce frank DNA strand breakage in 
Chinese hamster V79 cells (I1iakis and Lazar, 1987), human uterine 
sarcoma cells (Scudder et a1., 1988), L1210 mouse leukaemia cells 
(Potmesi1 et a1 1983 and 1984; Ross and Smith, 1982), P388 lymphocytic 
tumours (Goldenberg et a1., 1986) and human colon carcinoma cells 
(Johnston et a1., 1983). The DNA strand breakage observed for 
doxorubicin in the present study is likely to represent both protein 
associated and frank strand breakage. Doxorubicin strand breakage in 
vitro revealed by proteinase K have been shown to be due to 
topoisomerase II cleavable complex formation (Zwelling et a1., 1981)[see 
section 1.16.3]. The results of the present study have also shown 
doxorubicin to be an inhibitor of MCF-7 topoisomerase I activity with 
formation of topoisomerase I cleavable complexes (see section 3.3.3). 
SDS and/or proteinase K treatment of these cleavable complexes result in 
the formation of single strand breaks. Therefore, the inhibitory action 
of doxorubicin on topoisomerase I could contribute to the strand 
breakage observed for this agent in MCF-7 cells. Frank DNA strand 
breakage produced by doxorubicin in MCF-7 cells is likely to be due to 
the redox cycling activity of this agent observed in the present study 
(see chapter 2) which resulted in formation of hydroxyl radicals 
[section 2.3.1.6]. This is supported by the work of Potmesil et a1. 
(1984) who showed that doxorubicin produced frank DNA strand breakage in 
mouse leukaemic L1210 cells at concentrations> 2.8uM which were reduced 
in number by the oxygen free radical scavengers SOD, catalase, DMSO and 
ethanol. Furthermore, frank strand breakage was not observed under 
hypoxic conditions. The mechanism of hydroxyl radical attack on DNA is 
fully discussed in section 1.9.2.1 and illustrated in figures 3.19-3.22. 
Mitozantrone and CI941 [100uM] produced a similar level of DNA strand 
breakage to doxorubicin [table 3.5]. At an LD50 concentration, 
mitozantrone (5x10- 9M) produced a similar amount of strand scission to 
that produced by a concentration of 100uM (see figure 3.14). This 
indicates that mitozantrone mediated strand breakage is saturable at 
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Figure 3.5 Strand scission factors for doxorubicin, 
mitozantrone, CI941 and alkylaminoanthraquinones 












0.211 + 0.07 0.127 + 0.28 
0.0612 + 0.03 0.179 + 0.24 
0.129 + 0.06 0.436 + 0.17 
0.118 + 0.08 0.094* 
0.285 + 0.09 0.652 + 0.18 
0.129 + 0.04 0.534 + 0.08 
Values are mean + sd of three determinations 
[except *(2)] 
ED50 concentrations [M] were mitozantrone [5x10-9], 
CI941 [l.5x10-10], doxorubicin [3.0x10-6], 1AQ [6x10-8], 
1,4AQ [l.2x10-6], l,5AQ [12.3x10-6] and 1,8AQ [0.5x10-6]. 
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nlgn orug concen~ra~10nS. CI941 (2x10- 10M) produced 60% less strand 
breakage than at 100uM (figure 3.14). At an LD50 concentration (3.0xlO-
6M) doxorubicin produced a similar level of strand breakage to CI94l, 
but less than mitozantrone (see table 3.5). These results indicate 
that mitozantrone is more potent than CI941 at generating strand 
breakage in MCF-7 cells. However, at LD50 concentrations both 
mitozantrone and CI941 are considerable more potent than doxorubicin at 
producing strand breakage. This correlates with the increased cytotoxic 
potency of mitozantrone and CI941 relative to doxorubicin [table 4.5], 
indicating that DNA strand breakage is involved in the cell kill of 
these agents. Furthermore, mitozantrone was also been shown to be 
more efficient than doxorubicin at producing DNA strand breakage in T47D 
human breast cancer cells [Epstein et a1., 1988]. The relative potency 
of DNA strand breakage formation by doxorubicin, mitozantrone and CI941 
correlates with their DNA binding affinities [table 3.3]: mitozantrone 
> CI941 > doxorubicin. The DNA binding constants of mitozantrone and 
CI941 has previously been correlated in the present study with their 
enhanced abi1ty to inhibit MCF-7 topoisomerase I activity [section 
3.4.3.2]. Furthermore, mitozantrone has previously been shown to 
inhibit MCF-7 topoisomerase II activity (Crespi et a1. 1986) and produce 
protein associated strand breaks in vitro (Heinemann et a1., 1988; 
Epstein et a1., 1988). Therefore, it is likely that cellular DNA strand 
breakage by mitozantrone and CI941 in the present study are due to 
proteinase K treatment (part of the alkaline elution technique) 
revealing topoisomerase I and II cleavable complex mediated single and 
double strand breaks. The saturable nature of mitozantrone mediated DNA 
strand breakage in MCF-7 cells would also support this concept of an 
enzyme [topoisomerase] being involved. Moreover, mitozantrone and 
CI941 were found not to redox cycle in MCF-7 cells [2.4.2] in the 
present study, hence these agents are unlikely to produce hydroxyl 
radical mediated DNA strand breaks. The high DNA binding constants of 
mitozantrone and CI941 are likely to result in these agents accumulating 
in the nucleus, resulting in a persistance of the DNA lesions produced. 
This could account for the much increased cytotoxic potency of these 
agents relative to the other compounds in this study [see tables 4.5 and 
4.6]. Other workers have found that mitozantrone induced strand breaks 
persist after removal of drug, including Ho et a1. (1987) and Locher and 
Meyn (1983). As discussed in section 3.4.3 proteinase K revealed 
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single and double DNA strand breaks do not exist as strand breaks in 
vitro because they are masked by the presence of the topoisomerase-DNA 
complex. It is likely that an active process such as DNA transcription 
or replication needs to occur before topoisomerase cleavable complexes 
are converted into lethal DNA lesions. 
3.4.4.2 The effect of alkylaminoanthraquinones on DNA strand breakage 
in HCF-7 cells 
At a concentration of lOOuM lAQ, 1,SAQ and 1,8AQ produced a large amount 
of strand breakage [see figure 3.17]. In contrast, 1,4AQ (lOOuM) 
produced only a small amount of strand breakage, similar in quantity to 
that produced by doxorubicin, mitozantrone and CI941 at this 
concentration [see table 3.S]. The increased amount of strand scission 
by lAQ, 1,SAQ and 1,8AQ at lOOuM compared to 1,4AQ, mitozantrone and 
CI941 correlates with the increased propensity of these AQ's to redox 
cycle and form hydroxyl radicals in MCF-7 cells (see section 2.4.3). A 
role for hydroxyl radicals in the cellular DNA strand breakage produced 
by these agents is supported by the similar elution profile of MCF-7 
cellular DNA from cells treated with gamma radiation (appendix figure 
A13). Radiation has been proposed to mediate cellular DNA damage by 
hydroxyl radical formation (reviewed by Ward, 1987). The mechanism of 
hydroxyl radical mediated DNA strand breakage is discussed in sections 
1.9.2 and 3.4.1.1 and illustrated in figures 3.19-3.21. In contrast, 
1,4AQ, mitozantrone and CI941 have been shown not to redox cycle in MCF-
7 cells [sections 2.4.3 and 2.4.2]. At the LD50 concentrations of 
lAQ (4.0uM), 1,SAQ (12.3uM) and 1,8AQ (O.SuM) a decrease in DNA strand 
scission was observed compared to higher (lOOuM) concentrations of these 
agents, whereas, at 1.2uM (LD50 concentration) and lOOuM, a similar 
level of strand breakage was observed for 1,4AQ [table 3.5]. The AQ's 
produced a similar level of strand scission to doxorubicin, mitozantrone 
and CI941 at LD50 concentrations (table 3.S). However, the LD50 
concentrations of mitozantrone and CI941 were considerably lower than 
those for doxorubicin or AQ's. The lower level of strand breakage by 
lAQ, 1,5AQ and 1,8AQ at LD50 concentrations correlates with a lower 
level of hydroxyl radical formation at these concentrations. Similar to 
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mitozantrone and CI94l, the AQ's have also been shown to be inhibitors 
of topoisomerase I activity in MCF-7 cells in the present study [section 
3.4.3.2]. It is therefore likely that DNA strand breakage by l,4AQ is 
due to topoisomerase I or II cleavable complex formation. However, these 
compounds had reduced potency to inhibit this enzyme compared to 
mitozantrone and CI941 [see photograph 3.8]. It is likely that 
proteinase K revealed topoisomerase I or II cleavable complex mediated 
single and double strand breaks contribute to the DNA strand breakage 
observed for the AQ's in MCF-7 cells. 1,4AQ has been previously shown 
to produce protein associated strand breaks in Chinese hamster ovary 
cells, with 250x less efficiency than mitozantrone (Locher and Meyn, 
1983). Furthermore, 1,4AQ induced strand breaks were repaired more 
efficiently than those produced by mitozantrone [Locher and Meyn, 1983]. 
The higher efficiency of strand break formation by mitozantrone and 
CI94l in the present study, compared to AQ's, also correlates with the 
higher DNA binding constants of these compounds compared to the AQ's 
[see table 3.3]. 
The relationship between DNA strand breakage, redox cycling, inhibition 
of topoisomerase and cytotoxicity of the compounds in the present study 
will be further discussed in chapter 5. 
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CHAPTER 4 
An investigation of cytotoxicity and uptake of quinone 




An investigation of cytotoxicity and uptake of quinone 
containing antitumour agents in HCF-7 human breast 
cancer cells 
4.1 Introduction 
The previous chapters have investigated the propensity of the quinone 
antitumour agents in this study to redox cycle [chapter 2] and produce 
DNA strand breakage [chapter 3] in the MCF-7 cell line. In this chapter 
the cytotoxicity of these agents is investigated in order to relate 
cytotoxic potential to the propensity of these agents to redox cycle and 
generate DNA strand breakage in MCF-7 cells. 
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4.2 Methods 
4.2.1 Determination of cytotoxicity in HCF-7 cells 
Two methods were used to determine the cytotoxicity of quinone 
antitumour agents in MCF-7 cells. The first method involved determining 
the number of surviving cells after a 24 hour drug exposure. This 
method allowed determination of drug short term cytotoxicity. The 
second method involved exposing the cells to drug for one hour then 
growing on the cells for various time periods. This enabled the effect 
of the drug on the clonogenic potential of the cells to be determined. 
Method 1:- Firstly, several flasks of MCF-7 cells were grown up, 
harvested and resuspended in growth medium. The cells were dispersed by 
passing the suspension through a 25 gauge followed by a 21 gauge 
needle. The cells were counted using a Coulter counter and the cell 
concentration adjusted to 10Sml- l in growth medium and aliquots of cell 
suspension (lml) pipetted into a 12 well plate. At this point the well 
plates were incubated in a sealed plastic bag in an atmosphere of 5% 
CO2/95% air for 24 hours at 37C. After 24 hours the medium was poured 
off the cells and replaced with medium containing appropriate serial 
dilutions of a filtered [l.Ou acrodisc, Flow Labs] drug solution or 
growth medium in the case of controls. The well plates were then 
reincubated for 24 hours at 37C. After 24 hours the drug solutions were 
poured off and the wells washed twice using ice cold Dulbecco's 
phosphate buffered saline. EDTA, (0.1%, 0.5ml) was added to each well 
for 30 seconds and then poured off and the plates incubated for 15 
minutes at 37C. The cells were resuspended in lml of DPBS and dispersed 
by passage through a 25 gauge followed by a 21 gauge needle (several 
times). The cell suspension in each well was transfered to isotonic 
saline (20ml) by means of a syringe and the cell concentration 
determined using a Coulter counter. All results were related to 
untreated control cell counts. 
Method 2:- This method is essentially the same as method 1 except for 
256 
the following details:-The passaged MCF-7 cells were adjusted to a 
concentration of 104to 105m1- 1 pipetted into 12 well plates ~n 
L aliquots 
[lml]. After 24 hours incubation the medium was replaced with drug 
dilution or growth medium alone and incubated at 37C for 1 hour. After 
one hour the drug solutions were removed and the plates washed with ice 
cold DPBS (lm1) for one minute following which fresh growth medium (lml) 
was placed in each well. The plates were incubated for various time 
periods [96hrs-17days] at 37C with a media change every five days of 
incubation. The cell numbers were determined as method 1. 
In order to determine the effect of oxygen free radical scavengers on 
MCF-7 cell survival in the presence of quinone antitumour agents method 
2 was modified as fo1Iows:-
Prior to addition of drug the cells were incubated (37C) for thirty 
minutes in in serum supplemented RPMI-1640 (O.Sml) containing double the 
required final concentration of scavenger. Following this period more 
growth medium was added (0.5m1) containing double the required 
concentration of drug. Following one hour further incubation, the 
drug/scavenger containing medium was removed, the monolayer washed with 
ice cold PBS, fresh medium added and cell survival assessed following a 
further six day incubation as described above. 
4.2.2 Determination of quinone anti tumour agent uptake into HCF-l 
cells 
4.2.2.1 Using high performance liquid chromatography (HPLC) 
Drug uptake into MCF-7 cells was determined by measuring drug in the 
medium (by HPLC) after incubation of cells with drug. Incubations were 
carried out as follows. Firstly log phase MCF-7 cells were harvested 
and counted as described in appendix A1. The cells were suspended in 
RPMI-1640 growth medium supplemented with 10% foetal bovine serum (FBS) 
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at a concentration of 106 cells m1-1. The cells were dispersed by 
passage through a needle [as described in section 4.2.1] and 
centrifuged [900rpm, 10 minutes, 4C] using a refrigerated bench 
centrifuge [CR422, Jouan] to pellet the cells. RPMI-1640 medium 
supplemented with 10% FBS was placed in a glass conical flask [20m1] 
which had been treated with trich10romethylsilane to prevent binding of 
drug or adhesion of cells. An appropriate volume of drug was added to 
the medium to give a final concentration of ISuM. Three samples (200u1) 
were removed from the flask and transferred into eppendorf tubes (1.5m1) 
and used as controls. The drug-containing medium was pre-warmed to 37C 
in a water bath. To initiate the uptake study the cell pellet was 
resuspended in the drug-containing medium [to give a cell concentration 
of 106 cells ml- 1 ] and transfered to the incubation flask. Three 
samples (200u1) were immediately removed from the cell suspension and 
placed in eppendorf tubes. Ice cold ethanol [SOul] was added to the 
tubes [to precipitate serum protein] and the tubes spun for 2 seconds in 
a microcentrifuge [Hema-C, Jouan]. The supernatants were removed and 
placed in HPLC sample tubes [08-CPVIA, Chromaco1]. The cell pellet was 
then resuspended in ice cold PBS [lS0u1] and the tubes spun for 2 
seconds in a microcentrifuge. The supernatants were again removed and 
pooled with those of the first centrifugation step in the HPLC sample 
tubes. Finally the tubes were capped and sealed ready for HPLC 
autoinjection. The control samples were treated in an identical manner 
to above. Further triplicate samples of cell suspension were removed 
from the incubation flask at S, lS, 30, 60 and 90 minutes and treated as 
above. 
The drug rema~n~ng in the supernatant was quantitated using a Phillips 
HPLC [PU 4100 Liquid Chromatograph, PU 4110 uv/vis Detector (254nm), 
PU4700 autoinjector and Walters computer system JCL6000 with Chromat 
data capture system (Jones Chromat, 1988). The solvent system used 
consisted of CH
3
CN [28%] and ammonium formate (80mM, pH 3.25) [72%]. 
For each anthraquinone studied a calibration curve was constructed using 
drug standards (5-ISuM) prepared in RPMI-1640 medium supplemented with 
FBS [10%]. The drug concentration in each sample was calculated from 
the calibration curve [Maine, J, personal communication] and the results 




4.2.2.2 Using polarography 
Polarography is an electrochemical method in which the changes of 
current, resulting from the electrolysis of the solution under 
investigation are followed using a mercury electrode and a gradually 
applied voltage (reviewed by Bersier, 1983; Heyrovsky, 1968; Zuman, 
1964). Mitozantrone can undergo oxidation and reduction and can 
therefore be detected polarographically under oxidative or reductive 
conditions. This method was used to determine mitozantrone uptake into 
MCF-7 cells. Polarography was carried out using a 626 Polarecord 
combined with a 663VA stand [Metrohm]. The optimal protocol for 
determination of mitozantrone involved utilisation of a Stelte type 
micro cell with differential pulse polarography (50Mv pulse) and a 
hanging mercury drop electrode [HMDE] under reductive conditions. The 
following methods describe experiments which were carried out to 
characterise the polarographic determination of mitozantrone with a view 
to using this technique for determining cellular uptake of this drug. 
4.2.2.2a Determination of mitozantrone (O.5uM) polarographically 
The optimal settings for the polarograph were found to be hanging 
mercury drop electrode mode, differential pulse 50mV, drop size 1, scan 
speed 5, measurement period 2 seconds, voltage sweep -0.0 to -1.4V, 
damping 1 and sensitivity O.lnA/mm. 
Initially a background voltage s~eep was carried out using Dulbecco's 
phosphate buffered saline [DPBS] (O.lM, pH 7.4) after deaerating for 10 
minutes with a steady stream of nitrogen [oxygen free (BOC)]. Several 
h . d t ml.·tozantrone solution (0.5uM, in voltage sweeps were t en carrl.e ou on 
DPBS) after deaerating for 3-5 minutes. 
4.2.2.2b Preparation of a calibration curve for mitozantrone 
(O-lOuM) using polarography 
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A range of mitozantrone concentrations made up in DPBS w d . ere eterm1ned 
in triplicate using the polarographic parameters descr1'bed . . 1n sect10n 
4.2.2.2a. The height of the reduction peaks at -0.95 and -1.04V were 
measured for each drug concentration. Appendix figure A9 shows a 
typical calibration curve. 
4.2.2.2c Polarographic determination of mitozantrone uptake 
into HCF-7 cells 
MCF-7 cell suspension (106ml -l) in DPBS was placed in a glass conical 
flask [20ml] pre-coated with trichloromethylsilane [Sigma] and incubated 
in a water bath at 37C. Cell suspension [2ml] was removed and placed in 
a centrifuge tube [treated as above] at 37C for use as a drug-free 
control. A Mitozantrone stock solution (sroM) was added to the flask to 
give a final concentration of 10uM. After mixing, three samples [lml] 
were removed, placed in Eppendorf tubes and spun for 2 seconds using a 
microcentrifuge. The supernatants were removed, placed in clean 
Eppendorf tubes, and the cell pellets resuspended in ice cold DPBS 
[O.sml] and centrifuged as above. The supernatants of the two 
centrifugation steps were then pooled. Further triplicate samples of 
cell suspension were removed at 30, 60, 90, 120, 180, 240 and 300 
minutes and treated in an identical fashion. At this stage the 
supernatants could be stored in a freezer [-20C] for later analysis. 
Also at regular time intervals, samples of cell suspension [12sul] were 
removed from the drug containing and drug-free suspensions and the cell 
viability assessed using trypan blue exclusion [as described in appendix 
AI.9] . 
The concentration of mitozantrone in the supernatants was determined 
polarographically by measuring the peak height of the -0.9sV reduction 
peak. The polarographic parameters employed were as described in 
section 4.2.2.2a. As a standard, samples of a solution of mitozantrone 
[IOuM] in DPBS were treated in an identical manner to cell suspension, 
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the -0.95V peak heights of the experimental samples being compared to 
the mean peak height of the standards and expressed as a percentage of 
this value. From this the absolute amount (nmoles) of drug taken up by 
the cells could be calculated. The concentration of mitozantrone taken 
up by the cells was expressed as the amount of drug [nmoles] taken up 





Cytotoxicity and uptake of quinone antitumour agents in 
HCF-7 cells 
Cytotoxicity was determined by several different protocols as described 
in section 4.2.1. This enabled comparison of short term and long term 
cytotoxic effects of these agents as well as the effect of different 
exposure times on cytotoxicity. In addition, the effect of oxygen 
radical scavengers on cell survival after treatment with selected drugs 
was investigated. Figure 4.1 shows that when drug exposure was carried 
out 24-48 hours after seeding the MCF-7 cells were in an exponential 
growth phase. 
Drug uptake was measured by HPLC [as described in section 4.2.2] in 
order to determine whether any differences in cytotoxicity observed 
between drugs could be accounted for by differences in cellular uptake. 
4.3.1.1 Cytotoxicity of doxorubicin in MCF-7 cells 
Cytotoxicity of doxorubicin after a 24 hour exposure followed by 
immediate determination of the surviving cell fraction was investigated. 
Figure 4.2A shows the results of two experiments which were carried out. 
Doxorubicin was cytotoxic to MCF-7 cells between 0.01 and 100uM. The 
drug concentrations that killed 50% of the cells in two determinations 
[Lethal Dose 50% or LD50] were 0.17 and 0.38uM. The effect of 
doxorubicin on MCF-7 cells which were fully confluent was also 
determined and is shown in figure 4.2B. Exposure time was 24 hours 
followed by immediate counting of surviving cells. In this system 
doxorubicin failed to kill more than 40% of the cells. 
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Figure 4.2 Cytotoxicity of doxorubicin in exponentially 
growing [A] and quiescent [B] HCF-7 cells after a 24 hour 
exposure 
105 cells were seeded per well and cultured for 24 hours prior to drug 
exposure. Surviving cells were counted immediately after drug exposure. 
Final control cell numbers were 2.62 + O.sxlOs/ well. 
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Figure 4.3 Cytotoxicity of doxorubicin in HCF-7 cells after a 
24 hour exposure followed by a further 96 hour drug-free 
incubation 
5x104 cells were seeded per well and cultured for 48 hours prior to drug 
exposure. Agter a further 96 hour incubation control cell numbers were 
2.1 + O.lx10 Iwe11. Values are mean + sd of three determinations. 
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incubated [96 hours] after exposure to drug for 24 hours [figure 4.3]. 
The LD50 concentration observed for doxorubicin using this protocol was 
0.2uM. Uptake of quinone antitumour agents by MCF-7 cells was found to 
be maximal after 60 minutes of incubation [see section 4.3.2.1]. 
Cytotoxicity after a one hour drug exposure period was therefore 
~nvestigated. In addition the effect of extending the incubation period 
after drug exposure was investigated. Other workers have used one hour 
drug exposures with a range of incubation times post-exposure [see table 
4.6]. Figure 4.4 shows the effect of exposing MCF-7 cells to 
doxorubicin for one hour followed by 60 hour or 11 day further drug-free 
incubation. Appendix figure A8 shows the cytotoxicity of doxorubicin in 
MCF-7 cells following a one hour exposure and six day further growth 
period. Table 4.1 summarises the LD50 concentrations obtained using 
these different protocols. It can be seen from this table that the LD50 
concentration was inversely related to post-exposure incubation period. 
4.3.1.2 The effect of oxygen radical scavengers on 
doxorubicin cytotoxicity in HCF-7 cells 
The effect of oxygen free radical scavengers on the cytotoxicity of 
doxorubicin [3.0uM (LD50 concentration)] after a one hour exposure and 6 
day further drug free incubation is shown in figure 4.5. Cells were 
incubated with scavenger for 30 minutes prior to addition of drug. 
Scavenger and drug were incubated for a further hour before removal, 
washing [with PBS] and addition of fresh medium. DMSO [lOOmM] and 
catalase [3000 units m1- 1 ] slightly increased the proportion of 
surviving cells relative to cells treated with doxorubicin [18.4% and 
9.9% respectively]. However, N-acety1 cysteine [lOOmM] and superoxide 
dismutase [150ug m1- 1 ] had no protective effect. 
In a further study figure 4.6 shows the effect of increasing the 
scavenger concentration used. Catalase [6000 units ml-
1
], superoxide 
dismutase [600ug m1- 1 ] and SOD plus catalase [3000 units/300ug ml-
1
] 
increased cell survival by 16.9%, 11.1% and 15.7% respectively. DMSO 
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Figure 4.4 Cytotoxicity of doxorubicin in HCF-7 cells after a one hour 
exposure followed by a further 60 hour {A} or 11 day {B} 
drug-free incubation 
A: lOS cells were 
exposuIe to drug. 
B: 10 cells were 
exposure to drug. 
seeded per well and incubated for 24 hours prigr to 
Final control cell numbers were 1.38 + 0.14xlO /well. 
seeded per well and incubated for 24 hours prior to 
Final control cell numbers were SxlOS/well. Values 
are mean + sd of three determinations. 
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Table 4.1 Effect of post-exposure incubation time 
on the LD50 concentration of doxorubicin in MCF-7 
cells. 










Exposure time was one hour. Cells/incubate was 
105 [60], 104 [144], and 104 [264]. Data derived from Figure 






A B c D E F 
Figure 4.5 Effect of oxygen free radical scavengers on the cytotoxicity 
of doxorubicin in HCF-7 cells 
4 10 cells were seeded per well and cultured for 24 hours prior to 
exposure to drug. Cells were incubated with A: no drug , or B: 
doxorubicin [3uM] with C: DMSO [lOOmM] , D: catalase [300 0 uni t s ], E: 
SOD [lSOug] and F: n-acetyl cysteine [lOOmM] . Afzer 6 days f urther 
incubation control cell numbers were 4 . 0 + 1 . lS xlO j well . 
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Figure 4.6 Effect of oxygen free radical scav engers on the 
cytotoxicity of doxorubicin in HCF- 7 cells 
5 10 cells were seeded per well and cultured for 24 hours prior to drug 
exposure. Cells were incubated for one hour with A: no dr ug, or B: 
doxorubicin [3uM] with C: DMSO [200mM] , D: cata l a s e [6000 units ), E: 
SOD [600ug], F : catalase and SOD [3000 units /300ug ] . After 6 days 
further incubation the control cell numbers were 8.96 + 0.64xl0
4 
Values are mean + sd of three dete r minations . 
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4.3.1.3 Cytotoxicity of mitozantrone and CI941 in HCF-7 cells 
Figure 4.7A (also appendix figure A9) shows the effect of exposing MCF-7 
cells to mitozantrone or CI941 for 24 hours followed by immediately 
counting the surviving cells. The mean LOSO concentrations for 
mitozantrone and CI941 derived from this data were 2.4uM and O.SuM 
respectively. 
The effect of incubating cells for a further 96 hours after exposure to 
drug for 24 hours was also investigated. Figure 4.7B shows the 
cytotoxicity profile obtained. In this system mitozantrone had an LOSO 
of 1.62xlO- lOM and CI94l, a mean LOSO of 4.6xlO- l °uM [determined from 
two independent experiments]. The cytotoxicity range of these drugs was 
from 10- 12 to 10-SM. 
The effect of exposure of MCF-7 cells to mitozantrone and CI941 for one 
hour was investigated in a similar manner to doxorubicin. After a 60 
hour post-exposure incubation the LOSO concentrations obtained were 
1.3xlO- 7M for mitozantrone and 1.6xlO- SM for CI941 [figure 4.SA]. The 
effect of increasing the post-exposure incubation period to 6 days is 
shown in figure 4.SB. From this study LOSO concentrations of S.2xlO- 9M 
and 1.SxlO-lOM were derived for mitozantrone and CI941 respectively. 
Thus, increasing the post-exposure incubation period decreased the drug 
LOSO concentration. Figure 4.9 shows the cytotoxicity of mitozantrone 
after a one hour exposure and a further 11 or 17 day drug free 
incubation [with media change on day Sand S respectively]. The LOSO 
concentrations obtained using these protocols [shown in table 4.2] were 
inversely related to post-exposure incubation period. 
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Figure 4.7 Cytotoxicity of mitozantrone [.J and CI941 [D.J in HCF-7 
cells after a 24 hour exposure [AJ and a 24 hour exposure 
followed by a 96 hour drug-free incubation period [B]. 
A: Experimental details were a~ described in figure 4.2. 
cell numbers were 2.62 + O.5xIO Iwell. 
B: Experimental details were as described in figure 4.3. 
cell numbers were 2.25 + O.lxI05/well. 
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Figure 4.8 Cytotoxicity of mitozantrone f.} and CI941 fl:::.} in l1CF-7 
cells after a one hour exposure followed by a further 60 
hour drug-free incubation fA} and a further 6 day incubation 
fB} • 
A: Experimental details as figure 4.4. Final control cell numbers were 
1.38 + 0.14xlOS/well. B: 104 cells were seeded per well and cultured 
for 24 hgurs prior to drug exposure. Final control cell numbers were 3.2 
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Figure 4.9 Cytotoxicity of mitozantrone in HCF-7 cells after a one hour 
exposure followed by a further 11 or 17 days incubation 
[ .] - 104 cells were seeded per well and cultured for 24 hours prior to 
drug exposure. Cells were incubated for 11 days after drug exposure. 
The medium was changed on the fifth day of this incubation. Final 
control cell numbers were 3.19 + 0.3x104/we11. 
[ D) - Procedure as above. Cells were incubated for 17 days after drug 
exposure. The medium was changed every five zays after drug exposure. 
Final control cell numbers were 6.27 + 1.4x10 Iwell. 
Values are mean + sd of three determinations. 
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Table 4.2 Effect of post-exposure incubation time 
on the LD50 concentration of mitozantrone in 
MCF-7 cells. 








1.3 x 10-7 
5.2 x 10-9 
4.0 x 10-11 
1.2 x 10-11 
Exposure time was one hour. Cells/incubate were 
105 [60 hrs], 104 [144 hrs], 104 [lldays], and 104 [17 days]. 
Data derived from figures 4.8 and 4.9. 
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Figure 4.10 shows the cytotoxicity of the AQ's in MCF-7 following a 24 
hour exposure and immediate determination of the surviving cells. The 
LDSO values derived from this figure were 1AQ [13.6xI0- 6M], 1,4AQ 
[12.4x10- 6M], l,SAQ [10.0x10- 6M] ansd 1,8AQ [6.Sx10- 6M]. The effect of 
further incubating for 96 hours cells exposed to AQ's for 24 hours is 
shown in figure 4.11. The LDSOs derived from this figure were lAQ 
[8.Sx10- 9M], l,4AQ [S.3x10- 6M], l,SAQ.[2.6x10- 6M] and 1,8AQ [1.3x10- 6M]. 
The exposure time was reduced to one hour and the cytotoxicity 
determined after 6 days further drug free incubation. Figure 4.12 shows 
the cytotoxicity profile obtained from this study. The LDSO 
concentrations derived from this data were 1,4AQ [1.2x10- 6M], l,SAQ 
[12.3x10- 6M] and 1,8AQ [0.Sx10- 6M] (lAQ not determined). 
Figure 4.13 shows the cytotoxicity of 1AQ after a one hour exposure 
followed by 60 or 11 days post-exposure drug-free growth. The LDSO 
concentrations derived from this figure are shown in table 4.3. 
Table 4.4 summarises the LDSO values obtained for the AQ's with the 
different protocols used. 
4.3.1.5 The effect of oxygen scavengers on the survival of 
MCF-7 cells exposed to IAQ, 1,5AQ and 1,8AQ. 
Studies were carried out as described in section 4.2.1. The results 
obtained are shown in figure 4.14. The AQ concentrations [LDSO values] 
used were derived from figure 4.12 [l,SAQ and l,8AQ] and figure 4.13 
[lAQ]. 1,4AQ was not used as this drug was found not to redox cycle in 
MCF-7 cells [see section 2.4.3]. Catalase [6000 units ml-
1
] restored 
cell survival to 100% for 1AQ (4uM) and 1,8AQ (O.SuM) which alone 
produced a survival rate of 37.8 + 4.6% and 39.8 + 3.0% respectively. 
However, no significant increase in survival was seen with the I,SAQ. 
SOD [600ug m1- 1 ] restored cell survival from 39.8 + 3.0 to 83.3 + 2.9% 
for 1,8AQ, from 28.2 + 3.8 to 36.7 + 1.2% for 1,SAQ and had no effect on 
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Figure 4.10 Cytotoxicity of alkylaminoanthraquinones in HCF-7 cells 
after a 24 hour exposure 
A: [ ~] 1AQ and [0] 1, 4AQ: B : [ 0] 1, SAQ and [.] 1 , 8AQ 
5 x 10 cells were seeded per well and cultured for 24 hours P4ior to 
drug exposure. Final control cell numbers were 3.81 + 0.31x10 . 
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Figure 4.11 Cytotoxicity of alkylaminoanthraquinones in HCF-7 
cells after a 24 hour exposure followed by a further 96 
hour incubation. 
Curves are: [A] 1AQ, [0] 1, 4AQ, [0] 1, SAQ and [.] 1, 8AQ. 
Experimental details were as described in figure 4.3. 
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Figure 4.12 Cytotoxicity of alkylaminoanthraquinones in HCF-7 cells 
after a one hour exposure followed by a further 6 day drug-
free incubation. 
Curves are: [0] 1 , 4AQ, [0] l, SAQ and [.] l, 8AQ. 
Experimental details were as described in figure 4.8. 
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Figure 4.13 Cytotoxicity of lAQ in HCF-7 cells after a one hour 
exposure followed by a further 60 hour 
[D. J or 17 day [.J incubation 
Experimental details as figure 4.4 and figure 4.9. Values are mean + 
sd of three determinations. 
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Table 4.3 Effect of post-exposure incubation time 
on the LD50 concentration of lAQ in MCF-7 cells. 








Exposure time was one hour. Cells/incubate were 
105 [60 hrs] and 104 [lldays]. 










A B C 0 
Figure 4.14 Effect of oxygen radical scavengers on cytotoxicity of I AQ 
[~J, 1,5AQ [OJ and 1,8AQ [f2jJ in HCF-7 cells . 
A: Cells were incubated for one hour with IAQ (4uM) , I,SAQ (12.3uM ) 
and 1,8AQ (O.SuM) or AQ's plus B:catalase [6000 units], C: SOD [600ug] 
and D: DMSO [200mM]. 
Experimental details as figure 4 . 6 . 
Values are mean + sd of three determinations . 
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survival of cells exposed to LAQ. DMSO [200mM] . 1ncreased survival of 
cells exposed to lAQ from 37.8 + 4.6% to 53.2 + 5.0%, but produced no 
significant increase in survival for 1,5AQ and 1,8AQ. 
4.3.2 Uptake of quinone antitumour agents by MCF-7 cells 
Drug uptake was determined over a ninety minute period as described in 
section 4.2.2. Figure 3.11 shows that there was no significant decrease 
in cell survival over this period. 
4.3.2.1 Uptake of doxorubicin, mitozantrone and CI941 by 
MCF-7 cells 
Figure 4.15 shows uptake of doxorubicin (15uM) by MCF-7 cells [106ml -I] 
in serum supplemented growth medium. 
doxorubicin with cells [5.81 nmole/ 
of incubation. Following this time 
There was .a rapid association of 
106 cells] within the first minute 
a further 0.87 nmole/l06 cells was 
taken up during the ninety minute incubation period. 
Figure 4.16 shows the uptake of mitozantrone and CI941 (lsuM) by MCF-7 
cells. It can be seen that there was a rapid association of drug with 
the cells within the first minute of incubation with mitozantrone (5.07 
+ 1.23 nmole) or CI941 (3.96 + 0.56 nmole) [per 106cells]. Following 
this cellular uptake was similar for mitozantrone and CI941 The 
amount of drug taken up by the cells after 90 minutes was 6.17 + 0.5 
nmole for mitozantrone and 7.16 + 0.63 nmole for CI941 [per 106cells]. 
Mitozantrone uptake by MCF-7 cells was also determined using a 
polarographic method [section 4.2.2.2]. Figure 4.17 compares the uptake 
profile obtained for HPLC and polarQgraphic methods. The two systems 
differed in that uptake was determined in serum supplemented growth 
medium [15uM drug] prior to HPLC analysis and in phosphate buffered 
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Figure 4.15 Uptake of doxorubicin by HCF-l cells. 
Doxorubicin [1SuM] was incubated with 106 cells ml-
l
. 
Values are mean + sd of three determinations. 
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Figure 4.16 Uptake of mitozantrone I.J and CI941 I L::::. ] by I1CF-7 cells. 
Drugs [15uM] were incubated with 106cells ml- l . 
Values are mean + sd of three determinations. 
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Figure 4.17 Uptake of mitozantrone by HCF-7 cells as determined by HPLC 
[Oland polarography [.1· 
Drug concentration was 10uM (in PBS) fo~ po1arogra~hy and 15uM (in RPMI· 
1640, serum supplemented) for HPLC. 10 cells ml- were used for both 
protocols. Values are mean + sd of three determinations. 
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saline [lOuM drug] prior to polarographic analysis. The polarographic 
method showed a slightly higher level of uptake than that determined by 
HPLC, this may reflect the different conditions used [especially the 
presence of serum]. The polarographic method however, confirmed that no 
further uptake was occurring after 60 minutes. 
Figure 4.18 shows the viability of the MCF-7 cells [determined by trypan 
blue exclusion] over 330 minutes in the presence or absence of 
mitozantrone. This shows that there was no difference between control 
and drug treated cell survival over this time period. Cell viabilty was 
still 70% after 330 minutes compared to 90% immediately after 
harvesting. This indicated that during uptake experiments, cell death 
and resulting increase in cell permeability was not likely to have 
contributed to the uptake observed. 
4.3.2.2 Uptake of alkylaminoanthraquinones by MCF-7 cells 
Figure 4.19 shows the uptake profiles of all four AQ's [lSuM] by MCF-7 
cells. Rapid association of drug with cells was observed within the 
first minute of incubation for each AQ (nmolej 106cells)- lAQ (5.51 + 
0.89), 1,4AQ (2.88 + 0.2), 1,SAQ (3.09)and 1,8AQ (3.29 + 0.96). Table 
4.4 shows the uptake of the AQ's by MCF-7 cells after a one hour 
exposure. Uptake by 1,8AQ was significantly higher than the other 
anthraquinones after one hour. However, there was no significant 
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Figure 4.18 Survival of HCF-7 cells in the presence r.J or absence 
[[]l of mitozantrone (lOuH). 
Cell concentration (in PBS) was l06ml-l. Values are mean + sd of three 
determinations. Survival was assessed using the trypan blue exclusion 
assay (appendix Al.9). 
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Figure 4.19 Uptake of alkylaminoanthraquinones by HCF-7 cells 
A: 1AQ [A], 1,4AQ [0], B: 1,5AQ [0] and 1,8AQ [e]· Experimental 
details as figure 4.15. Values represent mean + sd of three 
determinations. 
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Uptake nmolel 106cells 
after 60 minutes 
5.48 + 0.62 
3.92 + 0.5 
5.1 
7.53 + 0.7 
Drug concentration was lSuM. Values are mean + sd of 





Cytotoxicity of quinone antitumour agents in HCF-7 human 
breast cancer cells 
The cytotoxicity of the quinone antitumour agents was determined in MCF-
7 cells for several reasons:-
1. To determine whether the MCF-7 cell line was a suitable model system 
for investigating the mechanism of action of these agents. 
2. To enable the cytotoxic potency of quinone based agents to be 
related to their propensity to redox cycle and produce DNA strand 
breakage in MCF-7 cells. 
As described in section 4.2.1 several different protocols were used to 
assess cytotoxicity. This en~bled a comparison of short and long term 
cytotoxic effects. Furthermore, this enabled the relationship between 
exposure time and cytotoxicity to be determined. 
LD50 [also known as LC50, EC50, ED50] concentration is the concentration 
of drug which is required to kill 50% of a cell population. This value 
is useful when the cytotoxic potency of several drugs need to be 
compared. Table 4.5 summarises the LD50 concentrations observed when 
the cytotoxicity of doxorubicin in MCF-7 cells was evaluated using 
several different protocols. Doxorubicin was least cytotoxic when 
quiescent cells [fully confluent cells] were exposed for 24 hours 
[figure 4.2]. This is consistent with doxorubicin cytotoxicity being 
specific for proliferating cells. The effect of a one hour exposure to 
doxorubicin was determined because doxorubicin uptake by MCF-7 cells was 
shown to be maximal after 60 minutes [figure 4.15]. Furthermore, this 
exposure time may be preferable due to the finding that doxorubicin has 
a half life of 14 hours in RPM! cell culture medium due to hydrolytic 
degradation to inactive products such as doxorubicinone (Beijnen et al., 
1986). Table 4.5 shows that the LD50 concentration of doxorubicin was 
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Table 4.5 Comparison of the cytotoxicity of doxorubicin, 
mitozantrone and CI941 in MCF-7 cells. 
LDSQ concentration C\I1 Exposure time [hrs] + 
further drug-free 
growth period 
dox mitoz 0941 
24 O.28xI0-6 2.4xl0-6 0.8xl0-6 
24 + 96hrs O.2xI 0-6 1.62xl0-IO 4.6xl0-1O 
1 + 60hrs 5.6xI0-6 1.3xl0-7 1.6xl0-
8 
1+ 6days 3.0xI0-6 5.2xI 0-9 1.5xl0-
IO 
1 + 11days O.06xI0-6 4.0xI0-
II nd 
nd = not determined 
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inversely related to the post-exposure incubation period. It is not 
possible to directly compare the cytotoxicity potency of doxorubicin 
obtained in this study with that from other studies with MCF-7 cells 
[see table 4.6] and other cell lines [table 4.7]. This is due to the 
widely differing protocols used by other workers to determine 
cytotoxicity. In addition, MCF-7 cells from different laboratories have 
been shown to have a wide range of biological properties despite 
possessing the same karyotype, including a ten fold range of 
tumourogenicity, differences in the level of expression of oestrogen and 
progesterone receptors, differences in growth rate and differences in 
response to hormones (Osborne et a1., 1987). These parameters could 
infuence the response of these cells to cytotoxic agents. In the 
present study, cell kill by doxorubicin was also dependent on the cell 
growth period after drug exposure. This is due to a larger difference 
between the number of control cells and treated cells becoming evident 
reflecting an inhibition of the proliferative ability of the treated 
cells. The results of this study would suggest that use of a short or 
no post-exposure incubation period gives an underestimate of cytotoxic 
potential. 
The cytotoxicity of mitozantrone and CI941 in MCF-7 cells was determined 
in order to compare their cytotoxic potency with that of doxorubicin. 
Table 4.5 compares the LD50 concentrations obtained for all three 
compounds. The LD50 of mitozantrone and CI941 was inversely related to 
the post-exposure incubation period. This suggests that there is a time 
delay before mitozantrone and CI941 cell kill is expressed. The potency 
of these two agents was consistently greater than doxorubicin in a 
series of one hour exposures with increasing post-exposure incubation 
periods [see table 4.5]. These results are consistent with the finding 
that mitozantrone is more cytotoxic than doxorubicin in other tumour 
cell lines [Dalton et a1., 1988; Epstein et a1., 1988; Drewinko et 
a1., 1983; Cowan et a1., 1983; Mergenthaler et a1., 1987]. Graham et 
a1. (1989) found that the LD50 of CI941 in CCRF-CEM cells was 8.0xlO-
9
M, 
a result consistent with the potency of CI941 in MCF-7 cells. The LDSO 
obtained for studies on mitozantrone cytotoxicity in a variety of human 
tumour cells are shown in table 4.8. However, no studies have 
previously been reported in MCF-7 cells. The data in 
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Table 4.6 Cytotoxicity of doxorubicin in MCF-7 human breast 
cancer cells as determined in other studies 
Exposure time + 
further drug-free growth 
period 
24hrs + 10-12 days 





5.0 Dusre et al (1989) 
0.5 Doroshow (1986) 
0.005 Mimnaugh et al (1989) 
0.025 Batist et al (1986) 
0.017 Yusa et al (1988) 
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Ha ttori human 
breas t cancer 
Exposure time + 
further drug-free 
growth period 
1hr + 10days 
1day + 5days 
1hr + 21days 
1hr + 6days 
1hr + 10-14days 
1hr + 6 days 
1hr + 7-10days 













17.0 x 10-9 
Reference 
Dalton et al., 
(1988) 















table 4.H aemonstrates that mitozantrone is an effective antitumour 
agent in vitro, although for reasons previously stated it is not 
reasonable to directly compare the cytotoxic potency of mitozantrone 
observed in different cell lines. Table 4.5 shows that CI941 was 
consistently more cytotoxic than mitozantrone following a one hour 
exposure. 
The cytotoxicity of the alkylaminoanthraquinones in MCF-7 cells was 
determined in a similar manner to that for doxorubicin, mitozantrone and 
CI94l. The results are summarised in table 4.9. Partridge (1985) 
studied the cytotoxicity of these agents in human leukaemic cells [HeLa] 
following a 24 hour exposure and found the order of cytotoxic potency to 
be (LD50uM):- 1,4AQ(1.O) > 1,5AQ(3.0) > 1,8AQ(6.0) > lAQ(20.0). This 
order of potency is different to that found in the present study (see 
table 9). This is possibly due to differences between the levels of 
enzymes critical for AQ action in these cell lines, for example 
topoisomerases [see section 1.7.1] and/ or reductase enzymes [see 
section 1.8.1]. The AQ's are clearly less potent than mitozantrone and 
CI941 in the MCF-7 cell line [compare table 4.9 and table 4.5]. 
Drewinko et al. (1983) and Nishio and Uyeki (1983) also found that 1,4AQ 
was less cytotoxic than mitozantrone. In the present study, 1,4AQ, 
1,5AQ and 1,8AQ were found to be less cytotoxic than doxorubicin in the 
MCF-7 cell line. However, lAQ was the most cytotoxic AQ in the present 
study, being more cytotoxic than doxorubicin in several of the protocols 
used (compare table 4.5 and 4.9). 
The different cytotoxic potentials of these quinone anti tumour agents 
the MCF-7 cell line clearly points to them having different modes of 
action or different propensities to exert a similar mode of action. 
This is discussed in chapter 5 with relation to the ability of these 
agents to redox cycle, inhibit MCF-7 topoisomerase I and produce DNA 
strand breakage in the MCF-7 cell line. 
4.4.2 Uptake of quinone antitumour agents by HCF-7 cells 
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Table 4.9 Comparison of the cytotoxicity of alkylaminoanthraquinones in MCF-7 cells. 




24 + 96hrs 
1 + 60hrs 
1+ 6days 
1 + 11days 







LDSO concentration [Ml 
1,4AQ 1,SAQ 1,8AQ 
12.4xl0-6 10.0xl0-6 6.5xl0-6 
5.3xl0-6 2.6xlO-6 1.3xlO-6 
nd nd nd 
1.2xlO-6 12.3xl0-6 O.5xl0-6 
nd nd nd 
The cytotoxiciLY U.l. quinone antitumour agents in MCF-7 cells has been 
discussed. To investigate whether or not any differences in the 
cytotoxicity observed could be accounted for by differences in the 
amounts of drugs taken up by MCF-7 cells, a series of drug uptake 
studies were carried out. Table 4.10 shows that there was no 
significant difference in the amount of doxorubicin, CI941 and 
mitozantrone taken up by the MCF-7 cells. Uptake of all three of these 
compounds reached steady state after one hour [see section 4.3.2.1]. 
Moreover, drug uptake into MCF-7 cells was not related to cell death and 
concomitant loss of membrane integrity of MCF-7 cells during the uptake 
assay [see figure 3.11]. Similar to the present study other researchers 
found doxorubicin uptake to reach steady state between 15 and 60 minutes 
[Skovsgaard, 1978; Friche et al., 1987; Paneerselvam, 1987; Broggini 
et al., 1988; Kessel and Wilberding, 1985] and mitozantrone uptake 
reached steady state after 30 minutes (Burns et al., 1987; Nishio and 
Uyeki, 1983). Doxorubicin has been shown to diffuse into cells by 
passive diffusion in the unionised form [reviewed by Siegfried et al., 
1985]. However, it has also been suggested that the uptake of 
doxorubicin is by facilitated diffusion due to the high affinity of 
doxorubicin for intracellular binding sites driving the diffusion 
gradient (reviewed by Siegfried et al., 1985). This uptake is 
opposed by an energy requiring efflux mechanism in some cell lines 
(Skovsgaard, 1977 and 1978; Inaba and Johnson, 1978; Dano, 1973), a 
process that has been found to be enhanced in resistant cells [reviewed 
by Siegfried et al., 1985]. A corresponding increase in the expression 
of a 170,000 dalton plasma membrane protein, putatively involved in 
active efflux has also been found in resistant cells [reviewed by 
Siegfried et al., 1985; Beck, 1987]. It is not known whether such an 
efflux system is present in MCF-7 cells or whether if such a system 
exists it is capable of removing other quinone antitumour agents such as 
mitozantrone, CI941 and AQ's. 
In this study, similar drug uptake profiles were observed for the 
alkylaminoanthraquinones, doxorubicin, CI941 and mitozantrone [see table 
4.10]. The uptake of the AQ's also reached steady state after one hour, 
the slight differences in cell uptake observed not being sufficient to 
explain the differences in cytotoxicity of these agents. 
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Table 4.10 Comparison of uptake of quinone antitumour 
drugs by MCF-7 cells. 
Compound Uptake nmolel 106cells 
o minutes 60 minutes 
doxorubicin 5.81* 7.08 + 1.02 
mitozantrone 5.07 + 1.23 6.63 + 1.5 
CI941 3.96 + 0.56 6.47 + 1.26 
1AQ 5.51 + 0.89 5.48 + 0.62 
1,4AQ 2.88 + 0.2 3.92 + 0.5 
1,SAQ 3.09* 5.1 * 
1,8AQ 3.29 + 0.96 7.53 + 0.7 
Drug concentration was 15uM. Values are mean + sd of 
at least three determinations [except *(2)]. 
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A phenomenon observed for all the quinone antitumour agents was a rapid 
association of drug with the cells within the first seconds of the 
incubation. This effect was observable visually, as the cell pellet was 
distinctly coloured by the drugs. This effect is likely to be due to a 
rapid binding of drug to the cell membrane. Doxorubicin [reviewed by 
Gianni et a1., 1983] and mitozantrone [Taylor et a1., 1981] have been 
shown to bind to membrane components with high affinity [see section 
1.16 and 1.17]. After this rapid association, only a small amount of 
further drug uptake was observed [see figures 4.15,4.16 and 4.19]. This 
binding effect has also been shown for other cell lines with both 
doxorubicin [Inaba and Johnson 1978; Skovsgaard 1978; Paneerselvam 
1987] and mitozantrone [Nishio and Uyeki, 1983; White and Durr, 1985; 
Wallace, 1987]. However, many workers have assumed that drug uptake is 
zero at time 0 and consequently have missed this component of drug 
interaction with the cell. Rapid association of drug with the cell 
membrane is probably followed by diffusion of drug into the cell due to 
a gradient facilitated by the affinity of quinone anti tumour agents for 
cellular components such as DNA. Indeed, despite this apparent 
extracellular membrane binding, doxorubicin is found to rapidly relocate 
mainly in the nucleus of the cell (reviewed by Gianni et al., 1983). 
4.4.3 The effect of oxygen free radical scavengers on the 
cytotoxicity of doxorubicin, 1AQ, 1,5AQ and 1,BAQ. 
The results in chapter 2 showed that doxorubicin, lAQ, l,5AQ and l,8AQ 
are capable of redox cycling in MCF-7 cells. Furthermore, these agents 
all formed highly reactive, cell damaging hydroxyl radicals in NADPH-
fortified MCF-7 S9 fraction as determined by spin trapping techniques 
[see figure 2.23]. In addition,-hydroxyl radicals were detected in an 
incubate of doxorubicin with intact viable MCF-7 cells [see figure 2.9]. 
Mitozantrone, CI941 and l,4AQ were not included in these studies as 
these compounds did not redox cycle or produce hydroxyl radicals in the 
i 2 4 2 d 2 4 3] To determine whether the above S9 system [see sect on . . an .. . 
formation of hydroxyl radicals by these redox cycling agents was 
related to their cytotoxic action in MCF-7 cells, the effect of oxygen 
free radical scavengers on the cytotoxicity of these agents was 
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investigated (as described in section 4.2.1). DMSO and catalase 
produced a slight increase in the survival of cells treated with an LD50 
concentration of doxorubicin [3.0uM] (figure 4.5). This is probably due 
to DMSO scavenging hydroxyl radicals and catalase preventing the 
formation of hydroxyl radicals by scavenging hydrogen peroxide. This 
would inhibit hydroxyl radical formation by preventing hydrogen peroxide 
from entering the iron catalysed Haber-Weiss reaction [equations 1,2 and 
3]. The oxygen radical scavengers N-acetyl cysteine and superoxide 
dismutase did not influence MCF-7 survival after treatment with 
doxorubicin. When the concentration of oxygen free radical scavengers 
were increased, catalase, superoxide dismutase and catalase plus 
superoxide dismutase increased MCF-7 cell survival to a small extent 
[figure 4.6]. However, a higher concentration of DMSO had no 
significant effect on cell survival. SOD scavenging activity can be 
rationalised by its involvement in inhibiting superoxide anion reduction 







The inability of the oxygen free radical scavengers to protect MCF-7 
cells totally against doxorubicin cytotoxicity suggests that doxorubicin 
mediated oxygen radical generation is occurring at a site inaccessible 
to these scavengers. It is also possible that doxorubicin mediated 
oxygen free radical formation is not entirely responsible for its 
cytotoxic action in MCF-7 cells. These results are consistent with the 
inability of the large molecular weight enzymes SOD and catalase to 
permeate the cell membrane. This is supported by the work of Cervantes 
et a1. (1988), who found that only high concentrations of hydroxyl 
radical scavengers which were capable of permeating the cell membrane 
could protect human ovarian cancer cells against doxorubicin 
cytotoxicity. In this study, DMSO, may not be reaching the site of 
hydroxyl radical generation at a sufficient concentration to provide 
sufficient protection whilst at higher concentrations [200mM] this 
scavenger could be damaging other cellular properties such as membrane 
permeability. Other workers have shown that SOD, catalase or DMSO 
produced a more profound inhibition of doxorubicin cytotoxicity in MCF-7 
cells (Doroshow, 1986a) and Ehrlich ascites tumour cells (Doroshow, 
1986b). The denatured enzymes were found to have no significant effect. 
SOD and catalase increased the survival rate of MCF-7 cells treated with 
l,8AQ (see figure 4.14). Similarly, catalase increased MCF-7 cell 
survival in cells treated with lAQ (figure 4.14). However, as with 
doxorubicin, DMSO [200mM] failed to protect against the cytotoxicity of 
lAQ or l,8AQ. SOD, catalase and DMSO provided no protection for MCF-7 
cells against the cytotoxicity of l,5AQ. The protection against lAQ and 
l,8AQ cytotoxicity provided by catalase, a macromolecule that presumably 
cannot penetrate the cell membrane, would suggest that this enzyme is 
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scavenging hydrogen peroxide (see equations 2 and 3) which is either 
being produced externally to the cell or is diffusing out of the cell. 
Similarly, SOD would appear to be scavenging extracellularly produced 
superoxide anions, since this charged species is too polar to be able to 
cross the cell membrane. The failure of SOD to protect MCF-7 cells 
against LAQ cytotoxcity could be explained by an absence of 
extracellular superoxide anion formation by this agent. The lack of 
protection of these oxygen radical scavenging enzymes against 1,SAQ 
cytotoxicity could indicate that oxygen free radical formation mediated 
by this drug could be occurring at intracellular sites inaccessible to 
these enzymes. 
These results could have important implications in rationalising the 
site(s) of enzymic activation of AQ's to produce reactive oxygen 
species by redox cycling and the site(s) where these reactive species 







5.1 Redox cycling by quinone antitumour agents in MCF-7 
cells 
This study has investigated the ability of quinone anti tumour agents to 
undergo flavin reductase mediated redox cycling in MCF-7 human breast 
cancer cells. Doxorubicin, an anthracyc1ine antitumour agent, was used 
as a reference in these studies since this agent has previously been 
shown to redox cycle in human (Basra et al., 1985) and animal, liver and 
heart tissues (reviewed by Gianni et al., 1983). In the present study 
doxorubicin was found to redox cycle in the MCF-7 cell line with 
resultant formation of hydroxyl radicals [see section 2.4.1]. Figure 
5.1 shows a schematic diagram of flavin reductase mediated doxorubicin 
redox cycling. Redox cycling by doxorubicin, correlated with the 
formation of DNA strand breaks [section 3.4.4.1] and the cytotoxicity 
[4.4.1] of doxorubicin in MCF-7 cells. A role for hydroxyl radicals in 
doxorubicin mediated MCF-7 cell DNA strand breakage was supported by the 
production of plasmid DNA strand breakage by doxorubicin in the presence 
of purified xanthine oxidase and cytochrome P450 reductase [section 
3.4.1.1]. Further evidence for doxorubicin free radical mediated cell 
damage in MCF-7 cells was provided by the finding that the reactive 
oxygen scavengers superoxide dismutase, catalase and DMSO partially 
protected against doxorubicin mediated MCF-7 cell kill [see section 
4.4.3]. The lack of complete protection was likely to be due to the 
inaccessibility these scavengers to some intracellular sites of reactive 
f . [d· d . t· 4 4 3] The results obtained oxygen ormat~on as ~scusse ~n sec ~on .. . 
for doxorubicin indicate that the MCF-7 cell line is suitable for the 
investigation of metabolic activation of quinone anti tumour agents and 
its cellular consequences. 
Mitozantrone and CI941 were developed with a view to producing 
antitumour agents with reduced cardiotoxicity compared to doxorubicin 




















cycling in heart tissue [see section 1 16 5] I h . . . n t e present study 
mitozantrone and CI941 were found not to be metabolically activated in 
MCF-7 cells. In addition, CI941 did not produce plasmid DNA strand 
breakage in the presence of purified xanthine oxidase and NADPH 
cytochrome P450 reductase [see section 3.4.1.2]. However, in contrast 
mitozantrone did produce plasmid DNA strand breakage in the presence of 
cytochrome P450 reductase [section 3.4.1.2] showing that this compound 
can be activated by this enzyme when it is removed from its normal 
cellular membrane environment. Despite the absence of redox cycling in 
MCF-7 cells, mitozantrone and C!94l, at a lower concentration than 
doxorubicin, both produced an equivalent amount of DNA strand breakage 
[3.4.4.1]. Furthermore, mitozantrone and CI941 were considerably more 
cytotoxic than doxorubicin in MCF-7 cells [see table 4.5]. 
This study also investigated redox cycling in MCF-7 cells by a series of 
alkylaminoanthraquinones based on mitozantrone (figure 1.35). lAQ, 
1,5AQ and 1,8AQ were found to redox cycle in MCF-7 cells with resultant 
formation of hydroxyl radicals [section 2.4.3]. These agents were also 
able to mediate strand breakage of plasmid DNA in the presence of 
purified NADPH cytochrome P450 reductase [3.4.1.3]. Hydroxyl radical 
formation in MCF-7 cell S9 fraction and plasmid DNA strand breakage in 
situ correlated with the production of frank DNA strand breakage in MCF-
7 cells (at 100uM) [section 3.4.4.2]. It is therefore likely that the 
cytotoxicity [section 4.4.1] of these compounds in MCF-7 cells is 
mediated by redox cycling mediated hydroxyl radical formation and 
resultant DNA strand breakage. As would be expected, decreasing the 
drug concentration and hence the amount of hydroxyl radicals formed, 
resulted in less DNA strand breakage in MCF-7 cells [ section 3.4.4.2]. 
A role for redox cycling in the mechanism of action of these agents was 
further supported by the protective effect of superoxide dismutase and 
catalase against the cytotoxicity of lAQ and 1,8AQ in MCF-7 cells [see 
section 4.4.3]. However, these oxygen radical scavengers did not 
protect MCF-7 cells against the cytotoxic effect of 1,5AQ, suggesting 
that the site of free radical formation by this compound was 
inaccessible to these enzymes [as discussed in section 4.4.3]. Despite 
being redox active and producing hydroxyl radicals, these compounds (at 
LD50 concentrations) produced an equal amount of DNA strand breakage to 
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mitozantrone and CI94l. Furthermore, these compounds are considerably 
less cytotoxic than mitozantrone and CI94l in MCF-7 cells [compare 
tables 4.5 and 4.9]. 
In contrast to LAQ, l,5AQ and l,8AQ, the l,4AQ derivative was found not 
to redox cycle in MCF-7 cells [2.4.3]. In addition, this compound 
(lOOuM) produced less cellular DNA strand breakage in MCF-7 cells 
[section 3.4.4.2]. Furthermore, this compound did not mediate strand 
breakage of plasmid DNA in the presence of purified reductases [section 
3.4.1.3]. However, despite the absence of redox cycling, this compound 
(at an LD50 concentration) produced an equal amount of DNA strand 
breakage to the other alkylaminoanthraquinones and the cytotoxicity of 
this compound was similar to that of the l,5AQ and l,8AQ [see table 
4.9]. Differences in cellular uptake could not explain the different 
levels of strand breakage and cytotoxicity caused by the agents in the 
present study (see section 4.4.2). 
As described in section 2.4 the reductase mediated redox cycling 
observed for doxorubicin, lAQ, l,5AQ and l,8AQ is likely to result in 
the formation of hydroxyl radicals via the iron catalysed Haber-Weiss 
reaction [see section 2.4.1]. However, in order to relate this redox 
activity to the DNA strand breakage observed in vitro for these 
compounds several points need to be considered:-
(1) The hydroxyl radical is a highly reactive species which can only 
diffuse 5-10 molecular diameters before it reacts [Pryor, 1988]. 
Therefore, in order to produce DNA damage there is a requirement for it 
to be produced in close proximity to the target site. In the case of 
MCF-7 cell DNA strand breakage the target is presumably the nucleosome. 
Nuclear activation of quinones has been shown to be feasible in some 
cell types, due to the presence of cytochrome P450 reductase in the 
nuclear envelope [Romano, 1983; Bachur, 1979]. The less reactive 
products of quinone redox cycling, namely superoxide anions and hydrogen 
ff f h th hydroxyl ra
dicals and could therefore peroxide, can di use urt er an 
participate in the iron-catalysed Haber-Weiss reaction mediated 
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formation of hydroxyl radicals in close proximity to the DNA. DNA 
strand breakage could therefore occur at sites d;stant f 
L rom the original 
site of reductase mediated activation of the qu;none. 
L Furthermore, the 
products of membrane lipid peroxidation have been shown to mediate DNA 
strand breakage [Hruszkiewycz, 1988; reviewed by Vaca, 1988]. In 
support of this doxorubicin has been shown to stimulate lipid 
peroxidation in animal tissues (reviewed by Powis, 1989). 
Spin trapping studies in intact viable MCF-7 cells revealed that 
doxorubicin-mediated hydroxyl radical formation appeared to be occuring 
extracellularly (section 2.3.1.6) due to the finding that the DMPO-OH 
adduct observed persisted upon removal of cells from the incubate. This 
suggests that the DMPO-OH adduct is diffusing out of the cell or that 
reactive oxygen species are being formed extracellularly since 
superoxide anions and hydroxyl radicals are unable to traverse the cell 
membrane due to their charge and/or reactivity. However, it is also 
possible that the doxorubicin semiquinone free radical may effectively 
be transferred across the cell membrane by a process involving electron 
transfer between doxorubicin molecules bound within the membrane [see 
figure 5.2]. Alternatively, the doxorubicin semiquinone free radical or 
hydrogen peroxide may be able to cross the cell membrane (figure 5.2). 
This is supported by the work of Ramakrishna et al. (1988a and 1988b) 
who showed that the radical anions of 5-nitrofurans, 2 and 5-
nitroimidazoles and the benzosemiquinone of 1,4-benzoquinone were 
formed intracellularly but could only be be detected extracellularly in 
rat hepatocytes. A further possibility for the presence of 
extracellular DMPO-OH is that the doxorubicin semiquinone free radical 
may be produced extracellularly via comproportionation (see figure 5.2 
and section 1.8.2). However, this supposes that a sufficient amount of 
the fully reduced doxorubicin metabolite is formed and can diffuse into 
the extracellular milieu (see section 1.8.2). 
The occurrence of extracellular hydroxyl radical spin adduct (DMPO-OH) 
by the mechanisms outlined above is further indicative that the free 
radicals produced intrace11ular1y by flavin reductase mediated 
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Furthermore, the lack of full protection by oxygen free radical 
scavengers against doxorubicin mediated MCF-7 cell kill, is further 
supportive that flavin reductase mediated doxorubicin red 1· ox cyc lng and 
resultant cell damage is occurring at intracellular sl'tes [ . see sectlon 
4.4.3]. 
(2) The second consideration is whether iron is available in vivo to 
catalyse the Haber-Weiss reaction as free iron is virtually absent in 
biological systems. Within the cell iron is stored in the protein 
ferritin which consists of a protein shell (apoferritin) enclosing iron 
in the form of a hydrated iron(III)oxide-phosphate complex. The protein 
shell is made up of 24 subunits and has pores that allow access to the 
interior (reviewed by Halliwell and Gutteridge, 1984). There is also a 
small pool of non-protein bound iron which is found attached to 
chelating agents such as ATP, GTP and citrate which could be available 
for the Haber-Weiss reaction since these have been shown to react with 
hydrogen peroxide in vitro [Floyd, 1983; Vile et 81. 1987]. 
Furthermore, some free iron is likely to be found bound to DNA phosphate 
groups as these have high affinity for iron. Recent evidence has 
indicated that doxorubicin can release iron from cellular storage depots 
including ferritin (Demant, 1984; Thomas and Aust, 1986) and non-
ferritin bound microsomal iron pools (Minotti, 1989). This reaction 
proceeds via reduction of ferritin bound iron(III) to iron(rr) mediated 
by the semiquinone free radical or superoxide anions which enter the 
pores of apotransferrin. More recent evidence has suggested that 
quinones with one electron reduction potentials more negative than that 
of ferritin [-O.24V) can release ferritin bound iron (Monteiro et al., 
1989). Therefore, it is possible that the redox cycling 
alkylaminoanthraquinones of the present study would be able to release 
ferritin bound iron (see table 2.3 for reduction potentials). Thus it 
seems likely that iron is available in vivo to catalyse hydroxyl radical 
formation via the Haber-Weiss reaction during quinone antitumour agent 
redox cycling [see section 1.8.2]. Furthermore, some tumour types are 
rich in deposits of iron, including some human breast tumours and tumour 
nodules in Hodgkins disease (reviewed by Halliwell and Gutteridge, 
1985). This may have clinical significance in the chemotherapeutic 
effect of redox cycling agents. The iron binding properties of quinone 
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antitumour agents may be important in determining cellular iron 
availability. In a further part of this study, doxorubicin-ferrous iron 
(1:2) and mitozantrone-ferrous iron (1:2) were found to mediate 
oxidative damage of plasmid DNA in the presence of reduced glutathione. 
This is presumably due to the high affinity these compounds have to bind 
iron (reviewed by Garnier-Suillerot, 1988). However, AQ-iron mixtures 
(1:2) did not mediate DNA damage in this system. This indicated that 
these compounds do not form iron complexes. Since these compounds to 
not have aromatic hydroxyl groups, this indicates the importance of 
these groups in iron-binding by mitozantrone and doxorubicin. This was 
confirmed by the finding that a series of anthrapyrazole anti tumour 
agents, including CI94l, were found to require a 10-OH group in order to 
mediate strand scission of plasmid DNA in the presence of ferric iron 
and glutathione. Iron binding by doxorubicin and mitozantrone could be 
important in the mechanism of MCF-7 cell kill in several ways:-
(a) Plasmid DNA strand breakage by quinone-iron complexes is likely to 
be mediated via formation of reactive oxygen species, including hydroxyl 
radicals, by glutathione mediated redox cycling of drug-bound iron [see 
section 3.4.2]. Therefore, this process could possibly be involved in 
the formation of cellular DNA strand breakage. Furthermore, this redox 
cycling mechanism is independent of the ability of the quinone to 
undergo flavin reductase mediated redox cycling. 
(b) Binding of adventitious cellular iron by compounds such as 
doxorubicin, with a high propensity to undergo flavin reductase mediated 
redox cycling, could provide iron for the Haber-Weiss reaction. In 
addition, the ketoaldehyde group ,of doxorubicin has been proposed to be 
able to reduce bound Fe(III) to Fe(II) hence propagating iron reduction 
independently of superoxide anions or glutathione (Gianni et al., 1988). 
These two possibilities are supported by the protective effect of the 
iron chelating agent ICRF-187 against doxorubicin-induced cardiotoxicity 
in cancer patients (reviewed by Myers et al., 1986). 
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5.2 The role of DNA binding in plasmid DNA strand breakage 
As described in section 5.1, doxorubicin, lAQ, l,5AQ and l,8AQ produced 
strand breakage of plasmid DNA in the presence of purified cytochrome 
P450 reductase. The mechanism of strand breakage is likely to involve 
enzyme mediated reductive activation of drug in a redox cycle process 
with resultant formation of hydroxyl radicals [see section 3.4.1]. The 
possible mechanisms of hydroxyl radical mediated strand scission have 
been described in section 3.4.1. However, it is difficult to ascertain 
whether drug-DNA binding is a prerequisite for strand breakage. 
Previous studies have shown that doxorubicin does not need to 
intercalate into DNA in order to mediate strand breakage in the presence 
of cytochrome P450 reductase (Berlin and Haseltine, 1981). Furthermore, 
studies have indicated that flavin reductases metabolically activate 
doxorubicin to a lesser extent when it is intercalated (Berlin and 
Haseltine, 1981; Ka1yanaraman et a1., 1980; Peters et al., 1986). In 
contrast, it has been shown that daunomycin can be reduced when 
intercalated (Rouscil1es et a1., 1989). However, it is likely that at 
the high drug concentrations (50-100uM) used in the present study that 
drug surface binding to DNA will occur since intercalation sites will be 
saturated (section 1.16.1). Surface-bound drug may be a better 
substrate for reductases than free or intercalated drug. The enzymic 
reduction of bound drug could therefore lead to site specific formation 
of reactive oxygen species or drug a1ky1ating species (Sinha and 
Gregory, 1981; Sinha, 1980; Wallace and Johnson, 1987) proximal to the 
DNA duplex [see section 3.4.1]. 
Similarly, the role of DNA binding in the mediation of plasmid DNA 
strand breakage by quinone-iron complexes in the presence of glutathione 
has not been fully elucidated. Doxorubicin-iron has been shown to form 
a ternary complex with DNA but it is not clear whether the iron in this 
complex can undergo glutathione mediated redox cycling [reviewed by 
Garnier-Sui11erot, 1988]. It has been shown that doxorubicin-iron 
complex dissociates upon intercalation (Bera1do et a1., 1985). 
However, as discussed above, surface bound drug-iron complex may 
participate in glutathione mediated redox cycling resulting in formation 
of hydroxyl radicals and consequently site specific DNA strand breakage 
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[see section 1.9.2.1]. 
5.3 The mechanism of cellular DNA strand breakage by quinone 
anti tumour agents 
The preponderance of evidence in this study shows that mitozantrone 
CI941 and 1,4AQ do not exert their MCF-7 DNA strand breakage and 
, 
cytotoxicity via reductase mediated redox cycling. This implies the 
presence of an alternative mechanism of action. This study investigated 
the ability of quinone antitumour agents to inhibit topoisomerase 
activity, identified as topoisomerase I (see section 1.7.3), in an MCF-7 
cell nuclear fraction. Doxorubicin (Tewey et al., 1984) and 
mitozantrone (Tewey et al., 1984; Crespi et al., 1986) have been 
previously shown to be inhibitors of mammalian topoisomerase II (see 
section 1.7.2) with concomitant formation of topoisomerase II-DNA 
cleavable complexes which on treatment with protein denaturants result 
in double and single strand break formation. In the present study 
doxorubicin and all the AQ's were found to form MCF-7 topoisomerase 1-
DNA cleavable complexes which formed single strand breaks on treatment 
with sodium dodecyl sulphate (see section 3.4.3). Mitozantrone and 
CI941 were more potent than the above compounds and totally inhibited 
topoisomerase activity without forming such cleavable complexes. This 
was also seen at high doxorubicin concentrations [photograph 3.6). This 
effect can be attributed to a profound disruption of the torsion of the 
topoisomerase I plasmid DNA substrate resulting in an inability of the 
enzyme to bind to its substrate at the drug concentration used [section 
3.4.3.1]. 
The significance of topoisomerase I cleavable complex in vivo is not 
clear. The strand breaks hidden by these complexes may not be critical 
in cell kill per se. It is likely that cellular processing of such 
complexes is required to convert them to a lethal event (see section 
3.4.3.2). The inverse relationship between the cellular growth period 
after drug exposure and the LD50 concentration of mitozantrone and CI941 
[see table 4.5] indicates the presence of a delay period prior to DNA 
strand breakage by mitozantrone and CI941 becoming lethal (see section 
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4.4.1). CeiiuiaL uroccssing could include 
r events such as DNA 
replication, DNA transcription and RNA and protein synthesis (reviewed 
by Bodley and Liu, 1988) [see section 1.7]. Furthermore to . , p01somerases 
have been implicated in regulation of cellular gene and oncogene 
expression and topoisomerase I and II inhibitors have been shown to 
influence these processes [see section 1.7]. In addition, mitozantrone 
and CI941 have been shown to be potent inhibitors of DNA and RNA 
synthesis (Nishio and Uyeki, 1983; Showalter et al., 1986). 
Topoisomerase I has been implicated in all these processes hence is 
intimately involved in cellular proliferation and the maintenance of the 
transformed phenotype of tumour cells (reviewed by Bishop, 1987). 
Consequently, topoisomerase cleavable complex formation by antitumour 
drugs is likely to result in a disruption of the cellular processes 
required for tumour cell proliferation. It has been shown that topo-
isomerase I and II cleavable complexes are formed reversibly and do not 
persist after removal of drug (Hsiang and Liu, 1989; Pommier et a1. I 
1984). However, agents such as mitozantrone and CI941 which are high 
affinity DNA binders may allow persistance of such complexes, long 
enough to allow cellular processing to a lethal event. This correlates 
with the more potent effect of mitozantrone and CI941 on MCF-7 topo-
isomerase I in comparison to the other agents in this study. Further-
more, this is supported by the increased cytotoxic potential of mitoz-
antrone and CI941 despite producing a similar level of DNA strand 
breakage (at LDSO concentrations) as the other less cytotoxic quinones 
of this study. The increased cytotoxic potential of mitozantrone and 
CI941 may be related to the MCF-7 cellular DNA lesions (eg topo-
isomerase-DNA cleavable complexes) these agents produce being more 
difficult to repair than that caused by redox cycling agents (see 
section 1.9.2.1). Therefore, these lesions would be likely to persist 
in the genome. This would be aided by the strong DNA binding affinity 
of mitozantrone and CI941 which results in their persistance in the 
nucleus even after removal of drug from the extracelular milieu (see 
table 3.3). Furthermore, potent inhibition of DNA synthesis by 
mitozantrone and CI941 (Nishio and Uyeki, 1983; Showalter et al., 1986) 
may result in inhibition of cellular repair processes when they persist 
in the nucleus. Collins and Johnson (1984) showed that DNA single 
strand breaks caused by clastogenic agents do not reseal in the presence 
of inhibitors of DNA synthesis. This is supported by the finding 
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doxorubicin and mitozantrone induced DNA strand breaks . lncrease and 
persist after removal of drug reg. Locher and Meyn, 1983; Deffie et 
a1., 1988; Broggini et a1., 1988]. 
1,4AQ does not redox cycle in MCF-7 cells therefore is likely to express 
MCF-7 DNA strand breakage and cytotoxicity via another mechanism. This 
could involve inhibition of topoisomerase I [see section 3.4.3]. 
However, this compound was not as cytotoxic as mitozantrone and CI94l in 
MCF-7 cells. This may be explained by 1,4AQ being a less potent 
inhibitor of MCF-7 topoisomerase I and having a lower binding affinity 
for DNA than mitozantrone and CI941 [table 3.3]. Formation of 
topoisomerase I-DNA cleavable complexes may contribute to the MCF-7 DNA 
strand breakage observed for doxorubicin, lAQ, 1,SAQ and 1,8AQ. 
However, the strand breakage produced by doxorubicin, 1AQ, 1,SAQ and 
1,8AQ is likely to be mainly due to reductase mediated redox cycling 
with resultant formation of hydroxyl radicals [see section 2.4.1 and 
2.4.3]. As described above mitozantrone and CI941 were more cytotoxic 
in MCF-7 cells than these compounds indicating that DNA strand breakage 
caused by mitozantrone and CI941 is more lethal to the cell than 
oxidative damage. The decreased cytotoxicity of redox cycling quinones 
in relation to mitozantrone and CI941 may be explained in several ways:-
(1) The presence of intracellular protective mechanisms in the MCF-7 
cell line such as glutathione, glutathione peroxidase, glutathione-
S-transferase, superoxide dismutase and catalase that will protect 
MCF-7 cells against reactive oxygen formation by quinone antitumour 
agents (Sinha et sl., 1987; Deffie et a1., 1988). Only when these 
defences are overwhelmed will reactive oxygen formation become a 
significant problem since these mechanisms are designed to cope 
with the constant flux of oxygen radical formation during 
b 1i However, reactive oxygen formation endogenous meta 0 c processes. 
may be a problem in cells or tissues deficient in the above 
protective mechanisms (see section 1.10). 
(2) Pryor, (1988) suggests that reactive oxygen formation brings about 
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a limited number of types of DNA damage caused by h t e reactions of 
the hydroxyl radical. Consequently, this limited spectrum of 
damage can be enzymatically repaired in a number of processes that 
do not differ for each reactive oxygen generating system 
encountered. As described in section 1.9.2.3 many types of damage 
produced by the hydroxyl radical, including single strand breaks, 
are repairable by specific DNA repair enzymes. However, double 
strand breaks are more difficult to repair correctly since base 
information has been lost on both DNA stra d [ t· 1 9 2 1] n s sec 10n . .. . 
Consequently, the formation of double strand breaks is thought to 
represent a more critical lesion with respect to cytotoxicity 
[Zij1stra et sl., 1987]. 
5.4 CONCLUSION 
This study represents the first systematic investigation of the role of 
reductase mediated redox cycling of a series of related quinone 
antitumour agents in tumour cell kill. This study has found that 
reductase mediated redox cycling is likely to be involved in the DNA 
strand breakage and cytotoxicity of doxorubicin, lAQ, 1,SAQ and 1,8AQ in 
MCF-7 human breast cancer cells. In contrast, despite the absence of 
redox cycling, mitozantrone and CI941 were considerably more cytotoxic 
in the MCF-7 cell line than the above agents. The cytotoxicity of 
mitozantrone and CI941 appears to be expressed, at least in part, via 
interaction with MCF-7 topoisomerase. l,4AQ, an agent which does not 
redox cycle in MCF-7 cells, would appear to exert its cytotoxicity via a 
less potent effect on topoisomerase activity than mitozantrone and 
CI941. 
In conclusion, despite the related anthraquinone based structure of the 
quinone antitumour agents in this study, these compounds possess 
different propensities with respect to their ability to undergo 
reductase mediated redox cycling, form cellular DNA strand breakage, 
bind iron, inhibit DNA topoisomerase I activity and kill MCF-7 cells. 










Figure 5.3 The structures of mitozantrone, CI941 and l,4AQ 
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to their structural differences. The most important structural 
modification with respect to mechanism revealed in the present studv 
appears to be the C1 and C4 positioning of the hydroxyethy1amino si~e 
chains on the anthraquinone chromophore of mitozantrone, CI941 and 1,4AQ 
which is related to the absence of flavin reductase metabolic activation 
of these compounds. As described previously this may be related to 
steric hinderance between the drug molecule and the flavin component of 
the reductase (section 3.4.1). Another important structural 
modification is the aromatic hydroxyl groups on position 5 and 8 of the 
anthraquinone chromophore. Despite having identical side chains to 
mitozantrone and CI94l, 1,4AQ does not have aromatic hydroxyl groups 
(see figure 5.3). The importance of these groups is reflected in the 
lower DNA binding affinity [see table 3.5], reduced inhibitory effect on 
MCF-7 topoisomerase I activity [section 3.4.3], reduced MCF-7 DNA strand 
breakage [section 3.4.4] and reduced MCF-7 cytotoxicity [section 4.4.1] 
of 1,4AQ in comparison to mitozantrone and CI941. This is supported by 
other studies which have found mitozantrone and 1,4AQ not to be 
metabolically activated (Basra, 1986; Kharasch and Novak, 1983a). 
However, mitozantrone is a more potent inhibitor of DNA synthesis 
(Nishio and Uyeki, 1983), more potent at forming cellular DNA strand 
breakage (Locher and Meyn, 1983) and more cytotoxic in cellular systems 
(Partridge, 1987). Furthermore, chromophore hydroxyl groups are 
important in determining the iron binding potential of mitozantrone and 
anthrapyrazoles [section 3.4.2]. The aromatic hydroxyl groups of 
mitozantrone and CI941 appear to be important in the enhanced MCF-7 
cytotoxicity, DNA binding, topoisomerase I inhibition and cellular DNA 
strand breakage of these agents compared to the other quinone agents of 
this study. Clearly, subtle structural modification of the 
anthraquinone chromophore can be used to alter the activity of quinone 
antitumour agents. Since the non-redox cycling agents mitozantrone and 
CI94l were the most cytotoxic agents of this study it appears that the 
ability to produce free radical mediated effects confers no increased 
cytotoxic potential on agents such as doxorubicin and 
alkylaminoanthraquinones. This indicates that future development of 
quinone anti tumour agents should concentrate on compounds which do not 
redox cycle. Furthermore, these agents should possess aromatic hydroxyl 
groups since these appear to be responsible for the enhanced 
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Al Cell culture 
Al.l Procedure for changing growth medium in a flask of cells 
Firstly the old medium was discarded and an appropriate quantity of 
fresh medium pipetted into the flask depending on its surface area 
[25cm2-l2ml, 100cm2-20ml, l50cm
2-30ml]. D epending on the cell type the 
medium was gassed for 60 seconds with 95% air 5% CO2 , Generally the 
medium was changed every other day until confluence was reached (when 
cells covered >70% of flask surface). 
Al.2 Passage or sub-culture of cell lines 
The old medium was discarded, and EDTA [0.1% in DPBS, 10ml] was added 
and left in contact with the cells for 30 seconds. The EDTA solution 
was then discarded and the flask incubated (upright) at 37C for 10-15 
minutes or until the cells slid off the flask surface. The cells were 
resuspended in fresh pre-warmed medium [5-l0ml] and innoculated into 
flasks containing pre-warmed medium at a reduced cell concentration to 
the original flask, usually using a 1:2 or 1:3 fold dilution. If 
required the medium was gassed with 95% air/ 5% CO2 for one minute. The 
flasks were incubated at 37C and checked regularly for confluency and 
contamination using an inverted microscope [Nikon TMS]. 
AI.3 Preparation of large cell numbers using roller bottles 
Glass roller bottles [730cm2 , BDH] were used when large volumes of cells 
The roller 
were required for preparation of subcellular fractions. 
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bottles were initially sterilised by autoclaving the k f h ' nec 0 t e bottle 
being covered by foil and the plastic caps being autoclaved separately. 
Cell suspension which had been well dispersed (prepared from lxlsOcm2 
confluent flask) was illnoculated into the bottle with fresh medium 
(40ml). The bottle was rolled [using an RMV Universal Roller, Luckham] 
at a setting of 40% speed overnight and then the speed increased to 50-
60% speed from then on. The medium needed to be replaced at least every 
other day. 
Al.3.1 Passage of cells in roller bottles 
EDTA solution [0.1%, 10mls] was placed in the bottle and the bottle 
rotated for one revolution at room temperature. The EDTA solution was 
then poured off and the bottle incubated for 10-15 minutes on the roller 
device at 37C. Following this the cells were resuspended in PBS/medium 
[20ml] by vigorously washing/rotating the sides of the bottle and the 
cell suspension removed. Residual cells in the bottle can be 
resuspended in growth medium [40ml] and the growth cycle re-initiated. 
Al.4 Preparation of RPHI-1640 medium 
L-Glutamine (200mM, lml) , foetal bovine serum or Nuserum IV (lOml) and 
penicillin 5000 IUml- l / streptomycin 5000 ugml-l (lml) were added to a 
bottle of RPMI-1640 medium with Hepes buffer (20mM) without sodium 
bicarbonate or L-glutamine. All constituents were purchased from Flow 
Laboratories [UK]. 
Al.5 Reconstitution of powdered RPHI-1640 medium 
Whilst gently stirring, RPM I 1640 powdered medium with Hepes buffer 
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(25mM) and L-g1utamine, without sodium bicarbonate (1 
litre sachet, Flow 
laboratories) was added to distilled water (900m1) and stirred until 
dissolved. The sachet was rinsed with a small volume of distilled water 
and this added to the above solution. Th I' e so ut10n was made up to the 
final volume with distilled water and filter sterilised immediately 
through a filter disc [O.2um, millipore]. The sterile medium was 
aliquoted into sterile bottles (lOOml) and incubated at 37C for 3 days 
to check for contamination. 
AI.6 Storage of cells in liquid nitrogen 
Storage of cell lines is an essential back up in the event of cell 
contamination and as a permanent store of cell lines not required in 
culture. The cells were prepared from culture as described above and 
resuspended in fresh medium (2ml) per confluent flask of cells. 
Dimethylsulphoxide [DMSO] was added to the suspension to a final 
concentration of 10%, the suspension mixed and aliquots (lml) dispensed 
into 2ml plastic ampoules [Nunc]. The vials were placed in a 
polystyrene box, the box taped up and placed in a -20C freezer for 45 
minutes. The box was then suspended in the vapour phase of an LR30A 
liquid nitrogen refrigerator (Union Carbide) for a further 45 minutes, 
the ampoules removed and placed in cylindrical ampoule straws 
(consisting of cardboard sleeve and metal holder). The straws were 
stored in a cryogenic refrigerator (IOXT, Taylor Wharton). 
AI.7 Removal of cells from storage under liquid nitrogen 
The vial of cells was removed from the cryogenic refrigerator and placed 
in a 37C water bath. As soon as the cells were thawed [approx 5 
minutes] the suspension was placed in a flask containing prewarmed 
growth medium [12ml]. The flask was incubated at 37C for 2 hours until 
the cells had adhered. The medium was then replaced to dilute the DMSO 
and the flask incubated at 37C. 
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Al.9 The trypan blue assay for cellular viability 
Trypan blue solution (0.4%, 100ul) was added to cell suspension [250ul] 
in an eppendorf tube, mixed well and left for 1 minute. The surface of 
an improved Neubauer haemocytometer (depth O.lmm) was moistened at the 
side of the counting chamber and the coverslip pressed into position, 
ensuring 'Newton's rings' were visible on both sides of the chamber. 
The counting chamber was filled with cell suspension using a Gilson 
pipette [lOul]. 
Non viable cells retain the trypan blue dye, appearing blue in colour, 
due to a disruption of membrane integrity. A differential count of 
viable to non viable cells was carried out using a microscope at low 
magnification [x20]. 
Al.9 Counting of cells 
The haemocytometer counting chamber consisted of a marked grid pattern 
with a central area bound by triplicate lines which was lmm
3
, this area 
being subdivided into 25 squares. The depth of fluid in the counting 
chamber was O.lmm, therefore the total volume of liquid over the central 
area was:-
O.lxlxl = 0.1 mm3 or 10-4ml 
3 
The total number of cells (n) over the central area or present in o.lmm 
gives a concentration of:-
If the suspension was diluted, this was taken into account:-
ego 250ul cells + 100ul trypan blue gives a xl.4 dilution, therefore the 
number of cells is given by:-
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A2.0 Determination of protein content in subcellular 
fractions 
Protein determinations were carried out using the Biorad protein assay 
[Biorad] which utilises a solution of Coomassie blue dye. The Biorad 
solution was diluted l:S with distilled water and then filtered. A 
series of bovine serum albumin [BSA] concentrations were prepared [0.1-
1.Omg ml- l ]. A series of triplicate test tubes were set up each 
containing stock BSA [lOOul] and diluted Biorad solution [Sml]. The 
tubes were mixed well and allowed to stand for 10 minutes at room 
temperature, following which the absorbance of each tube was read 
immediately at S9Snm against a blank [containing Biorad solution but no 
BSA]. A calibration curve was plotted and used to determine the protein 
concentration of samples [lOOul] of 'unknown', treated as above. See 
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Figure Al A typical calibration curve for the Biorad protein assay. 
Values are mean + sd of three determinations. 
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A3.0 Preparation of acetylated cytochrome C 
Horse heart cytochrome C [lOOmg] was dissolved in sodium acetate 
solution [lOml, 50% saturated], keeping on ice. Under continuous 
stirring at 4C, ten times excess acetic anhydrid~ with respect to the 
cytochrome c lysine residues was added [150ul] (one molecule of 
cytochrome c contains 19 lysine residues). The reaction was allowed to 
proceed for 30 minutes, following which, unreacted acetic anhydride was 
removed by dialysis using Spectrapor membrane tubing [molecular cut off 
6-BK, diameter l4.6mm]. The membrane was soaked in running water for 4 
hours prior to use, dialysis being carried out for 10 hours under cold 
running water. 
The acetylated cytochrome c was stored under liquid nitrogen until 
required. 
The extent of cytochrome c acetylation was determined using the 
ninhydrin reaction. A series of concentrations of native and acetylated 
cytochrome C were prepared [lO-BOuM]. Aliquots [lml] of these solutions 
were placed in test tubes and ninhydrin reagent [0.5ml] added to each 
tube and vortexed. The tubes were covered in parafilm and placed in a 
boiling water bath for 15 minutes and then cooled on ice for a further 
10 minutes. Ethanol [50%, 2.5ml] was added and the tubes vortexed. The 
absorbance of each tube was measured at 570nm against a blank. The 
extent of cytochrome c acetylation was calculated using the following 
formula:: 
% acetylation= 100(1-slope acetylated) 
slope native 
The slopes being determined from a plot of absorbance at 570nm against 
concentration of cytochrome C [native and acetylated]. See figure A2 
1 f hi 1 t cytochr
ome c concentration was determined 
for an examp e 0 t s po. 
11 . the extinction coefficient of 2lmM cm-
l 
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spectrophotometrica Y uS1ng 
1962] Before measuring the absorbance a few 550nm [Williams and Kamin, . 
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Figure A2 Determination of the deg~ee of acetylation of cytochrome c. 
% acetylation - lOO(l-slope acetylated rll]) 
slope native [[J] 
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reduce the cytochrome c. 
A4.0 Preparation of agarose gel for submarine gel 
electrophoresis 
Agarose [lg] was added to TAE buffer [llOml] and the solution microwaved 
at medium setting for S minutes. The molten agarose solution was 
poured into a gel mould, consisting of a horizontal perspex plate [12.S 
x 11.Scm] with temporary side walls constructed from adhesive tape. A 
perspex comb was inserted into the molten gel in order to form the 
sample wells. Once the gel had set the sample comb and temporary walls 
were removed and the gel plate was fully immersed in an electrophoresis 
tank filled with TAE buffer (800ml). 
A5.0 Reconstitution of powdered anthraquinone anti tumour 
agents 
A vial of the agent [HCl salt] was opened and a spatula full of the 
powder was transferred to a larger sealable vial [Sml]. A volume of 
distilled water was added and the vial sealed and crimped immediately. 
The concentration of drug was determined by measuring the absorbance of 
drug [lOul in lml distilled water] at the appropriate wavelength and 
calculation using the corresponding extinction coefficient [see below] . 
The drugs were stored at 4C at a concentration of 5-l0mM in light 
protected vials. 
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Table Ai Extinction coefficients and absorption maxima for 
anthraquinone anti tumour agents 









A6.0 Preparation of NADPH 
Extinction 
coefficient 








Several mg of NADPH was dissolved in distilled water [200-500u1] The 
concentration of NADPH was determined by measuring the absorbance at 
340nm [10u1 in 1m1 distilled water] and calculation using the extinction 
coefficient of 6.3mM cm- 1 [Handa and Sato, 1976]. The prepared stock 
solution was used on the same day and then discarded. 
A7.0 Preparation of cultured cell 89 homogenate 
The cultured cells were isolated (see section AI.O), suspended in a 
small volume of ice cold DPBS (107 m1- 1), sonicated for 5 minutes, and 
centrifuged at 10,000 rpm for 30 minutes. The supernatant (S9 fraction) 
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was collected and was stored in O.S-lml aliquots under liquid nitrogen 
if not required immediately. 
AS.O Preparation of denatured calf thymus DNA 
Calf thymus DNA [30mg, sodium salt, Sigma] was added to single strand 
eluting solution [90ml, pHl2.3] in a volumetric flask [lOOml]. The 
solution was left at room temperature overnight in order for the DNA to 
dissolve. The volume was made up to lOOml with eluting solution. The 
DNA was denatured by placing in a capped plastic universal tube [SOml] 
and heating in a water bath [60C] for one hour. 
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Figure A3 Calibration curve for the detection of supercoiled plasmid 
DNA on sgarose gels. 
The gel was photographed and the intensity of the DNA bands on the 
negative determined by laser densitometry [as described in section 
3.2.1). Values are mean + sd of three determinations. 
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radiation dose (Gray) 
Figure A4 Effect of gamma radiation on strand breakage of 
plasmid DNA. 
Supercoiled plasmid DNA (300ng) was exposed to gamma radiation at room 
temperature as described in section 3.2.4.2. The DNA species resolved 
by gel electrophoresis were open circular (0] and linear [.]. 
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Figure A5 Effect of hydrogen peroxide on strand breakage of plasmid 
DNA. 
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Figure A6 Calibration curve for the detection of denatured calf thymus 
DNA using Hoechst H33258. 
Hoechst concentration was SOnM [OJ I lSOnM [.] and 4S0nM [0]. Values 
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Figure A7 Elution profile of DNA isolated from HCF-7 cells treated with 
gamma radiation. 
MCF-7 cells [I06ml -l] were untreated f~J or exposed to 2 Gray 
[ .. J J 4 Gray [0] or 8 Gray [. J gamma radiation at OC [as described 
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Figure A8 Cytotoxicity of doxorubicin in HCF-l cells following a one 
hour exposure and 6 day further growth period. 
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Figure A9 Cytotoxicity of mitozantrone [.1 and CI941 [.6.1 in HCF-7 
cell$ following a 24 hour exposure. 
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Figure A10 Calibration curve for the polarographic determination of 
mitozantrone. 




An investigation of the oxidative activation of guinone 
antitumour agents by horseradish peroxidase 
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Addendum- An investigation of the oxidative activation of quinone 




2.1 Spectral studies on the effect of mitozantrone on 
HRP compound II formation 
2.2 Determination of strand breakage of supercoiled plasmid 
DNA by quinone anti tumour agents in the presence of 
HRP and hydrogen peroxide 
2.3 Esr studies on free radical generation by quinone 
anti tumour agents in the presence of HRP and hydrogen 
peroxide. 
3 Results 
3.1 The effect of mitozantrone on conversion of HRP 
compound I to compound II 
3.2 The effect of mitozantrone on plasmid DNA in the 
presence of HRP and hydrogen peroxide. 
3.3 The effect of doxorubicin, CI941 and alkylaminoanthra-
quinones on plasmid DNA in the presence of HRP and 
hydrogen peroxide. 
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4.1 Oxidative activation of mitozantrone by HRP. 
4.2 Oxidative activation of doxorubicin, CI941 and 
alkylaminoantbraquinones by HRP. 
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Figure 8 A schematic diagram for the oxidation of 
mitozantrone by HRP. 





Peroxidase mediated oxidative activation to reactive intermediates has 
been implicated in the toxicity of a wide range of xenobiotics (reviewed 
by Mason and Chignell, 1982). Figure 1 shows the proposed mechanism of 
action of horseradish peroxidase (HRP) on a substrate X. Chapter 2 of 
the present study has investigated the propensity of doxorubicin, 
mitozantrone, CI941 and the alkylaminoanthraquinones to undergo 
reductive activation by reductases in the process of redox cycling. 
Furthermore, chapter 3 has investigated the ability of these agents to 
mediate damage to cellular DNA in the presence of purified reductases. 
However, oxidative activation of these agents to free radical species 
which could damage DNA has not been previously considered. In the 
present study the propensity of mitozantrone to undergo oxidation by HRP 
was investigated. In addition, studies on the ability of these agents 
to produce DNA strand breakage in the presence of HRP were carried out. 
1 
ROOH ROH 




Figure 1 Peroxidase oxidation states and peroxidase 
mechanism. 
X= co-substrate 





2.1 Spectral studies on the effect of mitozantrone on HRP compound II 
formation 
Spectral studies on the interaction of mitozantrone with HRP Compound I 
were carried out following the addition of hydrogen peroxide (2uM) to 
HRP (2.4uM) at 37C. Spectral changes were followed using a uvjvis 
scanning spectrophotometer [552 spectrophotometer, Perkin Elmer] fitted 
with a temperature controller and temperature controlled Peltier cell 
[Perkin Elmer]. 
2.2 Determination of strand breakage of supercoiled plasmid DNA by 
quinone anti tumour agents in the presence of HRP and hydrogen 
peroxide 
The technique was carried out in an identical manner as described in 
section except the incubate consisted of MgCl2 [3mM] , Tris buffer [lOOmM, 
pH 7.0], DNA [300ng], hydrogen peroxide [0.05uM], horse radish 
peroxidase [0.036ug] and drug [0-50uM]. The above components were 
incubated for 45 minutes at 37C. 
2.3 Esr studies on free radical generation by quinone antitumour agents 
in the presence of HRP and hydrogen peroxidase. 
Esr studies were carried out as described in section except the 
( 56ug ml-incubate consisted of drug (3.28mM), horse radish peroxidase 
1), hydrogen peroxide (2.26mM) and phosphate buffer (lOOmM, pH 7.4). 
3 
3 Results 
3.1 The effect of mitozantrone on . f convers~on 0 HRP compound 
I to compound II 
Figure 2 shows that shows that the addition of hydrogen peroxide to HRP 
resulted in a bathochromic and hypochromic shift from the absorbance 
maximum of HRP [Fe(III), 403nm] to that characteristic of HRP compound I 
[410nm]. Compound I was unstable and slowly converted to HRP compound 
II [418nm]. When a stoichiometric amount of mitozantrone was added this 
conversion was accelerated. When excess mitozantrone was added HRP 
[Fe(III)] was regenerated. These results indicated that one and/or two 
electron oxidation of mitozantrone was being carried out by HRP. 
3.2 The effect of mitozantrone on plasmid DNA in the presence 
of HRP and hydrogen peroxide. 
Figure 3 [data derived from photograph 1] shows that mitozantrone (10uM) 
produced an increase in single strand breakage relative to the control 
in this system. It can be seen that mitozantrone (2SuM) produced a 
total loss of the DNA present, whist mitozantrone (SOuM) produced no 
significant strand breakage relative to the control. The loss of DNA 
observed with 2SuM mitozantrone was further investigated (figure 4). 
This figure shows that mitozantrone at this concentration caused total 
loss of the plasmid DNA in this system. However, all other combinations 
of the components of this system produced no effect indicating that the 
presence of the complete system containing mitozantrone was required for 
the total loss of DNA observed. At mitozantrone [2SuM] a blue 
precipitate was observed in the incubation tube following ethanol 





















Figure 2 Spectral changes of HRP in the presence of mitozantrone. 
1. Spectrum of HRP[Fe(III)] (O.72uM); 2. Spectrum of HRP after 
addition of hydrogen peroxide (1.2uM); 3. Spectrum of HRP compound II 
after addition of mitozantrone (O.25uM); 4. Spectrum showing 
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Photograph 1 Effect of mitozantrone on plasmid DNA in 
the presence of horseradish peroxidase and hydrogen peroxide. 
Plasmid DNA (300ng) was incubated (37C, 45min) with 
HRP (O.036ug) and hydrogen peroxide (O.05uM [lanes 
1-3], and mitozantrone 51lM [lanes 4-61, 251lM [lanes 7-9], 
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Figure 3 Effect of mitozantrone on plasmid DNA in the presence of 
HRP and hydrogen peroxide. 
DNA (300ng) was incubated (37C, 4Smin) with HRP (O.036ug), hydrogen 
peroxide (O.OSuM) and mitozantrone. The DNA species resolved by gel 
electrophoresis were supercoiled f r2 ] and open circular [0 J . 
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Figure 4 Effect of mitozantrone on plasmid DNA in the presence of 
HRP and hydrogen peroxide . 
DNA (300ng) [A] was incubated (37C, 4Smin) with HRP (O.036ug), hydrogen 
peroxide (O.OSuM) and mitozantrone (2SuM) in the following 
combinations:- HRP [B), H202 [C), HRP and H202 [D), HRP and 
mitozantrone [E), mitozantrone and H202 [F), mitozantrone [G) and HRP, 
H
2
02 and mitozantrone [H). DNA species resolved by gel electrophoresis 
were supercoiled [~] and open circular [0] · Values are mean + sd of 
three determinations. 
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5.5 LIl~ cII~~C v~ uvxorubicin, CI941 and alkylaminoanthraquinones on 
plasmid DNA in the presence of HRP and hydrogen peroxide. 
Figure 5 shows that doxorubicin and CI941 (25 and 50uM) produced no 
significant DNA strand breakage or loss of DNA in a system of HRPfH202 
relative to controls. The effect of AQ,s in this system was also 
investigated (figure 6). It can be seen that none of these compounds 
(25uM) produced significant strand breakage of DNA relative to controls. 
3.4 Esr studies on free radical formation by mitozantrone, doxorubicin 
and CI941 in the presence of HRP and hydrogen peroxide. 
These studies were carried out as described in section 2.3. Figure 7 
shows that a free radical with a peak to peak width of 20 Gauss was 
detected in the presence of mitozantrone in this system. This signal 
was dependent on the presence of HRP, H202 and mitozantrone. However, 
in the presence of doxorubicin or CI941 under identical experimental 
conditions no esr signal could be detected. 
4 Discussion 
4.1 Oxidative activation of mitozantrone by HRP. 
Mitozantrone produced characteristic spectral changes in the presence of 
HRP/H
20
2 indicative of mitozantrone being a substrate for one or two 
electron oxidation by this enzyme (figure 2). By analogy with the 
h b t (f1' ure 1) formation of a known action of HRP on ot er su stra es g 
This was 
mitozantrone free radical species is likely to occur. 
t of mitozantrone, HRP and hydrogen confirmed by esr studies on a sys em 
peroxide which showed the formation of a broad esr spectrum. This 
signal is likely to represent a polymeric mitozantrone free radical 
S
lowly on the esr time scale leading to the esr 
species which rotates 
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Figure 5 Effect of doxorubicin and CI941 on plasmid DNA in 
the presence of HRP and hydrogen peroxide . 
Experimental conditions were as described in figure 3 (concentration in 
uM). DNA species resolved by gel electrophoresis were supercoiled [ ~ J 
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Figure 6 Effect of alkylaminoanthraquinones (25uH) on pl asmid DNA in 
the presence of HRP and hydrogen peroxide . 
DNA (300ng) [A] was incubated (37C , 45min) with HRP (O.03 6ug), H202 
(O.05uM) [B] and lAQ [C], 1,4AQ [D) , 1 , 5AQ [E) and 1 ,8AQ [F). 
DNA species resolved by gel electropho re s i s were supercoiled [~) and 
open circular [[J] . Value s a re me an + s d of three determinations . 
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lOG 
Figure 7 Free radical formation by mitozantrone, in the presence of 
HRP and hydrogen peroxide. 
-1 Incubate consisted of HRP (56ug m1 ), hydrogen peroxide (2.26roM) and 
mitozantrone (3.2BmM). Esr parameters were as described in figure 2.7A. 
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mitozantrone produced concentration dependent single and double plasmid 
DNA strand breaks [1 and SuM] (figure 3). Furthermore, at 25uM, mito-
zantrone produced a total destruction of the DNA species present [figure 
3 and 4 photograph 1]. Also at this concentration a blue precipitate 
was observed in the incubation tubes after the ethanol precipitation and 
drying stage. This indicates that mitozantrone is forming DNA-
mitozantrone crosslinks which are likely to be too bulky to be resolved 
by gel electrophoresis. Mitozantrone (SOUM) appeared to have no effect 
on plasmid DNA [figure 3]. This is possibly due to formation of 
mitozantrone dimers at high drug concentration which are formed in 
competition to DNA interaction. The DNA damage caused by this 
HRP/H202/mitozantrone system provides further evidence for formation of 
a mitozantrone free radical intermediate. A schematic diagram for the 
activation of mitozantrone by HRP is shown in figure 8. The oxidation 
of mitozantrone by HRP in the present study is supported by the work of 
Kolodziejczyk et al. (1988) and Reszka et al. (1986) who showed that 
mitozantrone is oxidised by HRP to a cyclised cationic free radical 
species due to one electron oxidation of the aromatic nitrogen atoms. 
However, these workers did not investigate whether this species could 
mediate DNA damage. 
The results presented here have important implications for the mechanism 
of action of mitozantrone. This is because peroxidase enzymes are 
widely distributed in mammalian systems [see table 1] and offer a means 
b h ' h' t could exert its antitumour or toxic effects. y w ~c m~tozan rone 
Further studies are required to investigate whether mitozantrone can 
undergo oxidative activation by more physiological relevant peroxidases. 
4.2 Oxidative activation of doxorubicin, CI941 and 
alkylaminoanthraquinones by HRP. 
In contrast to mitozantrone, doxorubicin (figure S), CI941 (figure 5) 
and AQ's (figure 6) did not produce strand breakage in the presence of 
h d X
orubicin and CI941 did not form free radical 
HRP/H
2
02 . Furt ermore, 0 
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Figure 8 A schematic diagram for the oxidation of mitozantrone 
by horseradish peroxidase 
14 
compounds are not substrates for HRP, suggesting that oxidative 
activation does not play a role in their mechanism of action. In 
support of this, Kolodziejczk et al. (1989) showed that daunorubicin did 
not undergo oxidation by HRP. 
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Peroxidase Location 
M yeloperoxidase bone marrow 
phagocytic cells 
Uterine peroxidase uterus 
Prostaglandin-H- wide distribution 




Lactoperoxidase milk, saliva, 
lacrimal fluid 
Th yroid peroxidase thyroid 
Cytochrome P-450 wide distribution 
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